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Abstract 
Bone makes up a framework that provides protection for internal body organs. The 
homeostasis of bone is maintained by a balanced process involving old bone degradation and 
new bone formation. However, this balance can be altered in pathophysiological conditions 
such as in postmenopausal osteoporosis and in patients with rheumatoid arthritis (RA). In 
recent years, new therapies have been developed to reduce bone resorption. However, there is 
disparity in patients’ response to these therapies. The reasons are unclear although age, 
gender, ethnic background and lifestyle have all been suggested to play a part. For patients 
with chronic inflammatory conditions, treatment was revolutionised by the discovery and 
application of biologic therapies that target pro-inflammatory proteins and/or pathways. 
However, whilst the anti-inflammatory effect of these biologic agents is well-established, 
their effect on bone loss is just emerging. In RA, it is not clear whether the beneficial anti-
inflammatory effects of biologic anti-tumour necrosis factor alpha (TNFα) agents are 
accompanied by parallel improvements in bone erosion/density, whether there are differences 
between patient groups and what factors influence the response. In order to address these 
issues, a database on the factors that influence responsiveness of patients with osteoporosis to 
bisphosphonates, a treatment that suppresses bone resorption, was established. Based on the 
outcome of this study, the influence of the key factor(s) that affect bone response to treatment 
in combination with excess pro-inflammatory cytokine production on bone response in RA 
patients was determined. Significant improvement in bone mineral density (BMD) and plasma 
levels of bone biomarkers has been shown in this study with biologic anti-TNFα agents. The 
improvement in BMD was not always consistent with improvement the clinical response to 
treatment as assessed by changes in disease activity score 28(DAS28). The study also 
provides a mechanistic explanation for how blockade of TNFα in patients can reverse the 
balance of bone loss in patients with RA. Thus, the data show that treatment of patients with 
biologic anti-TNFα agents reduces the number of osteoclast precursors (OCs) in the blood. 
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1.1) Bone 
Bone is a specialised connective tissue involved in numerous vital functions in the 
body. These include giving the body a structure, protecting vital internal organs and acting a 
milieu for the bone marrow. For example, the skull acts as a helmet and protects the eyes, ears 
and brain. The ribs form a cage that surrounds and protects the lungs and the heart. 
Furthermore, bone has an essential metabolic function acting as a mineral reservoir of 
calcium, magnesium and phosphates that are required for the maintenance of blood 
homeostasis. In addition, bone forms a framework for the muscular system to facilitate 
movement (1).  
1.2) Structure and organisation of bone  
The human skeleton is comprised mainly of osseous (bone) tissue, which is composed 
of mineralised matrix with both organic and inorganic components. The inorganic matrix is 
mainly crystalline mineral salts and calcium phosphate present in the form of hydroxyapatite, 
Ca10 (PO4)6 (OH)6 on which bone hardness depends (2). Fewer amounts of manganese, 
chlorine, potassium are also present in bone crystals. The organic part of the matrix is 
primarily type I collagen, which forms more than 25% of bone. This collagen is in a fibre 
form with a triple helical molecular structure that provides bone with flexibility. Other 
organic components of bone are mucopolysaccharides, glycoproteins and lipids (1). 
Several types of bone exist within the human skeleton. The two major types are 
cortical bone, which makes up to 80% of all bone tissues and trabecular bone which makes up 
to 20%. Cortical, or compact bone, is dense and forms the protective exterior shell of long 
bones and vertebrae. It supports long bones to resist the stress of weight placed on them. In 
contrast, trabecular bone is a spongy-like structure which contains a network of fine and 
interlacing partitions, the trabeculae. Trabecular bone forms the main part of the vertebral 
body and the epiphyses of the long bones (Figure 1.1). Any bone loss is likely to initially 
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affect areas composed primarily of trabecular bone due to its higher rate of bone turnover 
(approximately eight times higher) than cortical bone (1,2). 
 
          
Figure 1.1: Types of bone that exist within the human femur. The figure depicts the 
distribution of cortical (compact) and trabecular (spongy) bone. Cortical bone forms the 
protective exterior shell of long bones and vertebrae while trabecular bone forms the main 
part of the vertebral body and the epiphyses of the long bones. The Figure is obtained and 
redrawn from reference number (1).  
 
 
1.3) Bone homeostasis 
 
Bone homeostasis is tightly regulated by remodelling, in which old bone is removed 
(bone resorption) and replaced with new bone (bone formation) (1-3). The two processes 
involve a number of bone cell types. The key cell types within the bony matrix are 
osteoclasts, osteoblasts and osteocytes (2). The cells that are responsible for bone formation 
and for producing bone tissue are osteoblasts. They are relatively immature cells line the bone 
and produce hormones, such as prostaglandins, enzymes such as alkaline phosphatase and 
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other matrix proteins such as osteocalcin, osteonectin, glycosaminoglycans, bone growth 
factors and sialoproteins (3).  
 
Osteocytes are generated from osteoblasts that have migrated into the bone matrix and 
work as mature bone cells which function as mechano-sensory receptors to adjust bone 
responses to stress and also control bone formation, matrix maintenance and calcium 
homeostasis (4). They are the most abundant bone cells and are distributed throughout the 
matrix. Despite been embedded in bone, osteocytes stick to the bone surface as well as to each 
other via cytoplasmic processes that go through the bone in tunnels known as canaliculi. In 
addition to its essential function during mechanical loading, osteocytes play a key role in bone 
homeostasis via the production of sclerostin, an inhibitor of bone formation (5). Recently, 
investigators revealed that osteocytes are important sources of receptor activator for nuclear 
factor кB ligand (RANK-L), a main factor for osteoclast development and bone loss, 
suggesting that they are key players in bone remodelling (6,7). 
 
Osteoclasts are large multinucleated cells derived from mononuclear precursor cells of 
the monocyte/macrophage lineage that absorb bone matrix and cause bone resorption. The 
cells are generated under the influence of mesenchymal cells, which provide signals essential 
for their differentiation. These signals involve RANK, RANK-L, osteoprotegerin (OPG) and 
macrophage-colony-stimulating factor (M-CSF). RANK is receptor bound to the membrane 
of osteoclasts. It binds to RANK-L and this engagement triggers signaling cascades that lead 
to osteoclast-mediated bone resorption. RANK-L exists in soluble as well as tissue-bound 
forms. It belongs to the tumour necrosis factor (TNF) superfamily of ligands and receptors 
and is the main osteoclastogenic cytokine. RANK-L is inhibited by its natural decoy receptor 
osteoprotegrin (OPG). OPG is a key inhibitor of bone resorption that exists in a soluble non-
signaling form (2-4,8). In both mouse and human, deletion of the gene that encodes OPG 
causes profound osteoporosis. In contrast, over expression of the gene that encodes OPG, 
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TNFRSF11B under a hepatic promoter in transgenic mice results in severe osteopetrosis as a 
consequence of a lack of osteoclasts. OPG expression is inhibited by pro-inflammatory 
cytokines such as TNFα, interleukin (IL)-1, IL-6, and IL-17 which, at the same time, enhance 
RANK-L expression with the net result being a rise in osteoclast formation and function (8). 
 
The bone remodelling process occurs at highly regulated stages that depend on two 
cell lineages interactions, the hematopoietic osteoclastic lineage and the mesenchymal 
osteoblastic lineage. The first stage involves activation and this includes the interaction of 
osteoclast and osteoblast precursor cells (Figure 1.2). This results in the differentiation, fusion 
and migration of the large multinucleated osteoclasts. These cells stick to the mineralised 
bone surface and start the resorption stage by releasing hydrogen ions and enzymes, 
particularly cathepsin K, which can resorb all the components of bone matrix including 
collagen resulting in the formation of cavities on the bone surface. After osteoclasts complete 
their work in bone removal, the reversal stage begins through the appearance of mononuclear 
cells on the bone surface with the release of growth factors which initiate the formation stage. 
Throughout the formation stage of the remodelling processes, the cavity formed by resorption 
can totally be filled in by successive layers of osteoblasts, which differentiate from their 
mesenchymal precursors (3). 
 
                                                                                                                                   
- 22 - 
 
 
Figure 1.2: Bone remodelling processes. A cartoon depicting the remodelling cycle 
that consists of four stages: activation, which includes recruitment and activation of 
mononuclear monocyte/macrophage osteoclast precursors from the circulation; 
resorption, in which old bone is digested by osteoclasts; reversal, which involves the 
appearance of mononuclear cells on bone surface and formation, in which 
osteoblasts generate new bone until the resorbed bone is completely replaced. 
Osteocytes are generated from osteoblasts and are the most abundant bone cells. The 
RANK, RANK-L and OPG system regulate osteoclast formation, activation, and 
resorption. The Figure is procured and modified from reference number (3). 
 
 
1.4) Factors that influence changes in bone metabolism 
 
Bone continuously remodels itself to maintain optimal mass and repair small and large 
damages such as fractures. There are a number of factors that affect bone metabolism and 
mass including deficient intake of calcium and vitamin D, sedentary lifestyle, smoking and 
excessive alcohol consumption (9). Bone mass is also influenced by genetic factors and 
ethnicity. For example, African-American females are more likely to achieve higher peak 
bone mass than Caucasian females. Furthermore, there is evidence that vertebral fractures are 
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less common in Afro-Caribbean than Caucasian women and that the incidence of these 
fractures in Japanese women is similar to that in Caucasian populations (10, 11). The 
scientific basis for this observation is unknown.  
 
The risk of bone loss is also enhanced by aging, menopausal status, diet, drugs, stress, 
injuries and by chronic inflammatory diseases, such as rheumatoid arthritis (RA) (9). In 
menopausal women, levels of oestrogen play an important role in the remodelling process. 
Oestrogen is, thus, responsible for maintaining bone density by stimulating osteoblasts to 
form new bone. The hormone is produced by the ovaries before menopause. After 
menopause, the ovaries stop producing oestrogen but the adrenal gland secretes small 
amounts of androgens and these are converted to oestrogen by the enzymes aromatase. As a 
result of reduced oestrogen levels in post-menopausal women, osteoblasts become less active 
resulting in decreased bone mass (12).  Furthermore, long-term treatment of patients with 
medications such as corticosteroids causes bone loss by several mechanisms, which will be 
discussed in more detail in section 1.6.1.2 on pathological conditions leading to bone loss. 
  
Bone metabolism is also influenced by major calcium-regulating hormones, including 
parathyroid hormone (PTH), calcitonin and 1,25-dihydroxy vitamin D. PTH is an effective 
stimulator of bone resorption and affects bone formation. Further, PTH tends to rise with age, 
which may lead to an increase in bone turnover and bone loss. In contrast, calcitonin 
(produced by the thyroid) is a potent inhibitor of bone resorption and osteoclast activity. 1,25-
dihydroxy vitamin D is essential for the differentiation of both osteoclasts and osteoblasts and 
can stimulate bone resorption and formation. Furthermore, bone formation and resorption can 
be stimulated by growth hormones which act systemically and also through the induction of 
local insulin-like growth factor (IGF) production (13). 
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1.4.1 Changes in bone metabolism with age 
In children, bone formation is most rapid as a consequence of more bone growth and 
lengthening. Before the age of 20 years, 90% of bone growth takes place. Bones grow their 
final 10% between the ages of 20 and 30 but become thicker rather than longer. At the age of 
30 to 35, bones reach their largest and strongest levels. This level is called the “peak bone 
mass”. The process of bone loss starts from the age of 35 to 40, as bone resorption exceeds 
bone formation (Figure 1.3) (3). It has been shown that the rate of bone loss accelerates to 
about 2% per year in the early postmenopausal years in females, where bone loss from the 
spine is greater than of other sites of the skeleton. It has also been demonstrated that 
approximately, 35% and 50% of cortical and trabecular bone is lost from the skeleton, 
respectively (14). 
 
     
Figure 1.3: Age-related changes in bone mass in men and women. The graph 
shows that at about 30 years of age bone density peaks. The process of bone loss 
begins from around the age of 35-40 years. In women, bone loss is more rapid than 
in men. The graph is redrawn from reference number (15).  
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1.5) Methods of assessment for changes in bone density 
 
A range of clinical and laboratory protocols are routinely used to monitor pathological 
changes in bone structure and density. Early diagnosis of pathological changes is essential to 
limit bone loss and effectively treat diseases such as osteoporosis.  Bone mineral density 
(BMD) is a measure of the amount of bone minerals (calcium hydroxyapatite) per unit 
volume of bone tissue. It is calculated as grams per square centimetre of bone tissue and is 
determined using a number of methods including dual energy X-ray absorptiometry (DEXA) 
and peripheral dual energy X-ray absorptiometry, among others. Laboratory tests for changes 
to bone conditions include measurement of serum levels of bone-specific alkaline 
phosphatase, osteocalcin, deoxypyridinoline and carboxyterminal cross-linking telopeptide of 
bone collagen (CTX) (3,16). 
 
BMD and bone mineral content (BMC) are used as standard units of measurement. 
BMD signifies total bone mineral mass (calcium hydroxyapatite) per unit area (g/cm2) of bone 
whereas BMC represents the total bone mineral mass in a specific region of the bone. 
Measurement of BMD at any skeletal site provides a predictive value of fracture incidence. 
However, measurement at the particular skeletal site of interest is usually most predictive for 
fractures at that site. Moreover, in order to predict osteoporotic fractures, assessment of the 
axial skeletal sites of the spine and femur has proved to be the most useful approach (17,18). 
The methods in general use for assessing bone are summarised below.  
 
1.5.1 Radiographic methods: 
a) Dual energy X-ray absorptiometry (DEXA) 
DEXA is currently the most widely used technique for the measurement of BMD in the 
diagnosis and follow-up of patients with osteoporosis due to its precision, accuracy and low 
radiation dose. The World Health Organization (WHO) standards for the diagnosis of 
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osteoporosis are based on DEXA (summarised in Table 1.1). DEXA, therefore, has become 
the gold standard for clinical bone densitometry measurements of the central and peripheral 
skeletal BMD (18-19). DEXA uses two X-ray beams of different energy levels that are 
absorbed differently by bone mineral and soft tissues. The method depends on measurement 
of the transmission of X-rays with high and low photon energies through various tissues in the 
body. The principle is based on the fact that absorption of X-rays in any material such as bone 
mineral and soft tissue (fat and muscle) is dependent on the X-ray energy as well as on the 
elemental composition of the attenuating material. Therefore, DEXA can accurately measure 
bone within soft tissue by separating the attenuation of transmission due to bone from that due 
to soft tissue. DEXA results, therefore, represent a composite measure of both cortical and 
trabecular bones in g/cm2 (19,20). DEXA scan of the lateral spine assesses mainly the 
vertebral body and avoids some measurement errors that can occur on anteroposterior (AP) 
spine testing, which also evaluates the posterior elements of the vertebrae, such as the 
pedicles, articulating and spinous processes (21). 
Table 1.1: The World Health Organization (WHO) classification of osteoporosis. 
 
 
 
 
 
 
Data in the Table are for the WHO guidelines for assessment of fracture risk and its 
application to screening for postmenopausal osteoporosis (19). 
 
 
 
 
 
Normal BMD within 1 SD of young adult reference range. 
     Osteopenia BMD more than 1 SD below the young adult mean but less than 
2.5 SD of this value. 
Osteoporosis BMD 2.5 SD or more below the young adult mean. 
Severe 
Osteoporosis 
BMD 2.5 SD or more below young adult mean and the presence 
of 1 or more fragility fractures. 
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b) Peripheral dual energy X-ray absorptiometry (PDEXA) 
This technique measures peripheral skeletal sites using dual energy X-ray. While PDEXA 
of the wrist and calcaneus is more suitable and less costly than conventional DEXA, 
variations between peripheral and central sites are common and may result in the 
underestimation of fracture risks. However, PDEXA is a more useful procedure for older 
patients because at that stage bone loss in the peripheral skeleton would have reached central 
skeletal sites (21,22). 
 
c) Single X-ray absorptiometry (SXA) 
This protocol uses the same general principles as DEXA. However, SXA does not allow 
for adjustment for soft tissues as it utilizes a single energy beam only. Therefore, the use of 
SXA is limited to distal appendicular skeletal structures that have little interfering soft tissue. 
The most common sites for SXA are the calcaneus, the distal radius and ulna. This technology 
can be a useful and an inexpensive predictor of fracture risks particularly in older women 
(21). 
d) Quantitative ultrasound (QUS) 
QUS is one of the latest technologies approved for the assessment of bone density. The 
technology uses non-ionizing radiation; hence, it has the potential of becoming a low-cost 
alternative to bone densitometry. Ultrasound is transmitted from a transducer with frequencies 
in the range 0.2-1.0 MHz through regions of interest, e.g. calcaneus where both broadband 
ultrasonic attenuation (BUA) and the speed of sound are measured and are used to estimate 
BMD. Several prospective studies indicate that the predictive capability of QUS for hip 
fracture is as good as DEXA prediction of the femoral neck and that QUS and DEXA both 
predict hip fractures better than DEXA of the lumbar spine. Presently, the most important 
limitation of QUS use is the time needed to observe a significant change in BMD.  Because 
the results of most clinical studies of therapy depend on the DEXA BMD, many researchers 
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believe that more information is needed before diagnosis of individuals can rely on QUS 
measures. At present, QUS is recommended as a screening instrument to help identify 
patients who should undergo further BMD testing. In the next few years, QUS could become 
a reproducible, inexpensive and noninvasive measure of osteoporosis risk (21,22). 
 
e) Quantitative computed tomography (QCT) 
QCT is an X-ray absorptiometric technique that uses a clinical computed tomography 
scanner to determine the true volumetric density (mg/cm3) of trabecular, or cortical bone in 
three dimension (3D). BMD can be calculated using this technology through the selection of 
bone regions of interest by the mean Hounsfield number (a quantitative scale for describing 
radiodensity) in the area selected. The ability of QCT to selectively assess the metabolically-
active and structurally-important trabecular bone in the vertebral body provides for an 
excellent ability to differentiate vertebral fractures from healthy vertebrae and to also measure 
bone loss.  
Currently, QCT is performed on the spine only but QCT measurement of the proximal femur 
is being developed in a few research centers. It has generally better sensitivity than other 
methods such as DEXA. However, its use is limited due to cost, high radiation dose and 
difficulty in being utilized when sequential measurements are needed (21). 
 
f) Radiographic absorptiometry 
This is a technique used for bone mass measurements from radiographs of peripheral sites, 
most commonly the hand, or heel. The technique relies on taking 2 X-rays of the site at 
slightly different angels and then analysing the data. Before imaging, for instance the hand, an 
aluminum alloy reference wedge is placed next to the middle phalanx of the index finger. The 
developed films are then sent to a central analysis unit and the average density of the middle 
phalanx of the middle 3 fingers is determined in radiographic absorptiometry units. These 
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units correlate with other bone density measurement methods. Despite the ease of application 
of this technology to existing x-ray technology, the usefulness of radiographic absorptiometry 
in predicting site-specific fracture risk remains to be established (21). 
 
1.5.2 Laboratory biomarkers of bone metabolism: 
The development of biomarkers to assess the rate of bone remodelling is one of the 
important advances in managing bone loss. The process of bone remodelling can be assessed 
using biomarkers of bone resorption and synthesis with measure of static bone density. Bone 
formation can be evaluated by proteins that are released from osteoblasts such as osteocalcin, 
specific alkaline phosphate and pro-collagen peptides while bone resorption is generally 
indicated by products of collagen breakdown. When osteoclasts degrade collagen, cross-links 
of collagen and their adjacent peptides are released into the circulation and excreted in urine 
(e.g. urinary N-telopeptide cross-links of collagen and C-telopeptide cross-links of collagen). 
Cross-linked type I collagen is the most widely used biomarker of bone resorption. Since 
bone resorption and formation are linked, biomarkers of turnover change in sequence. In 
response to therapy, for example, changes in bone resorption biomarkers precede those of 
bone formation (22). 
1.6) Pathological conditions associated with changes in bone metabolism  
 
Bone is maintained in a healthy state by balanced metabolism involving resorption and 
new bone formation. Alteration to this balance causes metabolic bone diseases including 
osteoporosis, rickets, osteomalacia, osteopetrosis and Paget’s disease of bone. These 
metabolic bone diseases may result in bone pain and loss of height (due to compression of 
vertebrae) and they predispose patients to fractures. 
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1.6.1) Osteoporosis 
Osteoporosis is a systemic skeletal disease characterised by low bone mass and 
microarchitectural deterioration of bone tissue with a consequent increase in bone fragility 
that could lead to fractures (16). This is a condition often seen in postmenopausal women with 
a rate of one in three over the age of 50 years worldwide affected (Figure 1.4) (17,21). 
Osteoporosis starts when the regular processes of bone formation and resorption 
become unbalanced culminating in net bone loss. Fractures can occur as a result of decreased 
bone mass and its strength. Vertebra, hips and wrists are the most common sites where 
osteoporotic fractures occur. Osteoporosis can be categorised as primary or secondary (21).  
 
             
                    
Figure 1.4: Trabecular bone tissue in a healthy adult and a patient with 
osteoporosis. In osteoporosis, bone mass and its microarchitecture deteriorate and 
become porous leading to bone fragility and fracture. The Figure is obtained and redrawn 
from reference number (1).  
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1.6.1.1) Primary osteoporosis 
Reduction in bone mass not mediated by chronic illnesses or by medication and is a 
consequence of aging and decreased gonadal function is referred to as primary osteoporosis. 
This is subdivided into two types: postmenopausal osteoporosis (also known as type I 
osteoporosis) and age-related osteoporosis (also referred to as type II osteoporosis) (21).  
a) Postmenopausal Osteoporosis 
Postmenopausal osteoporosis (type I) is the most common osteoporosis condition 
mediated by reduced levels, or lack of oestrogen production during the postmenopause (23). 
Oestrogen deficiency promotes osteoclasts degradation of bone without sufficient new bone 
formation by osteoblasts, resulting in osteoporosis. Normally, osteoclasts have receptors for 
oestrogen, oestrogen receptor alpha and beta (ERα and ERβ), which play a key role in the 
synthesis of inhibitory proteins and inhibit osteoclast formation when they bind to oestrogen. 
However, their role is affected when oestrogen production is deficient post-menopause, 
resulting in a large pool of osteoclast progenitors (23). Furthermore, osteoclast apoptosis is 
inhibited with all events together culminating in bone resorption (23). It has been 
demonstrated that osteoclast formation is inhibited by oestrogen in vitro when osteoclast 
precursors are co-cultured with osteoblastic cells. However, oestrogen did not directly change 
precursors of osteoclast when they were cultured alone (24). The outcome of this study 
strongly indicated that oestrogen regulation of osteoclast activity is controlled by osteoblasts 
(24). 
b) Age-related osteoporosis 
Age-related osteoporosis occurs both in men and in women. However, prevalence of 
the disease is 2-3 times higher in women than in men. Age-related osteoporosis in women 
involves two stages, a rapid stage that starts at menopause and takes 4–8 years followed by a 
slower continuous stage that continues throughout life (23). In contrast, men go only through 
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the slow continuous stage. Therefore, women normally lose more bone quicker than men. The 
slower rate of bone loss result from a group of factors including age-related deficiency of 
bone formation, reduced calcium and vitamin D intake, reduced physical activity and a 
decrease in calcium absorption through the intestine and the kidney due to the loss of 
oestrogen’s positive effects on calcium balance. As a result of the reduction in blood calcium, 
parathyroid hormone levels will increase leading to calcium depletion from bone to make up 
for the loss. The outcome of this process is an increase in bone resorption (23). In aging men, 
sex steroid deficiency is a key factor in age-related osteoporosis (23).  
 
1.6.1.2) Secondary osteoporosis 
In addition to primary osteoporosis, bone loss can occur secondary to a number of 
chronic conditions such as, endocrine disturbances, cancer, gastrointestinal diseases, renal 
failure and inflammatory diseases such as RA. The condition could also be induced with long-
term treatment with glucocorticoids. Therefore, secondary osteoporosis can occur at any age 
and affect men and women similarly (21). Some common examples of secondary osteoporosis 
are discussed below in more detail. 
 
a) Bone loss induced by cancer 
Bone cancer and, more frequently, metastasised cancers from outside of the skeleton 
to the bone can lead to osteoporosis. The outcome of both types of cancers is generally bone 
loss but some metastatic cancers can cause increase of bone formation. Breast and prostate 
cancers often metastasise to the bone leading to breaks (osteolytic lesions) or the increase in 
new bone formation (osteoblastic lesion). Cancer cells can secrete parathyroid hormone 
related peptide (PTHrP), which induces osteoclast differentiation via up-regulation of RANK-
L, thereby causing bone destruction (25). Tumour-induced bone resorption, in turn, induces 
the secretion of growth factors from bone which further promotes tumour growth (26). Bone 
destruction also occurs in most patients with multiple myeloma, leukemia, Burkitt’s 
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lymphoma and non-Hodgkins’s lymphoma, in which tumour cells secrete bone-resorbing 
cytokines (25). Severe bone pain, pathologic fractures, spinal cord compression and life-
threatening increases in blood calcium levels can be the consequences of bone destruction 
(26).  
b) Bone loss induced by Glucocorticoids 
Glucocorticoids (GCs) are effective immunomodulatory drugs frequently used to treat 
a wide range of inflammatory conditions including autoimmune diseases, such as RA, asthma, 
allergies and multiple sclerosis. However, several clinical complications including bone loss 
are caused by treatment with GCs (27). Bone loss is commonly noted within the first few 
months of treatment with GCs. With prolonged GC-based treatment a significant reduction in 
bone mass and an increased risk of fracture occurs (28). Treatment with GCs promotes bone 
loss mainly by targeting osteoblasts and reducing their function and promoting their 
apoptosis.  High GC levels induce apoptosis of osteocytes (29) and increase osteoclast 
formation and function by increasing RANK-L expression and decreasing OPG production by 
osteoblasts (27). Treatment with GCs also affects other body processes such reduction of 
calcium resorption in the intestine and an increase excretion in the kidneys. This causes an 
imbalance in calcium levels and a gradual depletion from the bone. In addition, GCs reduce 
sex hormones, which play key roles in bone metabolism (27). 
 
c) Bone loss induced by chronic inflammatory diseases 
Patients with chronic inflammatory joint diseases such as RA manifest periarticular 
bone loss due to erosions, generalised bone loss and are at a higher risk of fractures compared 
with matched healthy controls (30,31). Although, there are multiple causes for bone loss in 
inflammatory diseases, many animal models of arthritis as well as evidence from patients to 
indicate that inflammatory mediators, including TNFα play a major role in local and 
generalised bone loss (32). TNFα, a key cytokine in human inflammatory disorders, causes 
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bone erosions in experimental models and these effects are induced through the induction of 
osteoclasts. RANK, its ligand, RANK-L and OPG are significant mediators in inflammatory 
processes and are critically-involved in the pathophysiology of bone loss (32). Since RA 
represents a typical example of systemic inflammatory diseases that causes significant 
changes in bone metabolism, it will be discussed in more detail. In addition, the key role of 
TNFα plays in bone loss will be further explored.  
 
(i) Rheumatoid arthritis (RA) 
RA is a chronic symmetrical inflammatory destructive joint disease of unidentified 
etiology that affects 0.5-1% of the world’s population. The production of autoantibodies and 
pro-inflammatory cytokines such as TNFα causes chronic inflammation, which leads to joint 
damage, but generalised bone damage is also a feature of the disease (33). Bone damage in 
RA occurs very early in the course of the disease, progresses rapidly and is not repaired as it 
would be under physiological conditions (34). The detrimental effect of chronic inflammation 
on bone is evident in the increase of fracture risks in RA patients; the more inflammation that 
is present the greater the risk of fracture. Indeed, decreases of 2.5% in vertebral and 5% 
femoral neck BMD are apparent just in the first year of RA disease and such loss doubles in 
the second year if disease activity remains uncontrolled (35). With regards to mechanisms of 
bone loss in RA, the available evidence indicates that pro-inflammatory mediators, including 
TNFα, promote osteoclastogenesis. Although the perception has been that bone loss in RA 
due to pro-inflammatory mediators is most likely to be confined to the periarticular region of 
affected joints, emerging evidence from the use of biological anti-inflammatory agents 
provide compelling evidence for their involvement in generalised osteoporosis too. This 
evidence highlights the overlap between inflammatory pathways in RA and mechanisms of 
bone resorption including direct and indirect effects on osteoclastogenesis. Thus, mice 
engineered to lack osteoclasts do not develop bone erosion in arthritis induced by TNFα (36). 
                                                                                                                                   
- 35 - 
 
Further, this appears to occur through the ability of TNFα to induce RANK-L expression of 
T-lymphocytes and osteoclasts (37,38). Indeed, when RANK-L is inhibited, the formation of 
osteoclasts in arthritic joints is inhibited (39,40). Interestingly, however, inhibition of RANK-
L does not appear to have any impact on the inflammatory process (41,42). Thus, a phase 2 
clinical trial of denosumab in RA showed that the agent reduced bone erosion, but had no 
effect on disease activity (43). This data indicates that interfering with the RANK/RANK-
L/OPG pathways have few detrimental effects on the immune system. 
In contrast, data on the effect of biologic inhibitors of inflammation suggests that the 
inflammatory response in RA promotes RANK-L expression and bone resorption, not only in 
the periarticular region, but also generalised bone loss. Support for this notion is provided by 
observations in which treatment with biologic anti-inflammatory agents including anti-TNFα 
agents reduced RANK-L expression and increased OPG production (44). Furthermore, 
treatment of psoriatic arthritis patients with biologic anti-TNFα agents reduced the number of 
peripheral osteoclast precursors (45).  
The association between chronic inflammation and bone erosion in RA is clouded by 
the fact that a significant proportion of patients are treated with glucocorticoids (GCs). GCs 
are used for their anti-inflammatory efficacy, but their long-term use leads to bone loss as 
cited above. Therefore, it has been difficult to discern exactly how much each of these two 
events play in bone loss in RA. In this respect, it is interesting to note that a recent study 
revealed that osteoclast induction in RA is inhibited with a compound modulator of the 
monomer glucocorticoid receptor (46). This compound does not induce glucocorticoid 
receptor dimerisation but suppresses the production of pro-inflammatory cytokines in 
fibroblast-like synovial cells from patients with RA and in osteoblasts (46). This observation 
further highlights the direct relationship between chronic inflammation and bone loss in RA. 
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(ii) Early diagnosis of patients with RA 
 
In recent years, early diagnosis of RA has become feasible. This has been achieved as 
a result of the development of better diagnostic laboratory tests including new more predictive 
biomarkers and refined combinations of radiographic and surgical protocols (47,48). Thus, 
criteria for the diagnosis of RA currently includes the presence of elevated inflammatory 
mediators, erosions detected by radiography, the presence of subcutaneous nodules and 
positive tests for rheumatoid factor (RF) and autoantibodies to cyclic citrullinated peptides 
(CCPs).  Previously, the lack of specific and reliable sensitive biomarkers has meant that 
differential diagnosis of early RA has been difficult. The current clinical approach for RA 
management is to achieve remission and prevent joint and bone damage by applying early 
diagnosis and aggressive early treatment (47,48).  
a) Anti-CCP autoantibodies 
Laboratory tests for anti-CCP autoantibodies are the most relevant among the recently-
employed laboratory measures to aid in the early diagnosis of RA. These autoantibodies have 
a high specificity for RA of ~96% and are different from RF as they are not detectable in the 
blood of healthy individuals nor in patients with other connective tissue diseases. The 
specificity of RA diagnosis reaches ~100% when both RF and anti-CCP are positive in 
patients with early undifferentiated arthritis (49). In addition, recent studies have indicated 
that high levels of anti-CCP autoantibodies can predict disease chronicity and the likelihood 
of developing erosions. However, despite their high specificity, tests for anti-CCP 
autoantibodies are not very sensitive as they are detected only in up to 50% of patients with 
RA (49).  
In addition to their predictive diagnostic values, anti-citrullinated protein antibodies 
(ACPA) have been reported to be associated with bone resorption in RA. These 
autoantibodies help in the migration of cells to the synovium and contribute to the production 
of inflammatory cytokines which stimulate osteoclastogenesis. In addition, a recent study 
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provided evidence for a direct role of these autoantibodies in the stimulation of osteoclasts 
and their precursors independent of inflammation (50). Citrullinated vimentin, a common 
target for autoantibodies found in RA patients, has been shown to be expressed on the cell 
surface of osteoclasts and their precursors where it can be targeted by ACPA (51). The 
binding of ACPA to pre-osteoclasts leads to increased osteoclastogenesis due to the 
production of TNFα which results in increased bone resorption in vitro and in vivo. These 
findings suggest that these autoantibodies can directly influence bone metabolism.  
 
Although treatments that directly target ACPA or B-lymphocytes that produce such 
autoantibodies have not been developed yet, total ablation of B-cells by anti-CD20 
monoclonal antibody (rituximab) has been highly successful and has been approved by the 
National Institute of Clinical Excellence (NICE) for use in treatment of RA patients who have 
not responded to treatment with biologic anti-TNFα agents (50). Rituximab causes B-cell 
depletion and has been shown to lead to a significant reduction in autoantibody levels and 
bone loss after treatment (51).  
 
b) Radiographic procedures for the early detection and assessment of bone 
erosions in RA 
Conventional radiographic procedures are not able to help in the early identification of 
bone erosion in RA because they only show joint damage. However, the use of MRI has made 
it possible to detect early inflammatory changes in RA synovia including synovitis and joint 
effusion. Using MRI, bone erosions can be seen within the first four months of the onset of 
disease symptoms (52). However, there are some disadvantages with the routine use of MRI 
including limited availability, long times for investigation and high costs (53). 
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c) Ultrasound (US) techniques 
The application of US for assessing disease in patients with RA includes monitoring of 
response to treatment and for guiding intra-articular procedures. In recent years, US was 
widely used for the evaluation of the response to treatment with different drugs, especially in 
patients treated with biological therapies (54). The usefulness of joint examination by US has 
been evident in enabling early diagnosis of patients with undifferentiated arthritis (55). Active 
inflammatory changes such as synovitis and increased synovial blood flow can be detected 
using the Doppler ultrasound technique. This technique is more sensitive than clinical 
examination, especially for evaluating synovitis in early RA and is better than X-ray 
radiography for detecting erosive changes (55).  Furthermore, US is a quick, inexpensive and 
bedside imaging technique are accepted by young patients as it does not require anaesthesia, 
as with magnetic resonance, and does not involve radiation (56). 
 
(iii) Bone loss in RA: The role of the TNFα  
 
TNFα is a pleiotropic cytokine that affects a range of biological responses, cells, 
tissues and organs including the immune system (Figure 1.5) (57). In response to injury or 
infections, TNFα is initially produced by macrophages. This helps the immune system mount 
a response to the injury/infection and amplify the response further by attracting and activating 
adaptive immune cells and relevant proteins to the site resulting in acute inflammation. TNFα 
achieves its pro-inflammatory and immune effector functions by promoting lymphocyte and 
neutrophil adhesion, haemopoiesis, collagenase and prostaglandin E2 production and the 
induction of other pro-inflammatory cytokines. TNFα also contributes to proteoglycan 
breakdown, acute tubular necrosis and bone resorption (8).  
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Figure 1.5: Biological responses effected by TNFα.  A cartoon summarising the 
wide ranging effects of TNFα on cells, organs and tissues. The outcome of TNFα 
binding to its receptors on its targets is indicated. The figure is drawn based on 
information published in reference number (57). 
 
 
a) Osteoclastogenic effects of TNFα  
Bone resorption results from the activation of NF-κB transcription factor. NF-κB is 
primarily an inflammatory response transcription factor that is induced, amongst other 
stimuli, by RANK/RANK-L signaling. Activation of NF-κB is a key target for TNFα 
signaling through TNF receptor 1 (TNFR1), which is expressed on macrophages and 
osteoclast precursors. In this respect, TNFα is an established inducer of osteoclast formation 
and bone resorption (58). Thus, TNFα can promote the differentiation of pro-osteoclasts into 
mature osteoclasts even in the absence of signaling through RANK (59). Moreover, it has 
been shown that TNFα enhances osteoclast differentiation indirectly by increasing the 
expression of M-CSF and RANK-L in osteoblasts during inflammation (60). Furthermore, 
TNFα inhibits osteoclast apoptosis by activating the mammalian target of rapamycin/S6 
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kinase (mTOR) (61). These processes lead, ultimately, to increased bone resorption due to 
increases in the number and, potentially, long-lived osteoclasts in pro-inflammatory 
conditions (Figure 1.6). 
 
 
      
Figure 1.6: Pathways of bone loss influenced by TNFα. TNFα promotes 
osteoclastogenesis by directly activating macrophage and the differentiation of pre-
osteoclast. It also activates mature osteoclasts and inhibits apoptosis. TNFα also 
promotes bone degradation through inducing IL-6 and RANK-L production. Finally, 
TNFα suppresses osteoblastogenesis by inhibiting the proliferation and 
differentiation of mesenchymal stem cell (MSCs) into osteoblasts. TNFα also 
promotes osteoblast apoptosis. The Figure is adapted from reference number (60). 
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b) The effects of TNFα on osteoblastogenesis 
Excess TNFα production has been shown, both in in vitro and in animal models, to 
inhibit the proliferation and differentiation of osteoblasts and to promote their apoptosis. 
These effects appear to be induced through the TNFR1 and the activation of NF-κB, which is 
also involved in inhibiting osteoblast differentiation and activity (62-64). TNFα inhibits 
osteoblasts differentiation through reduced osterix expression, a key regulator of the initial 
stages of osteoblast differentiation (65). Furthermore, it has been reported that inhibition of 
the Wnt-β-catenin pathway by TNFα promotes the upregulation of the Wnt inhibitor, 
Dickkopf-related protein 1 (DKK1) (Figure 1.7) (66,67).  
 
In general, TNFα induces its biological effects by binding to either of its two cell-bound 
receptors, TNF-RI and II. It binds to these receptors and induces its biological effects as a 
trimeric molecule and initiates a cascade of signaling pathways. The two TNFα receptors can 
also be activated by lymphotoxin α (LTα), which has a similar structure and biological 
activities to TNFα. Soluble forms of the two TNFα receptors are, however, known to act as 
endogenous TNFα inhibitors including inhibiting bone resorption (8). Therefore, therapeutic 
inhibitors of TNFα have been believed at the outset to have a beneficial effect on BMD 
reduction and bone erosions in RA (68). This proposition has been verified by the use of 
biologic anti-TNFα agents in clinical practice to treat patients with RA. Currently, there are 3 
main biologic anti-TNFα agents routinely used in the clinic. These biologic anti-TNFα agents 
are more effective when used in combination with methotrexate. 
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Figure 1.7: TNFα promotes bone loss through impacting and activating a 
number of osteoclastogenic pathways and the production of proteins. TNFα 
promotes bone resorption through enhancing osteoclastogenesis and RANK+ 
osteoclast precursor cell proliferation. It also induces RANK-L production. TNFα 
also inhibits osteoblast maturation and function, in part, by increasing the expression 
of the Wnt antagonist DKK1 resulting in impaired bone formation. The figure is 
based on information published in reference number (62). 
 
 
1.6.2) Osteopetrosis 
Osteopetrosis is a group of rare genetic bone-remodelling disorders characterised by the 
failure of osteoclasts to resorb bone, leading to increased bone density. The reduction of bone 
resorption is a result of mutations that affect osteoclast function and formation. Many gene 
mutations of osteopetrosis have been demonstrated in molecular genetic studies. All of the 
identified gene mutations are encoded in proteins that engaged in bone loss controlled by 
osteoclasts (69).  
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1.6.3) Paget’s disease 
Paget’s disease is a chronic bone remodelling disorder characterised by high bone 
turnover, leading to unbalanced bone formation and resorption (70). Paget’s disease is thought 
to be a result of abnormal activation of osteoclasts, to which there is an observable increase in 
osteoblastic activity. Therefore, bone density is increased in Paget’s disease, however, 
because of the irregular bone pattern, the strength is reduced and fractures may occur. 
Furthermore, Paget’s disease has a genetic component that may increase frequency of 
osteosarcoma in the affected areas of the bone (70). 
 
1.7) Treatment of patients with osteoporosis 
  The aim in treating patients with osteoporosis is to inhibit and/or restrict the activity of 
osteoclasts, the enhancement of osteoblast activity and the regulation of bone marrow 
adipogenesis. The ultimate objective is to reduce risk factors of bone fracture. At present, key 
classes of agents include anti- resorption agents, which target osteoclasts and anabolic agents 
which modulate osteoblasts. There are three classes of drugs currently in use for treating 
osteoporosis: hormone replacement therapy (HRT), selective oestrogen receptor modulators 
(SERMs) and bisphosphonates.  
a) Hormone replacement therapy (HRT) 
HRT is used to reduce chances of osteoporosis and fractures occurring in postmenopausal 
women. HRT helps to avoid discomfort and health problems caused by reduced circulating 
oestrogen and progesterone levels. The binding of oestrogen to its receptors in bone 
stimulates the proliferation of osteoprogenitors and osteoblast-like cells and enhance the 
production of growth factors. The productions of hormones that influence bone metabolism 
(vitamin D3, parathyroid hormone, and calcitonin) are also stimulated by oestrogen (71). The 
use of HRT has been controversial, however, as risks of HRT may surpass its benefits. For 
example, a number of studies have shown that HRT could increase the risk of breast cancer, 
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thromboembolism and cardiovascular disease. Nevertheless, HRT is effective in preventing 
osteoporosis and, thus, reduces the risk of fractures (71-74).  
  
In order to obtain the greatest beneficial effects of HRT on bone status, treatment with HRT 
needs to start before the age of 60 and to be taken for at least 5 years. Generally, the effect of 
HRT on bone varies with dose and dosage requirement varies with age. A typical dosage of 
40-60pg/ml slows down the rate of bone resorption. This translates to a 5-10% increase in 
BMD within 1-3 years regardless of the time since menopause (71,73). 
 
b) Bisphosphonates 
Bisphosphonates are used clinically to inhibit resorption through a mechanism that differs 
from that of other anti-resorptive treatment (75). Bisphosphonates bind to hydroxyapatite 
binding sites on bony surfaces, particularly areas exposed to active resorption. When bone 
resorption is mediated by osteoclasts, bisphosphonates reduce the ability of osteoclasts to 
create ruffled borders, to stick to the bony surface and to secret proteins required for 
continued bone resorption. Furthermore, bisphosphonates reduce the number of the 
osteoclasts and their activity by promoting their apoptosis (75,76). 
 
There are many generations of bisphosphonates, all of which are synthetic analogues of 
cellular inorganic pyrophosphonates. The first generation includes non-nitrogen containing 
agents whereas the latest generations are aminobisphosphonates that are administered orally 
or intravenously (77).  
 
Bisphosphonates are also used for the treatment of patients with metastatic bone disease 
resulting from breast cancer to reduce fractures and hypercalcemia. Alendronate (Fosamax) 
and risedronate (Actonel) are the most commonly used bisphosphonates in clinical practice. 
Both have been shown to increase bone mass and significantly reduce fracture risks by 
approximately 50% in the spine and 30% at other sites in patients. However, as with other 
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drugs, bisphosphonates has side-effects, such gastrointestinal tract disturbance and, more 
seriously, as osteonecrosis of the jaw (77,78).   
 
Recent studies of bisphosphonate use have revealed additional effects for this class of 
drugs. For example, a study by Kobayashi and colleagues of Japanese patients reported 
inhibitory effects by bisphosphonates on glucocorticoid-induced RANK-L expression in 
human cells (79). These investigators concluded that bisphosphonates, but not non-steroidal 
anti-inflammatory drugs (cyclooxygenase inhibitors) suppressed RANK-L upregulation. In 
addition, a study by Valleala and colleagues reported that recurrent cyclical therapy of the 
bisphosphonate (Etidronate) has a beneficial effect on general bone metabolism as indicated 
by reduced serum levels of both N-terminal propeptide (PINP), an indicator of bone 
formation, and crosslinked C-telopeptide (ICTP), a marker of collagen degradation (80). 
Etidronate did not, however, prevent radiographic progression in patients with inflammatory 
disease such as RA. 
 
c) Selective oestrogen receptor modulators (SERMs) 
SERMs are used for their ability to bind oestrogen receptors and act either as 
oestrogen-agonists, or as oestrogen-antagonists depending on the targeted tissue and 
hormonal status. The first generation of SERM was tamoxifen, for which oestrogen-like 
agonist activity on bone was seen to occur at the same time with oestrogen antagonist activity 
on the breast. A drawback of tamoxifen use has been its oestrogen-like action on the 
endometrium. Second-generation SERMs have since been developed, such as raloxifene, 
which has oestrogen-like actions on bone, lipids and the coagulation system and oestrogen 
antagonist effects on the breast and uterus. Raloxifene has been used as an alternative to HRT 
in the treatment of osteoporosis without deleterious effects on the endometrium. The effect of 
raloxifene is dependent on dosage. Patients on raloxifene have a significant increase in BMD 
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at the lumbar spine, hip and whole body. Raloxifene can also cause a decrease in total 
cholesterol and LDL levels, with added benefits for patients with cardiovascular risk (81,82). 
d) Calcitonin (CT) 
CT is an endogenous polypeptide hormone that suppresses osteoclast-mediated bone 
resorption. It binds to its receptor on osteoclasts, leading to a fast loss of the osteoclast’s 
ruffled border, termination of motility and suppression of the ability of osteoclasts to release 
essential enzymes and protons that partake in bone resorption. The reduction of osteoclast 
bone resorption by calcitonin is dose-dependent but is not paralleled by a reduced activity of 
osteoblasts (83). Similarly to oestrogen, CT promotes an increase in bone mass, enhances 
intestinal calcium absorption and has a positive effect on calcium balance (17). 
 
The analgesic effects of CT have added beneficial effects for patients treated with 
hormones. Calcitonin can be administered either by injection or as a nasal spray. Injections 
of CT are normally given only as a short-term treatment for painful vertebral fractures, but the 
nasal spray may be used as a long-term treatment for osteoporosis (84). However, serious 
allergic reactions have been reported and skin testing before treatment should be considered 
(85). Injected calcitonin may cause hypocalcemic tetany and parenteral calcium is recurrently 
required during the first several administrations. Possible side effects of the nasal spray 
include hot flushes, nausea and blocked or runny nose (84). A Food and Drug Administration 
(FDA) advisory group advised that the CT benefits in postmenopausal osteoporosis is 
uncertain and is associated with serious side effects (86). A newly developed oral formulation 
of CT has been shown to have increased efficacy in phase II and III clinical trials. The 
introduction of this new formulation is likely to enhance patient compliance as it has fewer 
side effects (87,88). 
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e) Teriparatide (Forsteo) 
  Teriparatide is the first bone anabolic agent with established anti-fracture effects and an 
acceptable safety profile (89). It is a polypeptide synthesised using recombinant DNA 
technology and functions as an active part of human parathyroid hormone (PTH). PTH is the 
key regulator of calcium/phosphate metabolism in the bone and kidneys.  
  
Unlike anti-resorption agents, teriparatide increases bone formation, cortical thickness and 
trabecular bone connectivity (90). However, due to excessive new bone formation and 
osteosarcoma in long-term toxicology studies in rats, this treatment has been limited to a 
maximum of 24 months until further data is available (91). At present, teriparatide is used 
mainly as a final treatment option for established osteoporotic patients, particularly patients 
who have had fractures despite using other treatments (92). 
 
f) New anti-osteoporosis therapies 
Denosumab is an effective anti-resorptive agent that was approved recently by the FDA 
for treatment of postmenopausal women at high risk of fracture and to increase bone mass in 
patients who are at high risk for fracture due to treatments as in patients with cancer and 
patients with chronic inflammatory diseases such as RA. The agent is injected subcutaneously 
with long dosing intervals and no limitations relating to renal function. Denosumab is a fully 
human monoclonal antibody that binds to and inhibits RANK-L. When denosumab binds to 
RANK-L, it prevents RANK-L–RANK interaction in much a similar way to OPG, causing a 
reduction in osteoclast-mediated bone resorption (93). 
There has been an ever-increasing number of studies to show that denosumab increases BMD 
levels and reduces bone turnover biomarker levels in postmenopausal women with low BMD. 
It also increases BMD greater than alendronate does and decreases fracture risk at the lumbar 
spine, non-vertebral sites and the hip (94,95). 
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1.8) Biologic anti-inflammatory agents and their effect on bone loss in RA 
 
a) Etanercept 
Etanercept was the first biological agent to be approved for the treatment of patients with 
RA and, subsequently, for refractory juvenile RA. It is a recombinant dimeric form of the 
soluble TNFα receptor II that binds with high affinity to and inhibits the activity of both 
TNFα and LTα (8). It is administered subcutaneously twice weekly. In 2004, the TEMPO 
study reported that the combination of methotrexate and etanercept at 25mg twice weekly, 
resulted in improvement in disease activity and reduced bone erosion (96). Thus, 37% of the 
patients had improved DAS28 scores while 80% had no signs of joint damage (96,97). 
  
b) Infliximab 
Infliximab is a chimeric mouse-human monoclonal antibody that binds to and neutralises 
TNFα. Infliximab was initially approved for treatment of Crohn’s disease, but was 
subsequently used for the treatment of patients with RA, mostly in combination with 
methotrexate. Clinical evidence consistent with a beneficial effect of infliximab on BMD has 
started to appear in recent years (98,99). One of these studies was a case-control trial by 
Marotte and colleagues in which 99 patients with RA treated with infliximab had evidence for 
maintaining BMD in the lumbar spine and femoral neck after 1 year (99). In contrast, bone 
loss of 3.9% and 2.5% was seen at the same sites in the control group treated with 
methotrexate alone. Changes in biomarkers of bone turnover from baseline, or between 
groups, however, were not significantly different (99). 
c) Adalimumab 
Adalimumab is a parenterally-administered fully human monoclonal antibody which binds 
and neutralises TNFα. In a study by Weinblatt and colleagues, it was observed that the use of 
adalimumab in combination with methotrexate resulted in significant improvement in the 
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American College of Rheumatology 50 (ACR50) and DAS28 scores indicative of remission 
with significantly less radiographic disease progression (100).   
 
Although the introduction of biologic anti-TNFα agents has largely revolutionised the 
treatment of RA, a proportion of patients do not respond to these agents (around 35-40% at 
the end of 6 months) (101), experience toxicity or have contraindications such as cancers or 
previous TB.  
 
d) Rituximab 
Due to the key role B-lymphocytes play in the pathogenesis of RA, including acting as 
antigen presenting cells, activating T-cells and producing RF and anti-CCP autoantibodies, 
the depletion of these cells was used as another approach for treating RA patients. Rituximab 
is a chimeric human-murine monoclonal antibody that depletes B-cells by binding to CD20 
on the surface of B-cells. In clinical trials, rituximab was shown to be efficacious in treating 
patients with RA (102,103). Rituximab was approved 4 years ago in NICE for use in 
combination with methotrexate for the treatment of patients with RA who are refractory to at 
least one biologic anti-TNFα agent.  
Rituximab is administered by intravenous infusion on two separate occasions 14 days 
apart. The difference between biologic anti-TNFα agents and rituximab is that the latter is not 
associated with an increased risk of TB re-activation and previous history of cancer is not a 
contraindication. Emerging evidence indicates that rituximab substantially reduces 
autoantibody levels and bone loss in RA (104). Mechanistically, treatment of patients with 
rituximab decreases synovial osteoclast precursors and RANK-L expression and increases 
OPG/RANK-L ratio in blood (105,102). 
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e) Abatacept 
Abatacept was recently introduced for the treatment of patients with RA. It is a selective 
inhibitor of cognate T-lymphocyte interaction with other immune cells. It is a recombinant 
fusion protein composed of the Fc region of human IgG1 and the extracellular domain of 
cytotoxic T-lymphocyte antigen 4 (CTLA-4). Abatacept binds with high avidity to CD80 (B7-
1), CD86 (B7-2) and blocks their engagement with CD28 and T-lymphocyte activation. 
Clinical trials of abatacept in patients with RA have so far shown that patients refractory to 
methotrexate and biologic anti-TNFα agents respond well and have good ACR20 response 
rates at 6 months to 1 year. Moreover, the clinical response is maintained for up to 3 years 
(106). 
 
In addition, studies using dynamic contrast enhanced (DCE) MRI and arthroscopy-
acquired synovial biopsies have shown 15-40% improvement in MRI parameters together 
with increased plasma levels of OPG and reduced RANK-L in RA patients treated with 
abatacept (107). However, there are reports of higher rates of infection in abatacept-treated 
patients compared with patients treated with combination therapy involving biologic anti-
TNFα agents and methotrexate (106). Recently, NICE approved the use of abatacept in RA in 
patients who have failed anti-TNFα therapy and are unable to receive rituximab, or have 
failed rituximab as a result of a side-effect/poor tolerability. 
f) Tocilizumab 
Tocilizumab is a monoclonal anti-interleukin 6 receptor (IL-6R) antibody that blocks IL-6 
binding and disrupts the action. The AMBITION study evaluated the efficacy and safety of 
tocilizumab monotherapy versus methotrexate in patients with active RA refractory to 
methotrexate/biologic agents (108). The investigators concluded that tocilizumab 
monotherapy was more effective than methotrexate monotherapy leading to quick 
improvement in disease signs and symptoms and a favorable benefit-risk in patients for whom 
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treatment with methotrexate or other biological agents has previously failed (108). More 
recent evidence indicates that tocilizumab promotes the repair in bone erosions, particularly in 
large lesions with sclerosis (109). 
g) Anakinra 
Anakinra is a recombinant human interleukin-1 receptor (IL-1R) antagonist licensed for 
the treatment of patients with RA. In clinical trials, anakinra considerably reduced 
radiographic progression in RA patients compared with placebo. Furthermore, anakinra 
significantly decreased clinical symptoms of the disease when used as monotherapy, or in 
combination with methotrexate and it has been suggested that the agent protects bone and 
cartilage from progressive destruction in RA (110,111). However, more studies are needed to 
evaluate safety and efficacy of the agent. 
In addition to the above cited therapies, a range of new biologic agents have recently been 
developed for treating inflammatory conditions such as RA. These include a number of 
biologic anti-TNFα agents, such certolizumab pegol and gloimumab which were shown to be 
highly effective in treating patients with RA. Certolizumab pegol is characterised by rapid 
onset of action, longer half-life and reduced antigenicity compared with other biologic anti-
TNFα agents. Since certolizumab pegol only contains of the Fab fragment (antigen binding 
fragment) of the anti-TNFα antibody and lacks the IgG FC fragment, it does not activate the 
complement system nor induce antibody-mediated cellular cytotoxicity (112).  
 
Golimumab is a completely humanised monoclonal antibody shown to be effective in 
treating RA patients who fail other biologic TNFα agents. Golimumab has the advantage of 
being administered once monthly, subcutaneously or intravenously (113). A significant 
improvement in synovitis and bone erosion has been reported after a treatment with a 
combination therapy consisting of golimumab and methotrexate as compared with 
methotrexate alone (114).  
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In addition to the established effects of TNFα, IL-1 and IL-6 on inflammation and bone 
loss, several other cytokines such as IL-15, IL-17, IL-32, lymphotoxins and B-lymphocyte 
stimulator (BlyS) could play roles in sustaining the inflammatory process and bone loss in 
RA. Each of these cytokines, therefore, presents a potential target for therapy. Furthermore, 
other than such drugs that target cytokines and receptors, small inhibitor molecules, such as 
kinase inhibitors, which target intracellular kinases involved in signal transduction, are also 
currently being assessed (115). In summary, in the next few years there will be new avenues 
for the development of novel therapies of RA and its associated bone erosions and joint 
destruction. 
 
1.9) The relationship between Osteoporosis and RA 
 
As cited above, osteoclast activation is controlled by three principle components 
whose levels are influenced by TNFα: RANK, RANK-L and OPG. Higher levels of TNFα 
with inflammatory arthritides are associated with pathological changes to the bone. In RA, the 
pathological hallmark, however, is joint destruction with erosion of the bone, as a 
consequence of activated immune cells in the synovium which also promote osteoclasts 
generation and activation through TNFα signaling (116).  
 
Although the effect of TNFα, produced by activated T-cells and monocytes, in 
osteoporosis driven by inflammatory conditions, or by infection is well recognised, only 
recently the role of TNFα in the postmenopausal and senile osteoporosis, as well as bone loss 
caused by a variety of endocrine conditions has begun to be recognised (117). The 
pathogenesis of bone loss in osteoporosis is multi-factorial; however, aging and menopause 
are the two key determinants of osteoporosis. In vitro and in vivo, oestrogen plays a protective 
role against osteoporosis via suppression of TNFα, IL-1 and IL-6 expression (117). Decreased 
production of TNFα, IL-1 and IL-6 has been reported in cultures of mononuclear cells derived 
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from either oestrogen-treated postmenopausal women with osteoporosis, or untreated 
premenopausal women. However, elevated levels of TNFα and IL-1 were reported in cultures 
of mononuclear cells derived from ovariectomised premenopausal women and osteoporosis 
patients (117). Elevated TNFα promotes osteoclast differentiation and activation by inducing 
RANK-L expression, suggesting an association between TNFα in postmenopausal women 
and osteoporosis too (118). Furthermore, knockout mice deficient in either TNFα or TNFα 
receptor I are resistant to ovariectomy-induced bone loss (119), indicating that TNFα a key 
player in oestrogen deficiency-induced bone loss (120). In addition, T-cells have been 
reported to play an essential role in regulating bone loss induced by oestrogen deficiency 
through their ability to produce TNFα (117) (Figure 1.8). T-cell- deficient nude mice and wild 
type mice in whom T-cells have been deleted are protected from ovariectomy-induced bone 
loss (120). This observation reinforces the proposition that circulating T-cells are the major 
source of oestrogen-regulated TNFα. In general, the available evidence confirms the 
involvement of TNFα in both of postmenopausal and RA related osteoporosis. Further, 
neutralisation of TNFα protects oestrogen deficiency-induced bone loss, which supports the 
hypothesise that neutralisation of TNFα could prove an efficient strategy in the treatment of 
inflammation-related osteoporosis in the future.  
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Figure 1.8: The known roles of activated T-cells in promoting bone loss. Pro-
inflammatory cytokines such as TNFα, IL-1 and IL-17 that are produced by T-cells 
induce RANK-L expression in osteoblasts and osteoclast differentiation from 
progenitors via RANK-L-RANK engagement and signaling leading to bone 
resorption. The soluble decoy receptor for RANK-L, OPG, blocks both pathways 
which could be a potential therapeutic approach for patients with osteoporosis and 
RA. The Figure is obtained and redrawn from reference number (121).  
 
 
1.10)   Reduced bone loss in patients treated with biologic anti-TNFα agents  
 
Randomised controlled trials have shown that biologic anti-TNFα agents delay 
radiographic joint destruction (122,123). These findings raise possibility that these agents also 
have the ability to prevent generalised bone loss in the spine and hip and local bone loss in the 
joints in patients with RA.  
Lange and colleagues studied 26 patients (19 women) with persistently active RA 
(duration of 9.8 years) who were treated with biologic anti-TNFα agents (124). After 12 
                                                                                                                                   
- 55 - 
 
months of treatment with infliximab these investigators observed that there was a significant 
increase in BMD at the femoral neck (0.84±0.33 to 0.95±0.15g/cm2) and the spine (1.07±0.14 
to 1.10±0.23g/cm2). In addition, there was a trend for a correlation between improvement in 
BMD and reduced in DAS28 but not with changes in biomarkers of bone remodelling (124). 
In another study of 102 patients, 53 years of age on average, including 82 females with active 
and severe RA treated with infliximab for 1 year, spine and hip BMD were unchanged (125).  
The Behandel–Strategieen (BeSt) study prospectively compared the efficacy of 4 
treatment strategies in RA: sequential monotherapy of several disease modifying anti-
rheumatic drugs (DMARDs), step-up combination therapy, initial combination therapy with 
tapered high-dose prednisone and initial combination therapy with infliximab (126). These 
investigators reported that there were no significant changes in BMD after 1 year. Of 
importance is the strategy that underpinned this study: sequential assessment of patients with 
therapies aiming at complete control of inflammation. Other studies of biologic anti-TNFα 
agents reported that reduction of bone loss was associated with improvement in disease 
activity and a reduction in inflammation (100,125,127,128). These observations indicate that 
effective control of inflammation, rather than any specific drug therapy, is a likely mechanism 
by which bone loss is prevented. 
 
Despite accumulating evidence for improvements in radiographic progression of RA 
disease in patients treated with biologic anti-TNFα agents, especially etanercept and 
infliximab, the exact mechanism by which bone loss is reduced or prevented remains 
unknown. One study by Catrina and colleagues examined the effect of treatment with biologic 
anti-TNFα agents on the expression of OPG and RANK-L in synovial tissues of RA patients 
(129). These investigators established that treatment with infliximab or etanercept altered the 
ratio of OPG to RANK-L by osteoblasts and endothelial cells in ex vivo RA synovial biopsies 
and cultured cells. The investigators concluded that biologic anti-TNFα agents slowed down 
the development of RA-related joint damage and bone loss (129). Other recent studies have 
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suggested that bone loss in RA can be prevented by the combination of biologic anti-TNFα 
agents and systemic recombinant OPG administration (8,130). The efficacy of combination 
therapy with OPG and biologic anti-TNFα agents on inflammation and bone erosion was also 
studied in collagen-induced arthritis models in mice using urinary deoxypyridinoline, BMD 
measurements and histological scoring (130). These studies suggested that combination 
therapy with OPG and biologic anti-TNFα agents acts through multiple pathways to decrease 
bone resorption and maintain bone formation and, therefore, prevent loss in inflammatory 
diseases (130). 
 
In addition to the above cited studies, the effect of treatment of RA patients with 
biologic anti-TNFα agents on bone turnover biomarkers was studied. Osteocalcin (a bone 
formation biomarker) was considerably increased in 6 studies involving treatment of patients 
with biologic anti-TNFα agents (124,125,131-134). Three studies reported no changes in 
osteocalcin levels (99,135,136). Studies of the level of CTX (a biomarker of bone resorption) 
revealed that the level of this biomarker decreased in 5 of the studies (124,125,136-138) while 
another 2 studies reported that the level remained unchanged (99,134). The level of soluble 
RANK-L and OPG in RA patients treated with biologic anti-TNFα agents was also studied. 
Published reports indicate inconsistencies in the level of soluble RANK-L between no change 
(122) to reduction after treatment (125, 139). For OPG, levels are also noted to be consistent 
in (125,133) but reduced in another (139).  
Earlier studies of the effect of biologic TNFα antagonists on bone loss in RA have, at 
times, been contradictory because of patient heterogeneity and how baseline levels of BMD 
and which biomarkers were measured. Most studies have focused on studying the effect of 
treatment with infliximab with limited data on changes in bone loss or erosions. In addition, 
many studies do not indicate whether patients assessed were on potentially relevant 
medications, such as calcium or Vitamin D supplementation. This is important as these may 
impact changes in bone turnover. Several studies reported data only on baseline use of 
                                                                                                                                   
- 57 - 
 
corticosteroid and DMARDs without indications about alterations to dosages of these agents 
during the study, clinical change or adverse events. In addition, for most studies, the periods 
covered were in general less than 54 weeks which is relatively short for follow up studies of 
changes in bone turnover. Moreover, most of these studies didn’t evaluate the effect of 
treatment with biologic anti-TNFα agents on fractures but were involved in measuring bone 
loss in the spine and hip but not in the hands. For these reasons, the current study was 
conceived to use a range of clinical procedures and biomarkers to assess changes in bone. 
These include DEXA scans to measure generalised bone loss in lumbar spine and hip, digital 
X-ray radiogrammetry (DXR) to measure localised bone loss in hands and ELISAs to 
measure changes in bone turnover biomarkers including osteocalcine and CTX and bone 
metabolism biomarkers including OPG and RANK-L.  
The key pro-inflammatory cytokines TNFα, IL-1, IL-6 and IL-17 have effect on bone 
metabolism and have been known to induce generalised bone loss and subchondral bone 
resorption in arthritis. These pro-inflammatory cytokines act on osteoblasts to promote 
RANK-L expression and, thus, stimulate osteoclastogenesis (140-143). Furthermore, 
inflammatory osteoclastogenesis can be induced by granulocyte-macrophage colony-
stimulating factor (GM-CSF) which plays an important role in the differentiation of 
osteoclasts from its precursors (144,145). In addition, IL-20 and IL-22, which are members of 
the IL-10 cytokine family, have been shown to enhance RANK-L expression with the net 
effect being a rise in osteoclast formation and function (146,147).  All these cytokines that are 
involved in bone resorption have been assessed in the current study. In addition, the current 
study will explore new insights into the anti-catabolic effects of neutralising TNFα on bone 
tissues and determine how the level of osteoclast precursors (OCPs), RANK, RANK-L and 
OPG are affected by the treatment. 
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Hypothesis of the study 
The hypothesis that underlies the current study is that treatment of RA patients with 
biologic anti-TNFα agents reduces localised as well as generalised bone loss in the patients. If 
this proves to be correct, the data would, thus, suggest that there are clear overlaps between 
mechanisms that sustain chronic inflammation and those that drive osteoporosis. Because of 
the manner in which disease activity is measured in RA, with DAS28, improvements in bone 
turnover in RA may, or may not, be consistent with changes in the DAS28. Furthermore, it is 
likely that not all patients will show similar improvements due to a range of factors such as 
ethnic origin and lifestyle effects on bone loss. This study, therefore, is aimed at assessing the 
effect of age, gender, ethnic origin and lifestyle on bone loss given limitation on the number 
of patient recruitment to determine the link between inflammation and bone loss in RA.  
 
Aims and objectives 
Current studies provide compelling evidence for beneficial clinical response of the 
majority of patients with RA to treatment with biologic anti-TNFα agents. Thus, there is clear 
evidence for therapeutic efficacy of these agents on inflammation and improvement in the 
overall clinical response as measured by DAS28 in 60-70% of RA patients. However, there 
have been efforts at the re-appraisal of the clinical value of some of the subjective measures 
of responsiveness to biologic anti-TNFα agents in favour of more objective measures 
including improvement in bone metabolism and joint damage. There is, therefore, a need to 
assess if changes in bone density and erosion could be of higher, or of additional value to 
assess clinical responsiveness to biologic anti-TNFα agents. Furthermore, evidence that 
changes in key inflammatory cytokines including TNFα, IL-1, IL-6, IL-17, IL-20, IL-22 and 
GM-CSF promotes osteoclastogenesis but their role in bone turnover needs to be assessed in 
RA patients. There is also a need to determine if all RA patients treated with biologic anti-
TNFα agents show improvement in their bone turnover and, if not, determine the factors that 
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influence such a lack of responsiveness in some patients. The aim of the study is to assess the 
effect of treatment with biologic anti-TNFα agents on bone metabolism in responder and non-
responder RA patients in relation to the inflammatory response. The effect of age, gender, 
ethnic origin, lifestyle and the key inflammatory cytokines on changes in bone metabolism 
will be assessed in responder and non-responder RA patients.  
To achieve these objectives the study will:     
1- Verify whether, or not, beneficial clinical response to biologic anti-TNFα agents as 
measured by DAS28 corresponds with parallel improvement in bone density/erosion 
and turnover in RA patients.  
2- Incorporate the effect of age, gender, ethnic origin and lifestyle on the degree of 
changes in bone density after treatment into any such findings. 
3- Assess if excess production of pro-inflammatory cytokines in RA patients 
corresponds with a lack of, or reduced, improvement in bone density and erosion.  
4- Assess potential biomarker(s) that best demonstrates improvement in bone density 
in RA patients treated with biologic anti-TNFα agents. 
5- Analyse the effect of biologic anti-TNFα agents on the frequency of circulating 
OCPs cells in both in vivo and in vitro and correlate the data with the clinical response 
and with changes in biomarkers of bone turnover. 
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         Patients and Methods 
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2.1) Patients  
To assess key factors that affect BMD and the response of patients to treatment, the 
effect of age, gender, ancestral origin and some aspects of lifestyle in a cohort of 647 patients 
with primary osteoporosis attending the osteoporosis clinics at the Royal London and St 
Bartholomew’s Hospitals was studied. The patients included 533 females, 114 males with a 
mean age (±SD) of 68.3±11.6 years (51-87 years) (Figure 2.1) . Information on the smoking 
habits of most of the patients was available with 121 of the cohort confirmed to be smokers. 
 
The study also involved recruiting 117 RA patients who were prescribed treatment 
with biologic anti-TNFα agents (Figure 2.1). These patients were studied to assess the effect 
of treatment with this class drugs on BMD at lumbar spine and the hip. The cohort included 
62 patients on whom radiological data was available on their BMD before treatment with 
biologic anti-TNFα agents and at 2 years after treatment. This specific group included 49 
females and 13 males. The mean age of patient group was 69±12 years (40-79 years). All 
patients had active disease (mean DAS28±SD of 5.96±1.2) at the time they were prescribed 
biologic anti-TNFα agents.  
A another of 55 patients within the cohort of RA patients were studied to assess the 
status of their immune system including T- and B-lymphocyte and monocyte production of 
cytokines, plasma levels cytokines that have an effect on bone metabolism and also for the 
measurement of bone turnover biomarkers. The level of the following cytokines: IL-1β, IL-2, 
IL-6, IL-8, IL-10, IL-12, IL-17, IL-22, IL-23, GM-CSF, INFγ, MCP-1 and TNFα as produced 
by T- and B-lymphocytes and monocytes enriched from the blood of the patients and then 
activated ex vivo were studied. The blood samples were obtained immediately before and after 
1 and then 3 months after treatment with biologic anti-TNFα agents. Plasma levels of the 
following cytokine and bone turnover biomarkers from the same patients were also 
determined in this group of patients: TNFα, IL-1, IL-6, IL-17, IL-20, IL-22, GM-CSF, 
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RANK-L, OPG, osteocalcin and CTX. The 55 patients included 41 females and 14 males 
with a mean ±SD of age (range) of 57±14 (24-79) years. The mean ±SD of DAS28 of the 
patients was 5.8±0.8 at the time they were prescribed the anti-TNFα agents. BMDs of lumbar 
spine and hip were determined together with DXR for 10 of the patients.  
 
The effect of treatment with the biologic anti-TNFα agents on the circulating levels of 
blood osteoclast precursors cells (OCPs) in both ex vivo and in vitro experiments was also 
studied in 8 RA patients. Blood samples from the 8 patients were obtained immediately 
before treatment with the biologic anti-TNFα agent had started and at 1 and then 3 months 
after treatment. Blood mononuclear cells (PBMNCs) were isolated from these patients and 
studied by FACS analysis for ex vivo levels of the OCPs or cultures as described later. The 
patients included 7 females and 1 male with a mean ±SD age (range) of 54±17 (24-77) years. 
The mean ±SD of DAS28 of the patients was 5.4±0.9 at the time they were prescribed the 
treatment. This study also included obtaining blood samples from12 healthy individuals with 
a mean ±SD age (range) of 45±12 (27-62) years. All healthy individuals were males. 
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Figure 2.1: Flowcharts of the studies involved in this thesis. 
 
2.2) Methods     
2.2.1) Dual energy X-ray absorptiometry (DEXA) 
A Hologic Discovery QDR series Dual Energy X-ray Absorptiometry (DEXA) 
scanner located at Royal London Hospital at Whitechapel was used to measure BMD of the 
lumbar spine and the hip. The principles of this protocol are described in chapter 1. T and Z-
scores are used with BMD as standard units for diagnosis and follow up of changes in bone 
density. The T-score refers to the number of standard deviations (SDs) above or below the 
average BMD value for young normal adults (aged 20-35) matched for sex and race. The T-
score is calculated according to the following formula: 
 
            T-score = (patient’s BMD) - (mean BMD of young adult) / SD (young adult) 
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The Z-score refers to the number of SDs above or below the average BMD value for people of 
the same age, sex and race. This value is used for assessing BMD in older patients (148-150). 
The Z-score is calculated according to the following formula: 
 
            Z-score = (patient’s BMD) – (mean BMD of age matched) / SD (age matched) 
 
Variations in the precision of DEXA scanner should be less than 1.0% according to 
manufacturers’ specifications (148). Precision and accuracy are two main considerations for 
assessing the performance of a DEXA scanner in order to analyse the results of patients with 
confidence.  
         a) Precision and accuracy  
Since bone densitometry relies on ionizing radiation, care is always taken such that 
measurements are always reproducible in order to ensure maximum benefits for patients with 
least exposure to the radiation.  
 
Precision of the DEXA system is defined as the ability to obtain consistent BMD 
values upon repeat measurements for the same patient. Accuracy, in contrast, is a measure of 
the actual BMD value and is highly important when this value is compared with a reference 
population. Accuracy is expressed in percent and is defined as the % difference between 
measurements of a quantity to that quantity's actual (true) value (151). 
 
Clinical DEXA scanner precision is affected by a combination of short-term and long-
term variability, patient movements, body size and operator-dependent factors. Short-term 
precision is essential in setting lower bound accuracy on a system while long-term precision is 
important in the assessment of follow-up scans carried out at later dates (152). The measured 
value of precision assessment is called the precision error. Understanding this error is 
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important in clinical diagnosis of serial BMD studies in patients with bone metabolic diseases 
and those requiring therapeutic interference (152). In a series of frequent BMD tests, precision 
can be stated as either the standard deviation (SD), or % coefficient of variation (% CV, 
defined as 100 x SD/mean) (152). With a 1% precision system, results are interpreted as an 
increase, or a decrease at the 95% confidence level is only achieved if two readings obtained 
from a subject, within a year a part, are greater than 2.8 x % CV (151).  
 
 
       b) In vitro short-term precision 
In vitro short-term precision was measured by scanning an anthromorphic spine 
phantom, provided by the scanner’s manufacturer, 20 times per day. The phantom contains a 
human-like spine segment made of calcium hydroxyapatite, enclosed in a block of water-
simulant epoxy. This phantom has a BMD equal to 0.995g/cm2 (148). The phantom was used 
so that errors due to patient positioning did not affect measurements used for the purpose of 
this study, as the key objective was to evaluate the performance of the scanner over a range of 
bone density values, and avoid operator and patient sources of error (Figure 2.2). 
 
 
 
 
                                                                                                                                   
- 66 - 
 
 
 
Figure 2.2: Anthromorphic spine phantom used for daily quality assurance. The 
phantom contains a human-like spine segment made of calcium hydroxyapatite, 
enclosed in a block of water-simulant epoxy. This phantom has a BMD equal to 
0.995g/cm2. The picture was taken during in vitro short-term precision testing 
performed for the current study. 
 
Measurements were carried out by placing the phantom on the scanner’s table with 
repositioning of the phantom between scans using the positioning lasers of the scanner. Using 
the manufacturer’s software, BMD values of the spine phantom were evaluated by analysing 
images obtained from where bone edge determination was made automatically. To eliminate 
additional variability in precision caused by repositioning of the phantom, a second set of 20 
scans was carried out without repositioning of the phantom between scans. 
 
       c) In vitro long-term precision 
The long-term precision of the scanner was assessed on a daily basis using BMD 
measurements of the spine phantom as a routine part of quality control. These measurements 
were carried out daily for 28 months (August 2011 to Dec. 2013), the duration of the current 
study. Similar to the short-term precision, long-term precision was expressed in coefficients 
of variation (CV).  
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       d) Subject positioning and site of measurements  
BMD measurements were carried out on two sites. The first was the anterior-posterior 
lumbar spine including the vertebral bodies L1 through L4, and the average calculated and 
used as total spine BMD. The second was for total hip where the BMD average was 
calculated for femoral neck, Ward’s region, trochanter, and the shaft. The purpose of 
measuring BMD at these areas was because they provide best indications of bone loss (151). 
Measurement of femoral neck BMD is also essential as that of the lumbar spine can be 
unreliable because of inaccuracies introduced by calcification of the abdominal aorta, or by 
bony osteocytes (152,153).   
 
Proper positioning of all patients was performed strictly in order to eliminate the 
impact of variability in positioning on BMD measurements. For hip positioning, the femoral 
neck was placed in a plane parallel to the scanner’s table. This was achieved by placing the 
subject at the centre of the table. The hip was internally rotated 25o inwards and stabilised by 
a foot positioner as seen in Figure (2.3). The legs were then abducted from the midline of the 
body in order to straighten the femur. The lumbar spine scanning was carried out by 
positioning the subject comfortably and supine on the scanner’s table to have their spine 
straight. A knee positioner as seen in Figure (2.4) was placed under the subject’s lower legs to 
have the femurs as vertical as possible. This aids in straightening the lumbar lordosis. 
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Figure 2.3: Patient positioning for DEXA absorptiometry of the hip. The picture 
was taken during scanning one patient involved in current study. 
 
 
 
 
 
 
Figure 2.4: Patient positioning for lumbar spine BMD measurements using 
DEXA absorptiometry. The picture was taken during scanning one patient 
involved in current study. 
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        e) BMD scan reports 
Data acquired for the study were obtained from the BMD report of each subject. The 
BMD report contains demographic data, an image of the area scanned, location of the region 
of interest superimposed on the image, the BMD in g/cm2 of the bone region scanned 
(automatically calculated by the software) the T-score, Z-score, a graph showing the patient’s 
BMD compared with the manufacturer’s reference database for healthy individuals and state 
of the bone according to WHO classification (normal, osteopenic, osteoporotic) (Figures 2.5 
and 2.6). 
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Figure 2.5: BMD scan report of the hip. BMD average of femoral neck, Ward’s 
region, trochanter and shaft was calculated and used as the total for the hip. 
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Figure 2.6: BMD scan report of the anterior-posterior view of the spine. Views 
are of L1 through L4. The BMD of all four vertebrae was measured and the average 
calculated and used as total spine BMD. 
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2.2.2) Digital X-ray radiogrammetry (DXR) 
DXR is a new operator-independent diagnostic protocol that permits automated 
measurements of cortical BMD and of metacarpal index (MCI), based on estimates of cortical 
thickness using digitised radiography. The protocol provides quantitative data on periarticular 
osteoporosis in patients with RA and serves as a promising supplement to the X-ray scoring 
methods, allowing earlier diagnosis, which is essential for optimal and timely treatment. The 
computer algorithms employed in the DXR technique automatically define regions of interest 
around the narrowest parts of the second, third and fourth metacarpals and then identify the 
outer and inner cortical edges of the cortical bone parts examined. The mean of the cortical 
thickness and overall bone cortical thickness of the second, third and fourth metacarpals are 
estimated. Subsequently, the cortical volume per area is calculated for each bone (154).  
 
Because of the potential advantages the DXR will provide for the current study in enabling 
accurate quantification of changes in bone, Sectra Imtec AB, the company that carries out 
such analyses was approached for assistance with the study. It was agreed that the company 
carry out quantitative measurements of changes in bone density in the RA cohort for whom 
digital X-ray images were obtained. The company set up the parameters for acquiring the 
images at our end and awarded that lab a grant to cover half of the costs incured based on the 
analysis of 3 images for up to 60 treated patients at 3 separate visits to the clinic: before 
treatment and 6 and 12 months after treatment. The coefficient of variation for this method 
was determined to be 0.25%. 
 
  DXR precision:     
 a) In vitro short-term precision 
Short-term precision was measured by scanning a cadaver forearm phantom, provided 
by the scanner’s manufacturer, 31 times per day. The phantom contains a human-like hand 
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segment made of calcium hydroxyapatite, enclosed in a block of water-simulant epoxy. The 
phantom was used so that errors due to patient positioning did not affect measurements used 
for the purpose of this study. 
DXR calculates BMD from digital hand radiographs. The parameters for acquiring 
hand radiographs were film focus distance (FFD) 100cm; tube voltage 50kV; exposure dose 
5mAs. All the digital radiographs were analysed by the same computer software program at 
the manufacturer’s lab. To measure DXR-BMD, the system requires hand radiographs from a 
digitised X-ray system with known resolution. The computer automatically determines 
regions of interest (ROI) around the narrowest part of the 3 metacarpal bones in hand 
radiographs and measures cortical thickness, bone width, and porosity (Figure 2.7). 
DXR-BMD is defined as: c x VPAcomb x (1-p), where c is a density constant, VPA is 
volume per unit area, and p is porosity. To eliminate additional variability in precision caused 
by repositioning of the phantom, a second set of 31 scans was carried out without 
repositioning of the phantom between scans. 
 
       b) Long-term precision 
The long-term precision of the DXR was assessed on a daily basis using BMD 
measurements of the cadaver forearm phantom as a routine part of quality control. This 
procedure was performed at baseline, 3 months and 6 months. Similar to the short-term 
precision, long-term precision was expressed in coefficients of variation (CV). 
The precision (defined as the BMD data variability occurring with repeated 
measurements over time) of the DXR technique for the measurement of BMD has shown 
short-term precision with a CV of 0.25% and long-term precision with CV of 0.28% (154). 
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Figure 2.7: BMD scan report of the anterior-posterior view of the hand. For DXR 
assessment of BMD, the system requires hand radiographs from a digitised X-ray system with 
known high resolution (A). The computer automatically identifies regions of interest (ROI) 
around the narrowest part of the second, third, and fourth metacarpal bones on hand 
radiographs (B) and measures cortical thickness, bone width, and porosity in the region (C). 
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2.2.3) Separation and stimulation of T- and B-lymphocytes and monocytes  
T-lymphocytes, B-lymphocytes and monocytes were isolated from peripheral blood by 
negative selection, using RosetteSep enrichment cocktails kits (Stem Cell Technologies). 
Blood samples were mixed with the different cocktails depending on which cell was intended 
for enrichment at 50µl of the cocktail per ml blood. The cocktails contain bi-specific 
antibodies, with one part reacting with membrane proteins specific for unwanted immune 
cells and the other part reacting with glycophorin A on red blood cells (RBCs). Thus, the 
cocktail used for enriching T-lymphocytes contained antibody with specificity for CD16, 
CD19, CD36, CD56, CD66b, while the cocktail to enrich B cell cocktail contain antibodies 
recognising CD2, CD3, CD16, CD36, CD56, CD66b and the monocyte cocktail contained 
antibodies recognising CD2, CD3, CD8, CD19, CD56, CD66b and CD123. The 
blood/cocktail mixture was left for 20 minutes and subsequently mixed 1 to 1 with RPM1(cell 
culturing medium) containing 2% foetal bovine serum (FBS). For monocyte separation 
additionally 1 mM EDTA was included to stop monocytes attaching to the tube walls. 
Subsequently the cell separation mixtures were layered on top of Ficoll-Paque (GE Healthcare 
Amersham, UK) and subjected to centrifugation at 1200g for 20 minutes without brakes. 
Enriched immune cells were then re-suspended in RPMI supplemented containing 10% FBS, 
100units/ml penicillin and 10µg/ml streptomycin and simulated. T-lymphocytes were 
stimulated with 10µg/ml anti-CD3 pre-coated onto the plates and then 10µg/ml anti-CD28 
added to the cells. After 48 hours of culture, supernatants were collected for determination of 
cytokine production. Separated B-lymphocytes were stimulated with 10µg/ml antibody to 
human membrane immunoglobulin coated onto the plate together and with 10µg/ml antibody 
to human CD40. Enriched monocytes were stimulated for 48hrs with 1µg/ml 
lipopolysaccharide (LPS). In parallel, T-lymphocytes were also stimulated with 0.1µg/ml 
PMA and Ionomycin with addition of 1µl/ml golgiplugTM (BD Bioscience) overnight 
according to the manufacturer’s instructions for further assessment of total intracellular 
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cytokine levels. Supernatants and cell pellets from cell stimulations were stored at -80°C until 
analysed. T-lymphocytes stimulated with PMA + ionomycin and protected from secretion 
with golgi-plug were stained extracellularly using anti-CD4 antibody for 20 min, 
permeabilised using Leucoperm (ABD Serotec) and stained for intracellular cytokines 
using  specific fluorophore labelled antibodies detecting  IL-17, INFɣ, TNFα and GM-CSF 
according to the manufacturer’s instructions. The cells were fixed using 0.5% 
paraformaldehyde in PBS prior to further analysis.  
 
2.2.4) Enrichment of peripheral blood mononuclear cells (PBMNCs) for evaluating 
the effect of treatment with biologic anti-TNFα agents on osteoclastogenesis 
PBMNCs were enriched from whole blood obtained from 8 RA patients and 12 
healthy individuals by centrifugation on Ficoll-Paque gradients. The number of PBMNCs was 
determined using an equal volume of 0.5% Trypan blue mixed with the cell suspension and 
numbers and viability determined under an inverted light microscope. One million of the 
PBMNCs were then placed in a well of a 24-well culture plates with RPMI1640 medium 
containing 10% foetal calf serum (FCS) and antibiotics. 
The cultured cells were incubated in a humidified incubator at 37°C with 5% CO2 in the air 
for 14 days. The culture medium was replenished every 3 days and supernatants collected, 
centrifuged and stored at –20°C until tested to study the effects of treatment of the patients 
with biologic anti-TNFα agents on osteoclasts precursor differentiation. The cultured cells 
were treated with monocyte colony stimulating factor (M-CSF) at 25ng/ml, OPG (1µg) and 
RANK-L (100ng/ml) served as positive controls (all from R&D). 
After 14 days of culture, the cells were stained for tartrate-resistant acid phosphatase (Acid 
Phosphatase, Leukocyte (TRAP) Kit; Sigma-Aldrich, UK) and viewed and quantified by light 
microscopy. The number of TRAP-positive cells with 3 or more nuclei was counted as 
osteoclasts in cultures for monocytes from the RA patients and the healthy controls. The 
                                                                                                                                   
- 77 - 
 
scoring system used showed the data as the number of osteoclasts per 1 X 106 PBMNCs 
recorded as the number of TRAP-positive multinuclear cells. 
 
2.2.5) Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a highly sensitive and specific technique widely used to measure proteins 
and other biologically-relevant molecules including antibodies, cytokines and bone 
biomarkers in biological and clinical samples at ranges that vary from pg/ml to mg/ml 
(155,156). For the purpose of the studies reported in this thesis, a range of ELISA protocols 
were established for the measurement of bone turnover biomarkers and cytokines involved in 
regulating bone resorption and their sensitivity, specificity and reproducibility assessed. 
2.2.5.1) ELISA for protein involved in regulating bone resorption 
Plasma levels of RANK-L and OPG are measured as indicators of osteoclast activity. 
IL-20 cytokine was recently identified as an important pro-inflammatory cytokine from the 
IL-10 family of proteins that is involved in promoting bone resorption (146). Levels of 
RANK-L, OPG and IL-20 in the plasma of RA patients were measured using ELISA before 
and after treatment with biologic anti-TNFα agents in order to assess potential improvement 
in BMD. The capture ELISA protocol was carried out using sets of two monoclonal 
antibodies, one to coat the ELISA wells with to capture the protein of interest and the second 
was biotinylated and used to detect proteins captured in plasma from the patients. Bound 
RANK-L, OPG and IL-20 in the tested plasma samples were then revealed with horseradish 
peroxidase (HRP) conjugated streptavidin that specifically binds to the biotin on the detection 
Ab. The protocol was carried out by first attaching the coating Ab to the walls of ELISA 
microtiter plates by incubation at room temperature (RT) overnight. Next day, the plates were 
emptied of unbound coating Ab and washed 3 times with phosphate buffered saline 
containing 0.05% Tween 20 (PBS/Tween). Unoccupied sites in the wells were blocked with 
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blocking buffer (1% bovine serum albumin, BSA in PBS) at RT for 1 hour. The plates were 
then washed again 3 times with PBS/Tween and diluted plasma samples (1:10) or serial 
dilutions of recombinant proteins, used as standards, 1% BSA in PBS added to each well 
according to a prepared map. The plates were then incubated at RT for a further 2hrs. The 
samples were aspirated and plates washed 3 times with PBS/Tween. The biotinylated 
detection Abs were diluted to a concentration of 2ng/ml and added to each well and plates 
incubated for a further 2hrs at RT. The plates were aspirated again, washed 3 more times with 
PBS/Tween and Streptavidine-HRP (diluted 1:200 in BSA/PBS/Tween) added to each well 
and incubated for 20min at RT. The plates were aspirated and washed as before and freshly-
prepared substrate added to each well and incubated at RT for 20min. The reactions were 
stopped by adding the stop solution (4M H2SO4) with gently-tapping of the plate. Finally, the 
optical density values were measured by using the ELISA reader at 492nm. Concentrations of 
RANK-L, OPG, and IL-20 in each plasma were determined by interpolation from the standard 
curve constructed from the known input of recombinant proteins.  
               2.2.5.2)   ELISA of bone turnover biomarkers 
Bone turnover can be evaluated by measuring the level of biomarkers, proteins and/or 
polypeptides released from osteoblasts and osteoclasts such as osteocalcin, and collagen 
breakdown polypeptides. When osteoclasts degrade collagen, cross-links of collagen and their 
adjacent peptides are released into the circulation and excreted in urine (e.g. C-telopeptide 
cross-links of collagen type I, CTX). Levels of osteocalcin and CTX were measured using 
ELISA plates coated in the lab with specific antibodies to the target proteins and also by using 
commercially available kits (Serum CrossLaps® (CTX-I) and N-MID® Osteocalcin,  
Immunodiagnostic Systems PLC). ELISA plates were coated with specific monoclonal or 
polyclonal antibodies at 2-10μg/ml in PBS, depending on the specific biomarker detected, by 
incubation at room temperature for 2 hrs followed by overnight incubation at 4oC. The plates 
were washed 3 time with PBS/Tween, dried and then unoccupied sites on the plates quenched 
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with 1% BSA in PBS by incubation at RT for 2hrs. The plates were washed 3 more time with 
PBS/Tween and dilutions of plasma samples (1:10) and corresponding standards at a range of 
concentrations all diluent (1% BSA in PBS/Tween) added to the plates and incubated for 2hrs 
at RT. Bound biomarkers were detected with a detection antibody conjugated with biotin. The 
detection antibody was always specific for the target biomarkers and bound detected using 
HRP-conjugated Streptavidin. The plate was then washed 5 times with the washing buffer and 
substrate solution added to each well and incubated for 15min at RT. The reactions were 
stopped by adding the stop solution (4M H2SO4) with gently-tapping of the plate. Finally, the 
optical density values were measured by using the ELISA reader at 450nm. The level of each 
of the detected biomarker was determined by extrapolation from the standard curve 
constructed from the known inputs of the standard. 
 
              2.2.5.3) Reproducibility and accuracy of ELISA 
                a) The effect of rheumatoid factor (RF) autoantibody interference on the 
reproducibility/accuracy of ELISA for bone biomarkers 
 
RFs are auto-antibodies with specificity for IgG. These autoantibodies are mostly of 
the IgM isotype, although IgG, IgA and IgE RFs have can also be detected in the blood of 
patients with RA. These autoantibodies have specificity for antigenic epitopes in the Fc region 
of IgG. RF autoantibodies are found in the blood of about 80% of patients with RA and high 
levels have long been associated with the disease (157).  
 
Because of their reactivity with IgG of many species, it was critical that their effects 
on and interference with the detection of cytokines and other biomarkers be assessed. Thus, 
RFs present in the plasma of patients with RA could bind to the coating antibodies and 
interfere with the ability of the capture antibody to capture its target protein and hence the 
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amount of protein measured underestimated, or not detected even when present. Alternatively, 
it is possible, theoretically at least, that IgM-RF non-specifically bind to the coated antibody 
and to capture the biotinylated detection antibody and, thus, give false positive results 
(158,159) (Figure 2.8). For these reasons, it was imperative that a comprehensive evaluation 
of the effect of RFs on the ELISA protocols be carried out. 
 
 
 
Figure 2.8: An illustration of the potential interference of RF that could bind to 
the coating antibody and causing false negative or positive results. RF, by 
binding to capture and/or detection antibodies has the potential to give both false 
negative and positive readings. 
 
To study the effect of RFs on the assay systems used, magnetic beads (Dynabeads® M-270 
Epoxy-life technologies) were coated with rabbit IgG at 25mg/ml and used to remove RF 
from diluted plasma samples. Plasma samples before and after their content of RF were 
removed/partially removed with IgG-coated magnetic beads were then tested in the ELISA 
protocols to assess the effect of the procedure on the level of proteins of interest. The 
efficiency with which RF was removed/partially removed was also assessed by carrying out 
ELISA for measuring the level of RF before and after the depletion from plasma with the 
IgG-coated magnetic beads. The data was then analysed and compared using Student's t-test. 
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b) ELISA for the measurement of RF  
The ELISA protocol for measuring RF is based on a protocol routinely used in the 
laboratory of Prof. Mageed. The assay is based on using rabbit-IgG bound on the surface of 
microtiter ELISA plate. The plates are coated with 50μl of rabbit IgG solution at 20μg/ml by 
incubation overnight at 4°C. The plates are then washed 3 times with PBS/Tween 20. Diluted 
RA patient plasma (1:10 final dilution) with and without pre-incubation with the rabbit IgG-
coated plates and standard were then pipetted into the wells. The added plasma samples were 
then titrated 1:2 across the plate. After 2 hours incubation at room temperature, the plates 
were washed with PBS/Tween to remove unbound proteins and bound IgM-RF detected using 
peroxidase conjugated F(ab2) of goat IgG anti-IgM (1:5000) added to the plates and incubated 
for 2 hrs. The plates were washed 3 more times with PBS/Tween and bound peroxidase 
revealed with its substrate (o-phenylene di-amine) solution and the reaction stopped with 
H2SO4. The titer of the RF in the plasma with and without pre-incubation with rabbit IgG-
coated beads was then determined using an ELISA reader at wavelength of 492nm.  
 
2.2.6) Measurement of cytokine levels produced by immune cells from RA patients 
treated with biologic anti-TNFα agents in relation to changes in BMD 
The effect of treating RA patients with biologic anti-TNFα agents on the immune 
system and the relation of these to changes in BMD was studied by isolating T- and B- 
lymphocytes and monocytes and studying cytokine production by these cells ex vivo. The 
experiments were carried out with the help of Drs. Taher and Bystrom in Prof. Mageed’s lab. 
Blood monocytes, B-lymphocytes and T-lymphocytes were enriched to high purity using 
negative selection protocols that rely on using RosetteSep kits from Stem Cell Technologies 
(160). These cells were then assessed for their purity by flow cytometry and stimulated ex 
vivo as cited above and level of key cytokines determined by a multiplex-based protocol from 
Meso Scale Discovery (MSD).  
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               a) Cytokine analysis 
Plasma and cell culture supernatants, from in vitro activated enriched B- and T- 
lymphocytes and monocytes, were diluted (plasma used undiluted for GM-CSF detection or 
diluted 1:5 for plasma TNFα, IL-1β, IL-6 and MCP-1 detection supernatants in assay buffers 
and plates from MSD (StemCell Technologies) according to the manufacturer’s instructions. 
TNFα, IL-6, IL-1β, GM-CSF, INFɣ and IL-10 were assessed using a multiplex assay on MSD 
plates while IL-17 and MCP-1 were assessed as separate ELISA. The IL-17 assay was carried 
out using MDS plates while measurement of MCP-1 levels was carried out by ELISA using 
antibodies from R&D systems (Minneapolis, MN, Oxford, UK) and standard binding plates 
from MSD technologies.  
2.2.7) MSD protocols for the measurement of cytokines 
Cytokines produced by immune cells activated in vitro were measured using the MSD 
assay platform (MSD, Gaithersburg, MD) according to the manufacturer’s instructions. The 
MSD platform is based on the proprietary combination of electrochemiluminescence 
detection and patterned arrays. The MSD assay is highly sensitive and simultaneously 
provides quantitative data on multiple cytokines using small volumes of clinical samples 
including supernatants from cultured cells (25μl). The assay has a detection limit 4000 to 1.2 
pg/ml. Briefly, 25μl of supernatants (and recombinant human cytokine standards) were 
incubated for 2 hours on a custom-designed human cytokine 96-well microtiter plate bearing a 
patterned array of capture antibodies on the bottom of the wells. After washing, a mixture of 
specific anti-cytokine detection antibodies (each at 1μg/ml) conjugated to the ruthenium-
based MSD Sulfo-TAG™ reagent were added. The plates were washed 3 times and the MSD 
Read Buffer T (2x) added and results read on a Sector Imager 6000 incorporating a CCD. 
Cytokine concentrations were determined with Softmax Pro Version 4.6 software, using curve 
fitting models (log-log or four-parameter log-logistic) as suggested by the manufacturer for 
the specific cytokine (161). For the purpose of the study, part of which described in this 
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thesis, 14 different cytokines were measured, 10 using multiplex MSD plates and 4 including 
IL-17, IL-23, MCP-1 and IL-22 on single cytokine measurement plates.  
 
 
2.2.8) Inhibition of osteoclastogenesis by OPG and anti-TNFα 
PBMNCs from 3 healthy controls were seeded into 96-well flat-bottomed culture 
plates at 1 × 106 cells per well with 50% culture supernatants of PBMNCs obtained from RA 
patients cultured for the purpose of assessing the effect of treatment of patients on the 
production of osteoclastogenic factors. The culture supernatants were mixed with an equal 
volume of fresh culture medium in a total of 200μl. To further assess the effect of inhibiting 
TNFα in the culture supernatants from the RA patients, anti-TNFα antibody (Infliximab; 
courtesy of Prof. A. Jawad) was added at a final concentration of 2.5μg/ml. To assess the 
effect OPG on reducing the differentiation of osteoclast in the culture system, OPG-Fc (R&D 
Systems Inc.) was added at a final concentration of 1.0μg/ml. The medium was replenished 
twice weekly and after 14 days with the same mix in culture. The cultured cells were then 
stained for TRAP and multinucleated cells were counted as described section 2.1. The results 
were compared for PBMNCs from healthy controls cultured with supernatants from the RA 
cells before and after treatment with biologic anti-TNFα agents and compared with the same 
cells cultured in the presence of TNFα inhibitors or OPG.  
2.2.9) Fluorescence-activated cell sorting (FACS) analysis for measuring the 
frequency of OCPs before and after treatment of RA patients with biologic anti-
TNFα agents 
PBMNCs were isolated from the blood of patients with RA and healthy controls by 
centrifugation on Ficoll-Paque gradients. The cells were washed with and resuspended in PBS 
containing 4% foetal bovine serum (FBS). Aliquots of 0.1 x 106 cells were incubated with 
anti–human CD11b (clone ICRF44), anti–human CD14 (clone M5E2) (both from BD 
Pharmingen TM, UK) and RANK (R&D) antibodies. The latter staining was carried out to 
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determine the percentage of cells expressing RANK within the cell population because 
RANK is a key marker of OCPs. The cells were incubated for 30 minutes at 4oC, washed with 
4% FBS-PBS 3 times and fixed using 4% paraformaldehyde and stored at 4°C until analysed 
(within 24-48hrs). Data was acquired using a FACS Caliber flow cytometer and analysed by 
CellQuest software version 3.1 (both from Becton Dickinson Immunocytometry Systems, 
Bedford, Massachusetts, USA). 
2.2.10)  Disease activity score 28 (DAS28) measurements 
DAS28 is a scoring scheme developed for assessing the severity of disease in patients 
with RA. It is used as a guide for treatment decisions, for monitoring the response of patients 
to such treatments as well in clinical trials to assess the efficacy of new drugs. DAS28 is 
calculated by using a formula that includes counts for tender and swollen joints (28 joints), an 
evaluation of general health by the patient (on a scale of 0 to 100) and a measure of blood 
inflammatory markers (ESR or CRP). DAS28 greater than 5.1 is considered to be a marker of 
high disease activity, between 5.1 and 3.2 of moderate disease activity and less than 3.2 of 
low disease activity. In addition, a patient with DAS28 less than 2.6 is defined as been in 
remission (162). 
2.2.11)  RA patient selection 
The study of the effect of treating patients with biologic anti-TNFα agents on bone in 
RA patients was carried using data from patients routinely treated at the Department of 
Rheumatology at Barts and Royal London NHS Trust. Patients that met the American College 
of Rheumatology (ACR) criteria for RA who were at least 18 years of age, had the disease for 
at least 3 years and had a no response to, or developed resistance to non-steroidal anti-
inflammatory drugs (NSAID) and disease-modifying anti-rheumatic drugs (DMARDs) one of 
which is always methotrexate were included. A number of patients were studied in the 
laboratory of Prof. Mageed for their clinical and immunological responses to treatment with 
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biologic anti-TNFα agents. The study was approved by the local NHS and Central Office for 
Research Ethics Committee (COREC). The study protocol and information leaflets were 
prepared and routinely given to all patients studied. For the routine measurement of laboratory 
serological markers of RA (RF and anti-citrullinated peptide antibodies, CRP, ESR), cytokine 
production and bone metabolism, 25 ml of blood was drawn at the commencement of the 
treatment and at 1 month and then 3 month after treatment. Plasma levels of OPG, RANK-L, 
IL-1, IL-6, IL-17, IL-20, IL-22, TNFα, GM-CSF and bone turnover biomarkers were 
determined at similar time points. The data was compared between responder and non-
responder patients, responders from different ethnic backgrounds and different age, gender 
and with different lifestyles.  
2.2.12)  Statistical Methods 
For studying the impact of age, gender, ethnic origin and lifestyle on the response of 
osteoporosis patients to treatment, differences between the groups were determined using t-
test for continuous variables and chi squared test for category variables. Subgroup analyses 
were carried out to investigate differences in changes in BMD of the spine and the hip in 
different groups. Changes in BMD between these subgroups were analysed using an 
independent Student’s t-test or the Mann-Whitney U test, as necessary (Appendix). 
Associations between changes in BMD and risk factors were also assessed in a multivariate 
linear regression model adjusted for age, gender, ancestral origins and lifestyle.  
Changes of lumbar spine and hip BMD and DAS28 in RA patients were compared 
using the Wilcoxon signed rank sum test (Appendix). Correlations between changes of BMD 
and DAS28 were also tested using the Spearman correlation coefficient. p<0.05 values were 
considered significant for all analysis. Data were analysed by using SPSS 19 program. For the 
statistical training and continued advice I was ably helped and kindly supported by Ms Janice 
Thomas and Mr. Peter Brown.   
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3.1) Assessment of the DEXA protocol used in the study 
3.1.1) In-vitro short-term precision 
Before each set of measurements of BMD for patients, 20 scans were performed on the 
spine phantom provided by the manufacturer with a BMD of 0.995 g/cm2 (mean BMD 
0.996g/cm2, SD= 0.003g/cm2). For repositioning of the phantom between scans, short-term 
precision errors were expressed in percent coefficient of variation (CV) which was found to 
be 0.33%. For measurements obtained without repositioning of the phantom (mean BMD 
0.994g/cm2, SD=0.003g/cm2), the CV of short-term precision was 0.32%. With 99% 
confidence level, no significant differences (p=0.3) were found between the two values 
(Tables 3.1 and 3.2). 
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Table 3.1: Determination of short-term precision of the DEXA with repositioning. 
Twenty DEXA scans of a spine phantom were performed with repositioning of the phantom 
in-between the scans to assess short-term precision. 
Scan 
number 
BMD 
(g/cm2) 
Mean Standard 
Deviation 
CV % 
1 1  
 
 
 
 
 
0.996 
 
 
 
 
 
 
0.0033 
 
 
 
 
 
 
0.33 
2 0.995 
3 1 
4 1 
5 0.995 
6 0.997 
7 0.992 
8 0.995 
9 0.998 
10 0.994 
11 0.998 
12 0.999 
13 0.998 
14 0.996 
15 0.99 
16 0.998 
17 0.995 
18 0.99 
19 0.994 
20 0.99 
Data analysed as described in the Material and Methods. Results of the full statistical analyses 
are provided in Appendix1, Tables 1 and 2. 
 
 
 
 
 
 
 
 
 
                                                                                                                                   
- 89 - 
 
Table 3.2: Determination of short-term precision of the DEXA without repositioning. 
Twenty DEXA scans of a spine phantom were performed without repositioning to assess 
short-term precision. 
Scan 
number 
BMD 
(g/cm2) 
Mean Standard 
Deviation 
CV % 
1 0.999  
 
 
 
 
 
0.994 
 
 
 
 
 
 
0.0032 
 
 
 
 
 
 
0.32 
2 0.993 
3 1.000 
4 0.993 
5 0.994 
6 0.993 
7 0.993 
8 0.998 
9 0.996 
10 0.997 
11 0.992 
12 0.993 
13 0.993 
14 0.987 
15 0.997 
16 0.993 
17 0.997 
18 0.990 
19 0.994 
20 0.998 
Data analysed as described in the Material and Methods. Results of the full statistical analyses 
are provided in Appendix1, Tables 1 and 2. 
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3.1.2) In vitro long-term precision assessment 
The in vitro long-term precision of the DEXA scanner was carried out during a period of 
28 months. BMD measurements were derived from a spine phantom, as used for short-term 
precision, and errors in precision were expressed as CV. The mean BMD of the spine 
phantom was 0.997g/cm2, SD= 0.005g/cm2 and CV 0.5%. As demonstrated in Figure (3.1), all 
BMD measurements were within limits of ±1.5% of the mean (Table 3.3). 
 
 
 
 
Figure 3.1: Long-term in vitro precision of BMD measurements. BMD precision 
measurements were carried out routinely on a daily basis using the spine phantom to 
verify the quality control of the scanner. These measurements were carried out for 
28 months (August 2011 to Dec. 2013). 
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Table 3.3: Results of long-term in vitro precision of BMD measurements. 
Data obtained from long-term in vitro precision report. BMD precision measurements were 
carried out routinely on a daily basis using the spine phantom to verify the quality control of 
the scanner. 
 
 
3.1.3) Outcome of precision assessments 
Two sets of assessments were carried out to verify the precision of the DEXA machine: 
short-term and long-term precision. For short-term precision, repositioning of the phantom 
was performed in order to determine possible effects of operator-positioning on the precision 
of BMD measurements. For measurements of the long-term precision, the phantom was kept 
constant on the scanning table.  
As expected, operator-positioning slightly affected precision of the machine as there was a 
0.01% difference from 0.33% in the first position to 0.32% in the second. However, with a 
99% confidence interval, the differences were not statistically significant (p=0.8). 
 
In general, the short-term precision values for the Hologic QDR series DEXA scanner 
used in the studies were consistent with the precision values provided by the manufacturer 
stated to be less than 1% (1). With expert personnel, a change of approximately 0.05g/cm2 in 
BMD is normally observed as being significant at a 95% confidence interval (1,2). As seen in 
Tables 3.1 and 3.2, the differences between all BMD measurements were less than 0.05g/cm2 
which confirms the reproducibility of the results. Furthermore, the number of scans performed 
Setup 
 
Reference values Plot statistics 
Lumbar Spine  
phantom #12691 
System S/N: 80933  
Limits: ±1.5% of mean 
Mean: 0.995 (g/cm2) 
SD: 0.003 (g/cm2) 
Number of Points: 798 
Mean: 0.997 (g/cm2) 
SD: 0.005 (g/cm2) 
CV: 0.470 % 
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when plotted against the BMD in g/cm2, all BMD measurements were within the limits of ± 2 
SD (Figures 3.2 and 3.3).  
By comparing the CV resulted from long-term precision (CV=0.5%) to that of short-term 
precision (CV=0.33%) for the same scanner, the higher value for the former may be due to the 
influence of variability in the instrument performance through the months of long-term 
precision observations. However, as long as the value obtained is within the limits of the 
manufacturer’s specifications of the machine, the performance of this scanner was considered 
reliable in interpreting series of measurements for patients on follow-up studies. 
 
 
Figure 3.2: BMD measurements of short-term precision. Twenty DEXA scans of a 
spine phantom were performed with repositioning of the phantom in between the scans. 
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Figure 3.3: BMD measurements of short-term precision. Twenty DEXA scans of a spine 
phantom were performed without repositioning of the phantom in all scans. 
 
 
 
3.2) Assessment of accuracy and reproducibility of ELISA protocols 
 
3.2.1) The potential interference of RFs in the ELISA protocols for the measurement 
of bone biomarkers 
 
In order to assess if and by how much the presence of RFs in the plasma of patients 
with RA could interfere with the detection of bone biomarkers and other proteins studied such 
as cytokines, plasma dilutions were incubated with magnetic beads coated with rabbit IgG as 
a known target antigen for human RFs. Before testing the efficiency with which the removal 
of RF could impact the measurement outcome, the ability of the beads to remove RFs from 
plasma was determined. For this purpose, a microtiter ELISA plate was coated with rabbit 
IgG at 20μg/ml in BPS and a plasma sample from a patient with RA known to be positive for 
RF was diluted 1:100 and tested for RF content with and without pre-incubation with 25μl of 
the coated beads. The magnetic beads were then removed before adding to the plate by 
attaching the tube with the diluted plasma to a big collection magnet and carefully removing 
the diluted plasma without the magnetic beads which were attached to the big magnet. The 
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two diluted plasma samples were then added to the plates and titrated across the plate. Bound 
RF was revealed with horseradish peroxidase (HRP) conjugated goat F(ab)2 anti-human IgM. 
The results revealed that there was a notable reduction in optical density (OD) values obtained 
for RF binding in the diluted plasma that was pre-incubated with the rabbit IgG coated 
magnetic beads (Table 3.4 and Figure3.4). Overall, there was a mean reduction of 33% 
(p=0.0004) in the OD of RF with the beads.  
 
    Table 3.4: Assessment of the efficiency of rabbit IgG-coated magnetic beads in 
removing IgM RF from diluted plasma. 
Plasma 
dilution 
OD for RF without pre-
incubation with coated 
magnetic beads  
OD for RF binding after 
incubation with coated 
magnetic beads 
1:100 1.983 1.722 
1:200 1.974 1.714 
1:400 1.873 1.476 
1:800 1.658 1.138 
1:1600 1.364 0.801 
1:3200 0.994 0.475 
1:6400 0.654 0.321 
1:12800 0.412 0.221 
1:25600 0.272 0.162 
1:51200 0.191 0.133 
1:102400 0.152 0.116 
 
A plasma samples from a patient with RA known to have high levels of IgM RF was diluted 
1:100 in PBS and either left without further manipulation or mixed with 25μl of magnetic 
beads coated with rabbit IgG. The plasma was incubated at 37oC with constant mixing before 
removing the beads and adding the diluted plasma to the ELISA plate coated with rabbit IgG 
(Materials and Methods). OD values for the binding of IgM RFs were obtained with HRP-
conjugated goat F(ab)2 anti-human IgM at the wavelength of 492 nm. 
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Figure 3.4: The effect of magnetic beads on the removal of RF from diluted RA 
plasma. OD values obtained for RF binding to rabbit IgG coated ELISA plate after 
pre-incubation of the diluted plasma with rabbit IgG coated magnetic beads.  
 
 
In order to assess the possibility that RF could interfere with the detection of 
biomarkers such as RANK-L, the level of RANK-L was determined in plasma of 8 RA 
patients and 5 healthy controls with and without pre-incubation with rabbit IgG coated 
magnetic beads. In plasma from patients with no pre-incubation with rabbit IgG coated 
magnetic beads, the mean OD values of RANK-L before and 1 and 3 months after treatment 
with biologic anti-TNFα agents were 0.166, 0.162, and 0.173 nm (SD=0.1), respectively. 
After the partial removal of RF with the beads, the mean OD values of RANK-L were 0.173, 
0.163 and 0.174, suggesting an increase in OD values by 4.5% before treatment and 0.35% 
and 0.6% after 1 and 3 months of treatment (p=0.83)  (Figure 3.5).  
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Figure 3.5: The effect of IgM RF in plasma on the ability to detect RANK-L by 
ELISA. RANK-L was measured by ELISA in plasma of 8 RA patients and 5 
healthy controls (C). Plasma from the patients were tested either with pre-incubation 
with or without rabbit IgG coated magnetic beads. The plasma samples from the 8 
patients were collected either before treatment with biologic anti-TNFα agents or at 
1 month and then 3 months after treatment. 
 
 
3.2.2) Conclusions on the effect of RF interference in ELISA for RANK-L 
measurements 
 
In order to assess, and then reduce, the potential interference of RF in ELISA for 
RANK-L measurements, magnetic beads were coated with rabbit IgG and used to remove RF 
from plasma samples and compare RANK-L levels in treated and untreated plasma. Before 
assessing the effect of the removal of RF, the efficiency of the magnetic beads to remove IgM 
RF from the plasma was determined.  
The results of measuring IgM RF in plasma with and without pre-incubation with the 
beads revealed a significant reduction in OD for RF. The mean reduction in the OD of RF was 
33% (p=0.0004) after incubation with the beads. These results, thus, indicated that the beads 
did manage to reduce the level of RF although by no means all the IgM RFs were removed. 
However, the level of IgM RF removed could still be important as these RFs were removed 
with IgG from another species, in this case rabbit, which are the RFs that are likely to 
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interfere with the ELISAs in which IgG from species other than humans are used to capture 
the biomarkers of interest, in this case RANK-L. 
 
The OD values for RANK-L measurement by ELISA were 4.5%, 0.35, and 0.6% 
higher in the plasma of patients before, after 1 and 3 months of the treatment that were pre-
incubated with the rabbit IgG coated magnetic beads. However, with a 99% confidence 
interval, there was no significant difference between measurements of RANK-L whether the 
plasma samples were incubated with the beads or not (p=0.8). 
 
3.3) Evaluation of factors that influence the response of patients to anti-osteoporotic 
therapy   
 
As cited in chapter one, changes in hormonal status with age leads to increased bone 
resorption. In addition, in chronic inflammatory conditions of joints, such as seen in patients 
with RA, chronic inflammation promotes bone resorption and erosion. In contrast to the 
significant generalised bone loss in osteoporosis, however, the pathology of bone loss in RA 
that is associated with the disease is generally thought to be mainly focal but there is a 
significant body of evidence that these patients also suffer from generalised bone loss. In 
recent years, new therapies have been developed to reduce bone resorption in patients with 
osteoporosis. However, there is disparity in patient response to these therapies. The reasons 
are unclear although age, gender, ancestral origin and lifestyle have all been cited as potential 
factors. In parallel there has been a profound improvement in the clinical care of patients with 
RA with the use of new biologic anti-inflammatory agents but it remains unclear whether 
these agents are accompanied by parallel improvements in bone erosion/density whether local 
or generalised. It was therefore essential to evaluate the factors that determine the response of 
patients with osteoporosis to anti-osteoporotic agents to be able to provide an unbiased 
assessment of biologic anti-inflammatory agents on BMD in RA. In order to address these 
issues, an extensive audit was carried out to assess the factors that influence responsiveness of 
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patients with osteoporosis to bisphosphonates, a treatment that suppresses bone resorption. 
Based on the outcome of this audit, it was hoped that the influence of the key factor(s) that 
affect bone response would be incorporated into unbiased studies of the impact of biologic 
anti-inflammatory agents on bone response in RA patients. 
 
3.3.1) Changes in BMD of osteoporosis patients treated with bisphosphonates 
 
a) Patient enrolment 
A cohort of 647 patients (mean age 68.3±11.6 years) with primary osteoporosis 
attending the osteoporosis clinics at the Royal London and St Bartholomew’s Hospitals 
between April 2011 and August 2013 were studied. In this study of patients receiving 
bisphosphonates, changes in BMD (spine and hip) were measured in daily clinical practice 
during 2 years of treatment. For the purpose of the study, the impact of age, gender, ancestral 
origin and smoking on bone response was evaluated. Patients with osteoporosis were selected 
for a number of reasons including the availability of a large cohort of patients and that most 
were treated primarily for their bone disease with anti-osteoporotic medications 
(bisphosphonates). Patients who were bedridden, using steroids or anti-epileptics drugs, with 
diabetes mellitus, had renal disease, hyperthyroidism or cancers were excluded. Lumbar spine 
(L1-L4) and hip were assessed by DEXA scans (Hologic Discovery QDR series). Both sites 
were scanned simultaneously and were monitored for the progress of their response annually. 
Duration of bisphosphonate treatment was 1.95 ± 0.1 years (mean ± SD). For the purpose of 
this study, BMD “nonresponse” was defined as having BMD decrease from before treatment 
(baseline) at two of the measured sites at 2 years after treatment has started. BMD “response” 
was defined as having either no change, or increase from before treatment (baseline) at the 
measured sites at 2 years post treatment. The coefficient of variation (CV), measured with a 
local spine phantom for DEXA scan was acceptable (described in chapter 2). All patients 
received oral daily calcium (1000mg) and vitamin D (800IU). Demographic and clinical 
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characteristics were collected by interviewer-administered questionnaire before treatment and 
after 1 and 2 years during DEXA scan appointments. Data collected was comprised of age, 
lifestyle (smoking, alcohol consumption for more than 2 servings a day and physical 
exercise), personal and family history of fractures and current medications. 
 
b) Changes in BMD  
Mean changes in BMD in both lumbar spine and hip after one year were 0.017g/cm2 
(2.14%, p<0.001 vs baseline) and 0.006g/cm2 (0.5%, p<0.001 vs baseline). Furthermore, 
changes in BMD after 2 years of treatment were 0.032 g/cm2 (4.1%, p<0.001 vs baseline) and 
-0.002g/cm2 (-0.25%, p<0.001 vs baseline) in both lumbar spine and the hip respectively 
(Figure 3.6).  
 
Of the 647 patients included in this study 475 responded to treatment with 
bisphosphonates while 172 did not. The BMD of the lumbar spine and hip increased in 
responder patients by 0.056g/cm2 (7.1%, p<0.001 vs. baseline) and by 0.004g/cm2 (0.51%, 
p<0.001 vs. baseline), respectively. For non-responders, BMD decreased by a mean of -
0.031g/cm2 (-3.9%, p<0.001 vs. baseline) and -0.018g/cm2 (-2.3%, p<0.001 vs. baseline) in 
lumbar spine and the hip, respectively. Epidemiological data on the patient cohort studied, 
their brief medical history, lifestyle and BMD baseline are summarised in Tables 3.5 and 3.6. 
There were no statistically-significant differences between responder and non-responder 
patients in age, gender, risk factors and baseline BMD. 
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Figure 3.6: Changes in BMD after treatment of osteoporosis patients with 
bisphosphonates. A total of 647 patients treated with bisphosphonates were included in this 
analysis. Mean lumbar spine and hip BMD were measured using DEXA scan at baseline 
(time 0) and at 1 and 2 years post treatment. The error bars represent +/- 2 standard deviations 
(SD). 
 
 
Table 3.5: Baseline BMD prior to initiation of the treatment for 
responder and non-responder osteoporosis patients.  
 
BMD values [mean (SD)] were measured by DEXA scan. According to WHO 
criteria, a patient with t-score ≤ -2.5 at any skeletal sites is diagnosed as having 
primary osteoporosis 
 
 
 
 
 
Parameter  Responder 
n=475 
Non-responder 
n=172 
All patients 
n=647 
Lumbar spine 
                           BMD (g/cm2) 
                              t-score 
 
0.793(0.11) 
-2.88(1.0) 
 
0.787 (0.1) 
-2.87 (0.9) 
 
0.791(0.1) 
-2.88 (0.96) 
Hip 
                           BMD (g/cm2) 
                                t-score 
 
0.784(0.12) 
-2.43(0.85) 
 
0.772 (0.11) 
-2.46 (0.84) 
 
0.781 (0.11) 
-2.44 (0.85) 
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Table 3.6: Epidemiological data on osteoporosis patients studied.     
 
Six hundred and forty seven patients were included in the study to assess the effect of age, 
gender, ancestral origin and smoking habits on the response to treatment with 
bisphosphonates. All patients whose data were analysed were from the cohort that attended 
the rheumatology clinics at the Royal London and St Barts Hospitals between April 2011 and 
August 2013. * Information on smoking habits of only 481 patients was available.  
 
 
 
 
Parameter 
Responder 
     n=475 
Non Responder 
     n= 172 
Total 
 647 
Age                                                             Mean (SD) 
Gender (female)                                           n (%) 
    Post-menopausal                                       n (%)   
 
Ancestral origin 
     Caucasians                                               n (%) 
     Asians                                                      n (%) 
     Afro-Caribbean                                        n (%) 
 
  Calcium Intake (mg/day),                      Mean (SD) 
      Vitamin D (µg)                                   Mean (SD) 
 
     Age group 
        Fifty                                                        n (%) 
        Sixty                                                       n (%) 
        Seventy                                                   n (%) 
        Eighty                                                     n (%) 
 
Fracture history (vertebral and peripheral)   n (%) 
 
Familial fracture                                            n (%) 
 
History of medically induced menopause    n (%) 
 
Been on HRT,                                                 n (%) 
Low Body Mass                                              n (%) 
 
OP treatment 
Alendronic Acid (70 mg once/w)                      n (%) 
IV Zolendronic Acid 5mg/year                          n (%)                     
Risendronic Acid (35 mg/w)                              n (%) 
Pamidronate (30 mg/3months)                           n (%) 
 
Lifestyle (history) 
Smoker                                                               n (%) 
Non-smoker                                                        n (%) 
Alcohol consumption (more than 2 servings)    n (%) 
Physical (weight bearing exercises)                   n (%) 
68.6 (11.8) 
382 (80.4) 
366 (96) 
 
 
383 (81) 
  68 (14) 
  21 (5) 
 
586 (370) 
5.6 (3.7) 
 
 
  89  (19) 
139  (29) 
159  (33) 
  88  (19) 
 
79 (17) 
 
60 (13) 
 
29 (6) 
 
51 (11) 
42  (8) 
 
 
278 (58) 
133 (28) 
  37 (8) 
  27 (6) 
 
 
86* (18) 
266 (56) 
  38  (8) 
117  (25) 
  67.5 (11) 
151 (87.8) 
144 (95) 
 
 
135 (79) 
  28 (16) 
    9 (5) 
 
600 (360) 
5.7  (3.6) 
 
 
 30  (17) 
 75  (44) 
 39  (23) 
 28  (16) 
 
 38 (22) 
 
 27 (16) 
 
 14 (8) 
 
22 (13) 
25 (15) 
 
 
89 (52) 
 46 (27) 
 31 (18) 
   6 (3) 
 
 
35 (20) 
94 (55) 
  6  (3) 
 39 (23) 
68.3 (11.6) 
533 
510 
 
 
520 
  97 
  30 
 
590 (367) 
5.6  (3.7) 
 
 
119 
214 
198 
116 
 
117 
 
87 
 
43 
 
73 
67 
 
 
367 
179 
  68 
  36 
 
 
121 
360 
  44 
156 
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c) Factors that influence changes in BMD in patients treated with 
bisphosphonates  
 
In order to assess the impact of individual factors on the response of osteoporosis 
patients to treatment with bisphosphonates, the effect of gender on changes in BMD was first 
investigated. Improvement in BMD among all male patients was statistically significant after 
2 years of treatment when compared with baseline values (Table 3.7). The BMD of the 
lumbar spine and the hip increased in males by 0.057g/cm2 (6.9%, p<0.001 vs. before 
treatment) and by 0.021g/cm2 (2.48%, p<0.001 vs. before treatment), respectively. For female 
patients, changes in BMD of the lumbar spine and hip were 0.028g/cm2 (3.58%, p<0.001 vs. 
before treatment) and -0.006g/cm2 (-0.78%, p<0.001 vs. before treatment), respectively 
(Figure 3.7). 
 
 Table 3.7: Change in BMD in male and female osteoporosis patients treated   
with bisphosphonates. 
Group statistics and independent samples test for changes in BMD in male and female 
patients are presented as the mean and data analysed as described in the Materials and 
Methods. Full statistical analyses are described in Appendix 1, Table 3 and 4. 
 
 
Gender N BMD  values  
before treatment 
 (SD) 
Mean 
% BMD 
change 
Std. 
Error 
 of Mean 
 
Change in lumbar BMD        Male 
                     
Female                                                         
 
114 
 
533 
 
0.828(0.11) 
 
0.783(0.11) 
 
6.90 
 
3.54 
 
0.8 
 
0.3 
Change in hip BMD              Male 
                     
Female                                              
114 
 
533 
0.846(0.13) 
 
0.767(0.11) 
2.48 
 
-0.78 
0.57 
 
0.22 
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Figure 3.7: Changes in BMD at lumbar spine (A) and hip (B) in male and female 
osteoporosis patients after 2 years post-treatment with bisphosphonates. Data on 
533 females and 114 male patients were analysed as described in the Materials and 
Methods chapter. BMD values are presented as the mean +/- SEM. 
Analysis of effect of gender within the same age groups showed that male patients had a 
higher improvement in BMD as compared with female patients in the same age group (Table 
3.8). However, the change in BMD of male patients in the eighties age groups was lower than 
female patients, but, caution should be taken in over interpretation of these results due to the 
low number of male patients in this age group (10 male patients only) (Figure 3.8).  
Table 3.8: Change in BMD in male and female osteoporosis patients 
according to age treated with bisphosphonates. 
Change in lumbar BMD N Mean  
% BMD change 
Std. Error 
of Mean (SEM) 
Male 
                         Fifties 
                                        Sixties 
                                     Seventies 
                                     Eighties 
 
25 
33 
46 
10 
 
6.66 
9.14 
7.9 
3.9 
 
1.4 
1.9 
1.3 
1.7 
 Female 
                                             Fifties 
                                               Sixties 
                                          Seventies 
                                             Eighties                                                                                                                                      
 
94 
181 
152 
106 
 
3.1 
2.95 
1.7 
4.7
 
1 
0.6 
0.5 
0.5
Group statistics and independent sample tests for changes in BMD in osteoporosis patients 
divided according to gender and age groups are presented as the mean and data analysed as 
described in the Materials and Methods chapter. 
                                                                                                                                   
- 104 - 
 
 
Figure 3.8: Changes in BMD in osteoporosis patients in relation to age in males 
and females. The 647 male and female osteoporosis patients were divided into 
subgroups based on age range to assess the effect of age in males and females on 
changes in lumbar BMD after treatment with bisphosphonates. 
 
Variation in BMD among different age groups was analysed by ANOVA (Table 3.9).  Lower 
improvement in hip BMD among older patients was statistically significant after 2 years of 
treatment when compared with younger patients. In contrast, significant differences between 
the age groups in the lumbar spine BMD could not be demonstrated. Furthermore, patients in 
their sixties responded less well than other groups (Figure 3.9).  
          Table 3.9: Changes in BMD in response to bisphosphonates according to age. 
Age N Mean 
% BMD change 
Std. Error 
of Mean (SEM) 
Change in lumbar BMD      
                                               Fifties 
                                              Sixties 
                                          Seventies 
                                            Eighties                                                                                                                                      
 
119 
214 
198 
116 
 
4.54 
2.86 
4.6 
5.1
 
0.72 
0.52 
0.65 
0.87
Change in hip BMD     
                                              Fifties 
                                               Sixties 
                                          Seventies 
                                            Eighties                                                                                                                                      
 
119 
214 
198 
116 
 
1.1 
0.4 
-0.54 
-2.44 
 
0.5 
0.4 
0.3 
0.6
Group statistics and independent sample tests for changes in BMD in osteoporosis patients 
divided according to age are presented as the mean and data analysed as described in the 
Materials and Methods chapter.  
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Figure 3.9: Changes in BMD in osteoporosis patients shown on the basis of differences 
according to age groups. The analyses include 119 patients in their fifties, 214 in their 
sixties, 198 in their seventies and 116 in their eighties.  
Differences in BMD in the lumbar spine and the hip between patients from different 
ethnic origins were not statistically significant (Table 3.10). There was more improvement in 
BMD in Caucasian patients than in Asian and Afro-Caribbean patients. However, the number 
of Afro-Caribbean patients available to include in the analysis was low which has impacted 
the statistical analysis. Generally, however, Afro-Caribbean patients had higher BMD before 
treatment (0.855 and 0.914 g/cm2) compared with Caucasian (0.796 and 0.773g/cm2) and 
Asian patients (0.746 and 0.783g/cm2) for lumbar spine and hip respectively (Figure 3.10).  
Table 3.10: Changes in BMD of osteoporosis patients divided according to ethnic origin 
in response to bisphosphonates.  
                              
                                     Ethnic origin 
 
N 
Baseline BMD 
(mean SD) 
Mean BMD 
change 
Std. Error 
(SEM) 
     Lumbar BMD  change                                 
Caucasias                                                          
Asians 
                                  Afro-Caribbean 
520 
  97 
 30 
 
0.795 (0.1)
0.748 (0.1) 
0.855 (0.1) 
 
4.24
3.3 
3.4 
 
0.32 
0.69 
0.92 
      Hip BMD  change                                      
Caucasias                                                                       
Asians 
                                  Afro-Caribbean 
 
520 
  97 
 30 
 
0.773 (0.1)
0.783 (0.1) 
0.914 (0.1) 
 
-0.4 
0.96 
-0.2 
 
0.3 
0.7 
0.9 
Group statistics and independent sample tests for changes in BMD in osteoporosis patients 
divided according to ethnic origin. The data is presented as the mean and SEM and analysed 
as described in the Materials and Methods. 
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Figure 3.10: Changes in lumbar spine BMD in patients based on ethnic origin. A total of 
520 Caucasian, 97 Asian and 30 Afro-Caribbean osteoporosis patients treated with 
bisphosphonates were included in this analysis. The data are for all patients irrespective of 
whether they were responders or non-responders to the treatment. 
 
With respect to the effect of smoking on changes in BMD, a considerably lower 
improvement in BMD of the lumbar spine and the hip was observed in smoker patients 
compared with non-smokers (p=0.001) (Table 3.11). Changes in BMD of smokers’ lumbar 
spine and hip were 0.017g/cm2 (2.18%) and -0.01g/cm2 (-1.61%), respectively, and 0.04g/cm2 
(4.96%) and 0.006g/cm2 (0.7%) for BMD of lumbar spine and hip of non-smokers (Figure 
3.11).   
Table 3.11: Changes in BMD in smoker and non-smoker osteoporosis patients.   
 
                                 Smoke 
 
N 
Baseline BMD 
(mean SD) 
Mean BMD 
change 
Std. Error 
(SEM) 
Lumbar BMD           Smoker 
change                      Non smoker                                       
121 
360
0.781(0.1) 
0.80(0.1)
2.18 
4.96 
0.5 
0.4 
Hip BMD                Smoker 
change                    Non smoker 
121 
360 
0.761(0.11) 
0.787(0.11) 
-1.61 
0.7 
0.4 
0.3 
 
Group statistics and independent sample tests for changes in BMD in osteoporosis patients 
divided according to smokers and non-smokers. Full statistical analysis is provided in 
Appendix 1, Tables 5 and 6. 
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Figure 3.11: The effect of smoking on changes in lumbar and hip BMD in osteoporosis 
patients treated with bisphosphonates. BMD data on 121 smoker and 360 non-smoker 
osteoporosis patients treated with bisphosphonates were analysed. BMD values after 2 years 
of treatment were compared with baseline (before treatment). Error bars: +/- SEM.  
 
 
In addition, Spearman’s correlation coefficient analyses were performed to assess the 
relationship between patient characteristics (age, gender, ancestral origin and smoking) and 
changes in BMD at both lumbar spine and the hip (Table 3.12). Being female and smoking 
correlated significantly with lower improvement in BMD at the lumbar spine as well as in the 
hip (p<0.001). Changes in BMD at the hip were significantly higher in younger patients. The 
ethnic origin was not significantly related to changes in BMD levels. Finally, there were no 
significant correlations between changes in lumbar spine and hip BMD and other clinical 
characteristics such as history of medically-induced menopause, been on HRT and having low 
body mass (p>0.05). 
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Table 3.12: Correlation between lumbar spine and hip BMD in osteoporosis patients 
treated with bisphosphonates with age, gender, ethnic origin and smoking. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Correlations were analysed using Spearman’s correlation coefficient analysis. 
 
 
 
d) The effect of drug formulation for route of administration and patient 
compliance on the response to anti-osteoporotic agents 
 
It is established that due to side effects associated with oral administration of 
bisphosphonates that patient compliance could be a factor in determining the beneficial 
therapeutic effects of these agents. Therefore, an audit was carried out to assess the impact of 
drug route and possible compliance of patients on the effect of bisphosphonates. To address 
these issues, data from patients receiving the orally-administered bisphosphonate agent 
alendronate and the intravenously-administered zoledronate were compared. There were no 
significant differences in age, gender, ethnicity and lifestyle between the two groups of 
patients. The mean age of patients studied was 67.5±12.5 years for the alendronate group and 
69.6±11.1 for the zoledronate group. The proportion of post-menopausal women in each 
group was 94 and 98% for the alendronate and the zoledronate group, respectively. Baseline 
BMD in both treatment groups at the hip and lumbar spine sites were comparable (Table 
3.13). BMD at the lumbar spine increased from baseline after two years in patients receiving 
either alendronate or zoledronate. However, the increase was significantly greater in patients 
 
 
Patient 
characteristics 
Hip BMD  
Changes 
Lumbar spine      
BMD changes 
 
 
r 
 
p-value 
 
r 
 
p-value 
 
Age 
 
-0.20 
 
<0.001 
 
0.05 
 
0.22 
 
Gender (female) 
 
-0.46 
 
<0.001 
 
-0.36 
 
<0.001 
 
Ethnic origin 
 
0.06 
 
0.11 
 
0.05 
 
0.24 
 
Smoking 
 
-0.26 
 
<0.001 
 
- 0.34 
 
<0.001 
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receiving zoledronate (% BMD change 3.58% for alendronate vs. 5.69% for zoledronate; 
p<0.001) (Figure 3.12A). BMD of the hip in patients receiving alendronate increased by 
0.41% from baseline after two years of treatment, whereas the zoledronate group increased by 
1.7%; p<0.001 (Figure 3.12B). 
      
Table 3.13: Epidemiological data, medication and life style of the patient cohort studied 
for treatment efficacy with alendronate and zoledronate. 
 
No statistically significant differences were observed between the treatment groups. 
 
 
Parameter 
 
Oral alendronate 
70mg once weekly 
n=118 
IV  zoledronate 
5mg/year 
           n= 116 
Age, mean in years (SD) 
Gender (female), n (%) 
    Post-menopausal, n (%)   
Fracture history (vertebral and peripheral), n (%) 
Familial fracture, n (%) 
Calcium Intake (mg/day), mean (SD) 
Vitamin D (µg), mean (SD) 
 
 
History of medically induced menopause, n (%) 
 
Been on HRT, n (%) 
Low Body Mass, n (%) 
 
Lifestyle (history), n (%) 
     Smoking 
     Alcohol consumption (more than 2 servings) 
     Physical (weight bearing exercises)  
 
Ethnic origin, n (%) 
     Caucasian                                                                
Asian                                                                                       
Afro-Caribbean         
 
Lumbar spine BMD (g/cm2) (SD)    
Total hip BMD (g/cm2) (SD)                        
67.5 (12.5) 
98 (83) 
92 (94) 
19 (16) 
16 (14) 
692 (266) 
6.40 (2.9) 
 
 
10 (9) 
 
8 (7) 
6 (5) 
 
 
17 (15) 
7 (6) 
12 (10) 
 
 
92 (78) 
20 (17) 
   6 (5) 
 
 
0.82 (0.1) 
0.79 (0.1) 
69.6 (11.1) 
100 (86) 
98 (98) 
28 (24) 
17 (15) 
697 (259) 
6.45 (2.9) 
 
 
9 (8) 
 
9 (8) 
9 (8) 
 
 
17 (15) 
5 (5) 
20 (17) 
 
 
98 (84) 
14 (12) 
  4  (4) 
 
 
0.75 (0.1) 
0.75 (0.1) 
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Figure 3.12: Change in BMD from baseline in response to treatment with 
alendronate and zoledronate. The assessment was carried out after two years of 
treatment at: (a) the lumbar spine and (b) the hip sites in patients with osteoporosis 
receiving oral alendronate or intravenous zoledronate. BMD of the hip and lumbar spine 
were determined by DEXA scan at baseline (time 0) and at 1 and 2 years post treatment 
initiation. 
 
 
e) Conclusions on the assessment of factors that influence the response of 
patients to anti-osteoporotic therapy 
 
Of patients with osteoporosis treated with bisphosphonates, 27% were non-
responders with evidence of reduction in BMD 2 years after start of treatment at the measured 
sites while 73% were responders with stable, or increased BMD at the measured sites 2 years 
after start of treatment.  
 
Mean changes in BMD in both lumbar spine and the hip in all patients after 2 
years of treatment were 0.032g/cm2 (+4.1%, p<0.001 vs. baseline) and -0.002g/cm2 (-0.25%, 
p<0.001 vs baseline), respectively. The difference in values of BMD at the hip and lumbar 
spine sites would be due to the higher rate of bone remodelling in cancellous bones, more 
abundant in the lumbar spine than cortical bones, abundant in hips (163). In this study, the 
results of assessing the impact of bisphosphonates on BMD are consistent with results of 
earlier studies (164-167).  
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The study also revealed a greater increase in BMD in male patients compared 
with female patients. This finding can be explained by the fact that postmenopausal women 
between the ages of 50-60 are prone to higher rates of osteoporosis due to ovarian failure and 
significant oestrogen reduction that accelerate bone resorption by 90% at menopause. These 
observations have been confirmed by biomarkers, whereas bone formation markers increase 
by only 45% and this imbalance between bone resorption and bone formation leads to lower 
improvement in BMD in females (163,168). In contrast, testosterone hormone in males has 
beneficial effects on BMD improvements with therapy (168). 
 
The data on smoking were interesting as they showed a significant association 
with lower BMD improvement. Association between smoking and changes in BMD has been 
documented previously (169-171). Thus, many investigators have linked reduced 
improvement in BMD after treatment with smoking habit both in treated as well as untreated 
patients (169-171).  
 
Overall, findings from this study are consistent with those of other investigators 
(172,173). Thus, data showing higher baseline BMD in the lumbar spine and the hip of Afro-
Caribbean patients compared with Caucasian and Asian patients is consistent with previous 
reports (172). However, the current study did not have a large cohort of patients of Afro-
Caribbean origin to make the data comprehensive and significant.  
 
Interestingly, data on improvement in BMD in osteoporosis patients showed that 
the route of administration of the drug and, hence, possible compliance with the agent could 
also impact the response to treatment. In general, however, the data indicates that age, gender, 
ancestral origin and smoking habits underpin variations in the response of patients to 
treatment directed as osteoporosis; in this case bisphosphonate. These factors will, therefore, 
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should be taken into consideration when analysing the effect of treating RA patients with 
biologic anti-inflammatory agents.  
Finally, although the results of these methodological assessments and refinements 
have revealed important benchmarks for consideration when analysing the effect of biologic 
anti-inflammatory on BMD in RA patient, the data, nevertheless, have limitations. Firstly, the 
analysis of ethnicity in relation to the response to bisphosphonates is likely to have been 
affected by the small sample size of Afro-Caribbean patients. Furthermore, sample size was 
also a consideration when assessing the relationship between changes in BMD and fractures, 
the main endpoint of interest for clinicians. Secondly, the analyses could have been stronger 
had it been combined with measurements of blood and urine biomarkers of bone formation 
and resorption including the level of sex hormones. A third limitation of the study is the 
duration of time between assessments of changes to BMD as we had to wait for 1-2 years to 
assess a patient’s response to the bisphosphonates (174). This could be important as some 
studies have shown significant reductions in blood biomarkers of bone turnover within days 
to months of starting treatment with bisphosphonates (175). 
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Chapter Four 
The effect of biologic anti-TNFα agents on bone 
in patients with RA: clinical and laboratory 
evidence 
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4.1 Introduction  
 
RA, perhaps uniquely, manifests local and systemic bone pathology (68). Local bone 
damage in RA patients appears as juxta-articular osteopenia and subchondral bone erosion, 
the hallmark of joint destruction, which essentially influences the functional outcome of the 
disease. In contrast, generalised bone loss in RA represents a silent and slowly evolving 
counterpart to local bone loss (176,131). In the recent literature, there is a clear association 
between localised bone loss, most notably in the hands, in RA patients and generalised bone 
loss, such as seen in the spine and hip, suggesting a common pathway for this loss of bone in 
RA. Changes to the homeostasis of the RANK-L and OPG system provide a theoretical 
backdrop for such a common mechanism (177). RANK-L expression is one among the key 
factors that is upregulated by several pro-inflammatory cytokines including TNFα, IL-1, IL-6, 
IL-17, IL-20 and IL-22 (146,178). In addition to its role in initiating and maintaining chronic 
inflammation, TNFα has osteoclastogenic properties and, thus, can promote bone resorption 
(179). Indeed, the assessment of biomarkers of bone turnover in RA shows an increase in 
bone resorption as the dominant pathological mechanism mediated by TNFα (180). Although 
biologic anti-TNFα agents have been suggested to successfully slow down, or even arrest, 
local bone resorption as well as inhibiting inflammation in mice (181), their potential to 
interfere with local and, more importantly, generalised bone loss in RA patients has not been 
adequately explored. Furthermore, it is unclear if bone metabolism is affected in all patients 
treated with biologic anti-TNFα agents, the degree of variability in responsiveness and the 
factors that determine such variability.  This chapter aims to address these issues and also 
study changes in biomarkers of bone turnover, including RANK-L and OPG before and 
following treatment with biologic anti-TNFα agents. 
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4.2 Materials and Methods: 
 
4.2.1 Retrospective study on the effects of treatment with biologic anti-TNFα on BMD: 
 
a) Patient enrolment 
 
In the first phase of this study, the effect of biologic anti-TNFα agents on patients on 
whom BMD data was available was studied in 62 patients. This cohort of patients included 49 
females and 13 males. The mean age of patients was 69±12 years (40-79 years). All patients 
had active disease (mean DAS28±SD of 5.96±1.2) at the time they were prescribed treatment 
with biologic anti-TNFα agents. Patients receiving, or having received bisphosphonates or 
hormone replacement therapy were excluded from the analysis. Twenty seven of the patients 
were treated with etanercept, 26 with infliximab and 9 with adalimumab. Lumbar and hip 
BMD were measured by DEXA scan before the start of treatment and 1 and 2 years later. In 
combination with the biologic anti-TNFα agents, 47 patients received methotrexate 
(12.5mg/day), 8 patients received leflunamide (10mg/day) and 14 patients received 
prednisolone (7.5 mg/day). Nine patients were taking calcium (1g/day) and vitamin D (800 
IU/day). 
 
Table 4.1 summarises the baseline information on patients included in the analysis. 
The patients were divided according to their clinical response to the treatment with biologic 
anti-TNFα agents to identify further effects on changes in BMD. There were no significant 
differences between responder and non-responder patients in age, on the use of disease 
modifying anti-rheumatic drugs (DMARD) and DAS28. However, non-responder patients 
included postmenopausal females. 
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Table 4.1: RA patients included in the analysis of the effects of biologic anti-TNFα 
agents on BMD.     
Sixty two RA patients were included in the analysis to assess the effect of treatment with 
biologic anti-TNFα agents on BMD. The data was analysed as described in the Materials 
and Methods chapter. All patients whose data were analysed were from the cohort that 
attends the rheumatology clinics at Barts & the London Trust. 
 
 
4.2.2 Prospective study on the effects of treatment with biologic anti-TNFα on BMD: 
 
a) Patient enrolment 
Following on from the audit study to assess the effect of treatment on BMD in RA 
patients with biologic anti-TNFα agents, a prospective study was carried out on an additional 
cohort of 55 patients from whom clinical samples were obtained in addition to obtaining data 
on their BMD to assess effect of treatment on the immune response including measuring 
cytokines and biomarkers of bone turnover in conjunction with the treatment. The mean age 
of the patients was 58 years (range: 24-79 years). The patients all had severe disease with a 
mean and standard deviation (SD) DAS28 of 5.8±0.8 at the time they were prescribed 
treatment with biologic anti-TNFα agents. All patients who were recruited for the study had 
failed other disease-modifying anti rheumatic drugs (DMARDs), one of which was always 
methotrexate. The patients included 41 females and 14 males. Patients receiving, or having 
Parameters  Responder 
 
n=41 
Non-
responder 
n=21 
Gender                                             
                                                                 Male     (%) 
                                                                 Female (%) 
                                                                   -(Post-menopausal) (%)                                                 
 
10 (24) 
31 (76) 
27 (87) 
 
  3 (14) 
18 (86) 
17 (94)
Age (year)                                                            median (range) 68.5 (40-79) 69.5 (41-78) 
Disease activity score 28                                         Mean(SD) 5.84 (0.9) 6.2 (0.8) 
Calcium and Vitamin D intake                           n (%)  4 (10)   5 (24) 
Disease modifying anti-rheumatic drug use          n (%)   37 (90) 18 (86) 
Use Prednisone                                                               n (%) 8 (20)   6 (29) 
Mean BMD at lumbar spine before treatment  (g/cm2)    0.939 0.876 
Mean BMD at hip before treatment                  (g/cm2)     0.856 0.787 
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received, bisphosphonates or hormone replacement therapy were excluded from the study. 
Eighteen patients were treated with etanercept, 16 with certolizumab, 9 with adalimumab, 7 
with infliximab and 5 with golimumab. In combination with the biologic anti-TNFα agents, 
51 patients were receiving methotrexate (12.5mg/day) and 16 patients were also receiving 
prednisolone (7.5 mg/day). Thirteen patients were taking calcium (1g/day) and vitamin D 
(800IU/day). Lumbar and hip BMD was measured by DEXA scan before the start of 
treatment and 12 months later. BMDs of the hand at baseline and after six months were 
measured on plain radiographs of the right hand using digital X-ray radiogrammetry (DXR; 
Pronosco X posure system, system 2.0, Sectra, Linkaping, Sweden).  
 
b) Lymphocyte isolation and measurement of blood biomarkers of immunity and 
bone turnover: 
 
For assessing status of the immune system and its impact on bone turnover and 
response to the treatment and the level of cytokines and bone turnover biomarkers, 25ml of 
blood were drawn from the patients at the commencement of the treatment and at 1 month and 
then 3 months after treatment. At similar time points, plasma levels and the level of cytokines 
produced by enriched and ex vivo stimulated T- and B-lymphocytes and monocytes in culture 
supernatants were measured using multiplex MSD kits. The level of the following cytokines 
was measured: TNFα, IL-1, IL-6, IL-17, IL-22 and GM-CSF using the MSD kits. Plasma 
levels of IL-20 and the following bone turnover biomarkers were measured by ELISA: C-
telopeptide cross-links of collagen type I (CTX), osteocalcin and osteoclast-regulating 
proteins including RANK-L and OPG, (Described in detail in the Materials and Methods 
chapter).  
 
The recruitment of patients and experimental procedures were approved by the 
local NHS and Central Office for Research Ethics Committee (COREC) (REC reference 
number: 06/Q0605/8). The study protocol and information leaflets were prepared and were 
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routinely handed to all patients recruited. Demographic information and details of the 55 RA 
patients included in the study are summarised in Table 4.2. 
 
 Table 4.2: Demographic information and details of RA patients included in this study.  
Patients were divided according to their clinical response to the treatment. Fifty five RA 
patients were recruited for the study to determine if and how biologic anti-TNFα agents affects 
bone turnover and association between bone and the immune system in responder and non-
responder RA patients.* Information on the smoking habits of only 21 patients was available. 
** Information on ethnic origin of 12 patients wasn’t available.  
  
Parameters  Responder 
 
n=42 
Non-
responder 
n=13 
All 
patients 
n=55 
Gender                                             
                                           Male    (%) 
                                           Female (%) 
- (Post-menopausal) (%)                                                 
 
12 (29) 
30 (71) 
17 (57) 
 
 2 (15) 
11 (85) 
6 (55) 
 
14 
41 
23 
Age (year)                                             Mean (range) 61 (24-79) 55 (32-78) 58 
Disease activity score 28                  Mean (SD)                                      5.6 (0.8) 6.2 (0.8) 5.8 (0.8) 
Calcium and Vitamin D intake               n (%)  8 (19)   5 (38) 13 
Smoking* 
-    Past               n (%) 
-    Never            n (%) 
-    Current          n (%) 
 
6 (14) 
7 (17) 
2 (5) 
 
1 (8) 
3 (23) 
2 (15) 
 
7 
10 
 4 
Ethnic origin** 
-    White            n (%) 
-    Asian             n (%) 
-    Black             n (%) 
 
17 (40) 
13 (31) 
  2 (5) 
 
4 (31) 
6 (46) 
 1 (8) 
 
21 
19 
  3 
Methotrexate use                                            n (%)                                                          39 (93) 12 (92) 51 
Use Prednisone                                               n (%)                                                          12 (29)   4 (31) 16 
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4.3 Results 
4.3.1 Retrospective study:  
a) Changes in BMD 
Measurement of changes in BMD in the patients before treatment and 2 years after, 
revealed significant changes in BMD (Table 4.3) with mean changes of BMD in both lumbar 
spine and the hip of  3.49% and -0.6%, (p<0.001 and p=0.4), respectively (Figure 4.1). BMD 
of the lumbar spine and hip increased in responder patients after treatment by 0.0396g/cm2 
(3.96%, p<0.001 vs. before treatment) and 0.001g/cm2 (0.11%, p<0.001 vs. before treatment), 
respectively. Interestingly, clinically non-responder patients, according to their DAS28, 
showed an improvement in BMD of the lumbar spine with mean of 0.03g/cm2 (3.03%, 
p<0.001 vs. before treatment) and minor reductions in BMD values at the hip with a mean of -
0.008g/cm2 (-0.78%, p<0.001 vs. before treatment)) (Figure 4.2). This data suggests that 
biologic anti-TNFα agents have beneficial effects on BMD in RA patients. This beneficial 
effect may not parallel changes in DAS28 measures. 
  
Table 4.3: Changes in BMD in RA patients treated with biologic anti-TNFα 
agents at 2 years after treatment. 
     Before 
treatment 
(Mean±SD) 
2 years after 
treatment 
(Mean±SD) 
    P 
BMD of L1-4 in g/cm2 0.917±0.14 0.949±0.16 <0.001 
BMD of hip in g/cm2  0.832±0.11 0.827±0.11 0.4 
Data presented in the Table were obtained as described in the Materials and Methods chapter. 
The difference between before and after treatment was analysed using Wilcoxon signed rank 
test. P values <0.05 were considered statistically significant. The detailed approach used in 
the statistical analysis is provided in Appendix 2, Table 1 and 2. 
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Figure 4.1: Change in BMD from before to 2 years after treatment of RA patients with 
biologic anti-TNFα agents. (A) Measurement of BMD at the hip and (B) the lumbar spine 
sites in RA patients. BMD of the hip and lumbar spine were determined by DEXA scan 
before treatment (time 0) and after 2 years of treatment initiation. P values refer to the 
significance of differences in BMD from before to 2 years after treatment had started. 
 
 
 
 
 
Figure 4.2: Changes in BMD in responder and non-responder RA patients 
treated with biologic anti-TNFα agents. Data on changes in BMD in 62 RA patients 
treated with biologic anti-TNFα agents were compared between responder and non-
responder patients. Response to biologic anti-TNFα agents was based on 
improvement in DAS28 while BMD was measured using DEXA scans immediately 
before treatment and then 2 years after treatment had started. The error bars represent: 
+/- 2 SEM. 
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b) Correlation between patients characteristics and BMD values: 
On assessing correlations between BMD and patient personal data, interesting 
observations were made using Spearman’s correlation coefficient. Negative correlations were 
observed between postmenopausal female and BMD at the lumbar spine and the hip (r=-0.31, 
p=0.026 and r=-0.29, p=0.035, respectively).  
Changes in DAS28 at 3, 6, 12, and 18 months after treatment were significantly 
different from before treatment at p<0.01 (Figure 4.3). DAS28 and BMD at lumbar spine and 
the hip were correlated. The analysis revealed that increased DAS28 before treatment 
correlated significantly with reduction in BMD at the lumbar spine but not the hip, although 
there was a trend in that direction (r=-0.31, p=0.027, and r=-0.12, p=0.38 with lumbar spine 
and hip BMD, respectively) (Figure 4.4). Positive correlations were observed between 
reduction in DAS28 (initial DAS28 - DAS28 at 24 months post treatment) and improvement 
in BMD at the lumbar spine in responder patients but not the non-responder (r=0.4, p=0.01 
and r=0.2, p=0.4, respectively) (Figure 4.5). No significant correlations between changes in 
the lumbar spine and the hip BMD and other medications taken by the patients such as 
calcium, vitamin D or prednisone and DMARDS were observed (p>0.05). 
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Figure 4.3: Changes in DAS28 in responder and non-responder RA patients treated 
with biologic anti-TNFα agents at different time points during the clinical 
assessment process. The figure depicts changes in DAS28 at different time point 
following treatment with biologic anti-TNFα agents in 62 RA patients whose mean 
BMD changes are presented in Figure 4.2. DAS28 was measured before treatment and at 
1 month (1m), 3m, 6m, 12m and 18m after treatment had started. 
 
 
        
Figure 4.4: Correlations between DAS28 and BMD at lumbar spine (A) and hip (B) 
before treatment with biologic anti-TNFα agents.  Data on BMD in 62 RA patients 
were correlated with DAS28 before treatment with biologic anti-TNFα agents. BMD 
was measured using DEXA scan while DAS28 was measured as described in the 
Materials and Methods chapter. The data are for all patients irrespective of whether they 
were responders or non-responders.  
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Figure 4.5: Correlations between reduction in DAS28 at 24 months of treatment 
with biologic anti-TNFα agents and improvement in BMD at lumbar spine in 
responder (A) and non-responder patients (B). Improvement in BMD in responder 
and non-responder patients, based on improvement in DAS28, were correlated with 
changes in DAS28. BMD was measured using DEXA scan immediately before 
treatment and then 24 months after treatment had started. Correlations were calculated 
by using Spearman’s correlation coefficient (r).  
 
 
The impact of individual factors on changes in the BMD of RA patients was also 
investigated. For that reason, patients were divided into responders and non-responders to 
treatment with biologic anti-TNFα agents based on changes in their DAS28, and then the 
patients were divided into subgroups according to gender and age group. Variation in BMD 
among different groups was analysed by using contingency Tables (Fishers exact test/Chi2 
test) (Table 4.4). 
 
Better improvement in BMD was observed among responder patients when compared 
with non-responder patients; BMD improved in 27 responder patients (66%) compared with 
11 non-responder patients (52%), however this difference in BMD improvement was not 
statistically significant (p=0.4).  
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Although the cohort of studied responder patients included less males (10) compared 
with females (31), there was a tendency for better improvement in BMD, as expected from the 
analysis of osteoporosis patients cited in Chapter 3, among male patients compared with 
female patients. Thus, BMD of responder patients improved in 9 males (90%) compared to 18 
females (58%), however, the difference was not statistically significant (p=0.1). Regarding 
BMD in non-responder patients, no significant difference was observed in BMD between 
male and female patients. BMD improved in 2 males (67%) compared with 9 females (50%) 
(p=1.0).  The mean change in BMD in the lumbar spine and the hip in male patients was 
greater than in female patients, 0.036g/cm2 (3.57%) and 0.009g/cm2 (0.95%) vs. 0.025g/cm2 
(2.53%) and -0.005g/cm2 (-0.5%) (p=0.58, p=0.3), respectively.  
Furthermore, more improvement in BMD was observed in ≤50 year old patients 
compared with >50 year old patients. BMD in responder patients improved in 7 ≤50 year old 
patients (88%) compared with 20 >50 year old patients (61%). However, there was no 
significant difference in BMD improvement between the two age groups (p=0.2). In addition, 
BMD improved in 1 ≤50 year old patient and 10 >50 year old patients who did not respond to 
the treatment as measured by DAS28, with no significant changes between the two groups 
(p=0.6) (Table 4.4). The mean change in BMD in the lumbar spine and the hip in ≤50 year old 
patients was greater than in >50 year old patients, 0.027g/cm2 (2.7%) and 0.009g/cm2 (1.18%) 
vs. 0.02g/cm2 (2.2%) and -0.004g/cm2 (-0.4%) (p=0.8, p=0.2), respectively. It was not 
possible to study the effect of ethnic origin on changes in BMD in the RA patients since 95% 
of the treated patients were Caucasians. In addition, no data was available on smoking habits 
of the patients and, therefore, the effect of smoking on changes in BMD in the RA patients 
treated with biologic anti-TNFα agents could not be assessed.  
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Table 4.4: Patients with RA studied for the effect of treatment with biologic 
anti-TNFα agents on BMD.  
Parameters  
 
Improved BMD 
 
Non-improved 
BMD  
Total  
Response 
 Responders            
- Male       n (%) 
- Female    n (%) 
 Non responders    
- Male       n (%) 
- Female    n (%)  
 
 
9 (90) 
18 (58) 
 
2 (67) 
9 (50) 
 
 
1 (10) 
13 (42) 
 
1 (33) 
9 (50) 
 
 
10 
31 
 
3 
18 
 
 Responders            
- ≤ 50      n (%) 
- >50        n (%) 
 Non responders    
- ≤ 50      n (%)                                  
-  >50       n (%) 
 
 
7 (88) 
20 (61) 
 
1 (33) 
10 (56) 
 
 
1 (12) 
13 (39) 
 
2 (67) 
8 (44) 
 
 
8 
33 
 
3 
18 
RA patients were divided according to their response to treatment with biologic anti-TNFα 
agents, gender and age group. Improved BMD was defined as having either no change or 
an increase from before treatment at the measured sites at 2 years post treatment. Non-
improved BMD was defined as having BMD decrease from baseline at the measured sites 
at 2 years after treatment has started. The differences in BMD among patient groups were 
assessed by using contingency tables.  
 
 
c) The effect of treating RA patients with biologic anti-TNFα agents on BMD: 
Conclusions 
Of 62 RA patients treated with biologic anti-TNFα agents, 41 patients (66%) 
responded to the treatment, as defined by improvement of at least 1.2 in DAS28 score after 1 
year while 21 did not respond. Before start of treatment, no significant differences were 
observed in BMD at the lumber spine and the hip between responder and non-responder 
patients. However, the majority of non-responder patients were postmenopausal females, 
which may explain their noted lower mean BMD before treatment compared with responder 
patients. 
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Although most of the patients included in this audit were at relatively high risk of 
osteoporosis, not only because of their chronic inflammation but also more advanced age, 
being mostly female and using steroids, the results, nevertheless, showed notable 
improvement in BMD with biologic anti-TNFα agents. This improvement in BMD in the 
treated patients was not always consistent with improvements in DAS28 scores. This finding 
suggests that the effect of biologic anti-TNFα agents on bone overlaps but is not always 
consistent with their anti-inflammatory effects. However, this audit needs to be further 
verified in a larger cohort, but is, nevertheless, consistent with findings in experimental 
arthritis. Interestingly, TNFα blockade in arthritic mice has been shown to have a greater 
effect on cartilage degradation and joint destruction than on inflammation (182,183). 
Furthermore, the data may raise an issue about the role of other cytokines and pro-
inflammatory pathways in joint pathogenesis in RA and the possible involvement of these in 
the incomplete response of some patients with RA to treatment with biologic anti-TNFα 
agents. This suggests that other targeted therapeutic approaches, such as anti-IL-17 which has 
been shown to correlate with the absence of clinical response to TNFα antagonists in RA 
patients which may enhance the beneficial bone response to treatment (184). 
 
Although this analysis provides preliminary evidence to indicate the potential effect of 
biologic anti-TNFα agents on bone, it would be of interest if data on serum and urine 
biomarkers of bone turnover could be made available to confirm the association between 
treatments with biologic anti-TNFα agents, BMD and bone turnover. 
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4.3.2 A prospective study to assess the effect of biologic anti-TNFα agents on bone 
turnover and correlation with inflammation: 
 
a) Changes in disease activity  
 
The mean and standard deviation (SD) of DAS28 for the patients before treatment 
was 5.8 (0.8). This was reduced in the responder patients to 3.8 (0.9) after 1 month and 3.5 
(1.4) after 3 months of the start of treatment (p<0.001 at all-time points compared with before 
treatment). Forty two patients responded to treatment with the biologic anti-TNFα agents and 
with a reduction in DAS28 of ≥1.2. Thirteen of the patients did not respond to the treatment. 
 
b) Changes in BMD  
 
Ten of the treated 55 patients had DEXA scans before treatment had started and 
then another scan 1 year later. Before the start of treatment, mean BMD (±SD) values were 
1.031 (0.2) and 0.972 (0.2) at lumbar spine and hip, respectively. Eight patients (14.5%) had 
osteopenia (T-score <-1.0 but > -2.5) at either spine or hip. BMD of the lumbar spine and the 
hip remained unchanged during treatment with the biologic anti-TNFα agents (Figure 4.6). 
These values were 1.03±0.2g/cm2 and 0.97±0.2 before treatment and 1.02±0.2 and 
0.97±0.2g/cm2 1 year after treatment for lumbar spine and the hip, respectively. 
 
A further 10 of the patients had conventional radiographs before treatment had started and 
then another radiograph 6 months later. BMD of the hand, which was quantified by DXR, 
remained stable during the treatment with the biologic anti-TNFα agents (Figure 4.6), being 
0.57±0.1g/cm2 before treatment started and 0.57±0.1g/cm2 after treatment.  
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Figure 4.6: Changes in BMD of the hand, hip and lumbar spine before and after 
treatment with biologic anti-TNFα agents. Ten RA patients treated with biologic anti-
TNFα agents had DEXA scans of the lumbar spine and the hip before treatment started 
and 12 months after treatment. BMDs of the hand of the same patients were measured 
on plain radiographs of the right hand (anteroposterior view) before treatment and 6 
months after treatment and data analysed using digital X-ray radiogrammetry (DXR; 
Pronosco X posure system 2.0, Sectra, Linkaping, Sweden). The error bars represent +/- 
SD units. 
 
Before treatment had started, differences in BMD between responder and non-
responder patients, as defined by changes in DAS28, were not significant. However, all non-
responder patients who had BMD scans were postmenopausal females, which may explain, at 
least partly, their noted lower mean BMD before start of treatment compared with responder 
patients (Table 4.5). 
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Table 4.5: BMD prior to initiation of the treatment with biologic anti-TNFα 
agents for responder and non-responder RA patients.  
Parameters 
Responders 
n=7 
Non-responders 
n=3 
All patients 
n=10 
BMD of the L. spine (g/cm2) Mean 
(SD) before treatment  
1.069 (0.2) 0.941 (0.1) 
 
1.03 (0.2) 
 
BMD of the hip (g/cm2) Mean (SD) 
before treatment 
0.992 (0.3) 0.926 (0.1) 
 
0.972 (0.2) 
 
BMD of the hands (g/cm2) Mean (SD) 
before treatment 
0.58 (0.1) 0.52 (0.03) 
 
0.57 (0.1) 
 
Ten RA patients treated with biologic anti-TNFα agents had DEXA scans of the lumbar spine 
and the hip before treatment started and 12 months after treatment. BMDs of the hand of the 
same patients were measured on plain radiographs of the right hand before treatment and 6 
months after treatment and data analysed using DXR. 
 
No significant changes were observed in BMD of the lumbar spine and the hip in responder 
patients after one year of treatment. These values were 1.069±0.2g/cm2 and 0.992±0.3g/cm2 
before treatment and 1.063±0.2g/cm2 and 0.989±0.3g/cm2 1 year after treatment for lumbar 
spine and the hip, respectively. Interestingly, clinically non-responder patients, according to 
their DAS28, showed no significant changes in BMD of lumbar spine and the hip. These 
values were 0.941±0.1g/cm2 and 0.926±0.1 before treatment and 0.91±0.1 and 
0.931±0.1g/cm2 1 year after treatment for lumbar spine and the hip, respectively. 
Furthermore, no significant changes were observed in BMD of the hand in both responder and 
non-responder patients after 6 months of treatment.  These values were 0.58±0.1g/cm2 and 
0.52±0.03g/cm2 before treatment and 0.60±0.1g/cm2 and 0.52±0.03g/cm2 6 months after 
treatment for responders and non-responder patients respectively (Table 4.6).  
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Table 4.6: Changes in BMD of lumbar spine, hip and hand following treatment 
with biologic anti-TNFα agents. 
BMD (g/cm2) 
 
Before 
start of 
treatment  
After 6 
months 
After 12 
months 
p value 
Lumbar spin 
- Responders 
- Non responders  
 
1.069 (0.2) 
0.941 (0.1) 
  
1.063 (0.2) 
0.91 (0.1) 
 
0.6 
0.06 
Hip  
- Responders  
- Non responders 
 
0.992 (0.3) 
0.926 (0.1) 
  
0.989 (0.3) 
0.931 (0.1) 
 
0.8 
0.8 
Hand  
- Responders  
- Non responders 
 
0.58 (0.1) 
0.52 (0.03) 
 
0.60 (0.1) 
0.52 (0.03) 
 
 
 
0.9 
0.3 
Full BMD measurements, including the hands in addition to the traditional lumbar spine and 
the hip, were available from 10 patients for this analysis. All 10 RA patients were treated 
with biologic anti-TNFα agents. BMD values are shown as mean and (SD). Full statistical 
analysis is provided in Appendix 3, Tables 1, 2 and 3.  
 
 
4.3.3 Correlation between patients characteristics and BMD values: 
 
DAS28 and BMD at lumbar spine and hip were correlated. The analysis showed that 
increased DAS28 correlated with lower values of BMD at lumbar spine and hip although this 
was not statistically significant due to the effect of sample size (r=-0.4, p=0.2 and r=-0.3, 
p=0.5 with lumbar spine and hip BMD, respectively) (Figure 4.7). 
  
Positive correlations were observed between reduction in DAS28 and improvement in 
BMD of the lumbar spine and hip in responder patients compared with the non-responders 
(r=0.4, p=0.4 and r=0.7, p=0.04 vs. r=0.-1, p=0.9 and r=-0.3, p=0.8, respectively) (Figures 4.8 
and 9). However, most of these correlations did not reach statistically-significant levels due to 
the effect of sample size.  
                                                                                                                                   
- 131 - 
 
       
Figure 4.7: Relationships between DAS28 and BMD at lumbar spine (A) and the 
hip (B) before treatment with biologic anti-TNFα agents. BMD of 10 RA patients 
were correlated with DAS28 before treatment with biologic anti-TNFα agents. BMD 
was measured using DEXA scan while DAS28 was measured as described in the 
Materials and Methods chapter. The data are for all patients irrespective of whether they 
were responders or non-responders. 
 
 
Figure 4.8: Relationship between reduction in DAS28 and BMD in responder 
patients at lumbar spine (A) and hip (B) after 1 year of treatment with biologic 
anti-TNFα agents. BMD in 7 responder patients, based on improvement in DAS28, 
were correlated with reduction in DAS28 after one year. BMD was measured using 
DEXA scan. Correlations were calculated using Spearman’s correlation coefficient (r).  
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Figure 4.9: Relationships between reduction in DAS28 and improvement in BMD 
of non-responder patients at lumbar spine (A) and hip (B) after 1 year of treatment 
with biologic anti-TNFα agents. BMD in 3 non-responder patients were correlated 
with reduction in DAS28 after one year. BMD was measured using DEXA scan. 
Correlations were calculated by using Spearman’s correlation coefficient (r).  
 
Variation in improvement of BMD among different patient groups was analysed using 
contingency tables (Table 4.7). BMD improved in 3 responder patients (43%) compared with 
1 non-responder patient (33%) but, perhaps expectedly, this difference was not statistically 
significant (p=1.0), given the small sample size. Better improvements in BMD were observed, 
as expected from the analysis of in the analysis of both osteoporosis and RA patients cited 
above, among male patients when compared with female patients. However, the patient cohort 
scanned for their BMD included fewer males (n=2) compared with females (n=8). BMD 
improved in 1 male patients (50%) compared to 3 female patients (38%) but the difference in 
BMD improvement was not statistically significant (p=1.0) (Table 4.7). Mean BMD (±SD) 
values in the male patients were 1.22±0.1, 1.27±0.1 and 0.63±0.1g/cm2 before treatment and 
1.22±0.1, 1.25±0.1 and 0.64±0.1g/cm2 after treatment for lumbar spine, hip and hand, 
respectively. In contrast, BMD values in the female patients were 0.984±0.2, 0.897±0.1 and 
0.56±0.03g/cm2 before treatment and 0.967±0.2, 0.903±0.1 and 0.55±0.03g/cm2 after 
treatment for lumbar spine, hip and hand, respectively.   
                                                                                                                                   
- 133 - 
 
 
Although the sample size included 6 younger (≤ 50 years) and 4 older patients (>50 
years), no significant differences in BMD were observed among ≤ 50 year old patients 
compared with >50 year old patients. BMD improved in 3 of the ≤ 50 year old patients (50%) 
compared with 1 >50 year old patient (25%) (p=0.6) (Table 4.7). It was not possible to study 
the effect of ethnic origin on changes in BMD in the RA patients since 95% of the patients 
who had BMD scans were Caucasians. In addition, no adequate data was available on 
smoking habits for those patients and, therefore, the effect of smoking on changes in BMD in 
the RA patients could not be assessed.  
 
Table 4.7: Patients with RA studied for the effect of treatment with 
biologic anti-TNFα agents on BMD.  
Parameters  
 
Improved 
BMD 
 
Non-improved 
BMD  
Total  
Response 
 Responders              n (%) 
 Non responders        n (%) 
 
3 (43) 
1 (33) 
 
4 (57) 
2 (67) 
 
7 
3 
Gender 
 Male                        n (%) 
 Female                    n (%) 
 
1 (50) 
3 (38) 
 
1 (50) 
5 (62) 
 
2 
8 
Age 
 ≤ 50                           n (%) 
 > 50                      n (%) 
 
3 (50) 
1 (25) 
 
3 (50) 
3 (75) 
 
6 
4 
 
RA patients were divided according to their response to treatment with 
biologic anti-TNFα agents, gender and age group. Improved BMD was 
defined as having BMD either no change or increased at the measured sites 
after 1 year post treatment. Non-improved BMD was defined as having a 
BMD decreased at the measured sites after 1 year post treatment. The 
differences in BMD among the RA patient groups were assessed using 
contingency tables.  
 
In general, this analysis indicates that biologic anti-TNFα agents have beneficial 
effects on BMD in RA patients, as expected from the retrospective study of RA patients cited 
above but this beneficial effect may not parallel changes in DAS28 measures. Moreover, 
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despite all of the non-responder patient group were postmenopausal females, treatment with 
biologic anti-TNFα agents prevented both generalised bone loss, measured by DEXA scan of 
lumbar spine and the hip and localised bone loss, measured by the DXR scan of the hand. 
 
4.3.4 Association of changes in BMD with pro-inflammatory and bone resorptive 
cytokines.  
 
As cited in chapter one, the key pro-inflammatory cytokines TNFα, IL-1, IL-6 and IL-
17 contribute to generalised bone loss as well as subchondral bone resorption in RA. These 
pro-inflammatory cytokines act on osteoblasts to promote RANK-L expression and stimulate 
osteoclastogenesis. Furthermore, inflammatory osteoclastogenesis can be induced by GM-
CSF which plays an important role in the differentiation of osteoclasts from their precursors 
(144,145). In addition, IL-20 and IL-22 have been shown to be involved in bone loss through 
enhancing RANK-L expression with the net result being a rise in osteoclast formation and 
functions (146,147). Therefore, analysing the data on the level of key disease promoting 
cytokines with changes in BMD will help to identify the key cytokine(s) that are involved in 
bone damage in RA. 
 
a) Relationship between BMD with plasma levels of key pro-inflammatory and bone 
resorptive cytokines before and after treatment. 
 
BMD and changes in plasma level of TNFα was correlated. The analysis of the level 
of TNFα before treatment revealed a correlation between lower values of BMD at hand (r=-
0.6, p=0.4) with high levels of the cytokines. However, this correlation was not statistically 
significant, probably, due to the effect of sample size (Figure 4.10). Changes in plasma levels 
of TNFα were negatively correlated with improvement in BMD at lumbar spine and hip (r=-
0.8, p=0.1 and r=-0.9, p=0.01, respectively) (Figure 4.11).  
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Figure 4.10: Relationship between plasma levels of TNFα and BMD of the hand. 
Plasma levels of TNFα before treatment with biologic anti-TNFα agents were correlated 
with hand BMD of treated patients. BMD was assessed using DXR scan while TNFα 
levels were determined using ELISA. Plasma levels of TNFα were correlated with BMD 
using Spearman’s correlation coefficient (r).  
 
 
        
Figure 4.11: The relationships between improvement in BMD at lumbar spine (A) 
and hip (B) with changes in plasma levels of TNFα after treatment with biologic 
anti-TNFα agents. Changes in plasma levels of TNFα from before treatment to 3 
months after treatment were determined using ELISA. BMD was assessed using DEXA 
scan as described in the Materials and Methods chapter. Correlations were with 
Spearman’s correlation coefficient (r). 
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There was also a negative correlation, before treatment had started, between the level 
of plasma IL-1 and BMD of the lumbar spine, hip and the hand (r=-0.3, p=0.6; r=-0.3, p=0.5 
and r=-0.4, p=0.4, respectively). Changes in plasma level of IL-1 were negatively correlated 
with improvement in BMD of the hand after treatment with biologic anti-TNFα agents (r=-
0.6, p=0.3) (Figures 4.12 and 4.13). 
 
           
Figure 4.12: Relationship between plasma levels of IL-1 and BMD at lumbar spine 
and hip. IL-1 levels were determined in the plasma of treated patients using ELISA, 
while BMD of the Lumbar spine (A) and hip (B) was measured using DEXA. Levels of 
IL-1 were correlated with BMD before treatment with biologic anti-TNFα agents had 
started. Correlations were with Spearman’s correlation coefficient (r).  
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Figure 4.13: Relationships between plasma levels of IL-1 and BMD of the hand. IL-
1 levels were determined in plasma using ELISA.BMD of the hand was measured using 
DXR. Levels of IL-1 were correlated with BMD before treatment with biologic anti-
TNFα agents had started (A) then changes in IL-1 were correlated with improvement in 
hand BMD after treatment (B). Correlations were with Spearman’s correlation 
coefficient (r).  
 
There was a trend for correlations between reduced levels of IL-6 before treatment and 
increased BMD at the lumbar spine, hip and hand but the correlations were not statistically 
significant (r=-0.2, p=0.5; r=-0.2, p=0.6 and r=-0.4, p=0.3, respectively) (Figure 4.14). The 
analysis of the level of IL-6 after treatment revealed a correlation between improvement of 
BMD at hand (r=-0.5, p=0.3) with changes in the levels of the cytokine (Figure 4.15). 
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Figure 4.14: Relationship between plasma levels of IL-6 before treatment and BMD at 
lumbar spine and hip. The level of plasma IL-6 was determined using ELISA. BMD of 
the Lumbar spine (A) and hip (B) were measured using DEXA. Correlations were assessed 
using Spearman’s correlation coefficient (r).  
 
 
 
Figure 4.15: Relationship between plasma levels of IL-6 and BMD of the hand. 
Plasma levels of IL-6 were determined using ELISA.BMD of the hand was measured 
using DXR. Levels of IL-6 were correlated with BMD before treatment with biologic 
anti-TNFα agents had started (A) then changes in IL-6 were correlated with 
improvement in hand BMD after treatment (B). Correlations were with Spearman’s 
correlation coefficient (r).  
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Similar to IL-6, plasma levels of GM-CSF were also negatively correlated with BMD 
before treatment at the lumbar spine, hip and the hand (r=-0.5, p=0.3; r=-0.3, p=0.4; and r=-
0.3, p=0.4), respectively (Figure 4.16 and 17).   
 
       
Figure 4.16: Relationships between plasma levels of GM-CSF and BMD at lumbar 
spine (A) and hip (B). Plasma levels of GM-CSF were determined before treatment 
using ELISA. BMD was measured using DEXA scan. Correlations were with 
Spearman’s correlation coefficient (r).  
 
                       
Figure 4.17: Relationship between plasma levels of GM-CSF and BMD at the hand. 
BMD of the hand was measured using DXR. Plasma GM-CSF level and the statistical 
analyses were as described in the legend to Figure 4.16.  
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The relationship between plasma levels of IL-20 and BMD could not be analysed as 
the developed ELISA method could only help detect level of this cytokine only in 2 patients. 
Plasma levels of IL-22 negatively correlated with BMD of the lumbar spine, hip and 
the hand. These correlations were statistically significant (r=-0.8, p=0.03; r=-0.7, p=0.05 and 
r=-0.8, p=0.04 respectively) (Figures 4.18 and 4.19). 
       
Figure 4.18: Relationship between plasma levels of IL-22 and BMD at lumbar spine 
and hip. Plasma IL-22 levels were determined prior to treatment by ELISA. BMD and the 
statistical analyses were carried out as described for the previous correlation figures.  
                          
Figure 4.19: Relationship between plasma levels of IL-22 and BMD at the hand. 
Plasma IL-22 levels were determined by ELISA. BMD of the hand was measured using 
DXR and correlation determined by Spearman’s correlation coefficient (r).  
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b) Relationship between BMD and pro-inflammatory and bone resorptive cytokines 
produced by ex vivo stimulated immune cells  
 
The potential of immune cells to produce TNFα in RA patients treated with biologic 
anti-TNFα agents and relationship of such levels with improvement in BMD after treatment 
were correlated. The analysis involved enriching immune cells from the patients to high 
purity and stimulating the cells ex vivo for 48 hours before measuring the level of TNFα in 
culture supernatants from the cells in relation with changes in the BMD at the lumbar spine, 
hip and the hand. This analysis revealed a negative relationship although the data did not 
reach statistically significant levels, probably due to small sample size (r=-0.7, p=0.2; r=-0.5, 
p=0.4 and r=-0.2, p=0.7, respectively) (Figures 4.20 and 4.21).  
 
         
Figure 4.20: Relationships between levels of TNFα produced by ex vivo T- 
lymphocytes and BMD at lumbar spine and hip. The level of TNFα produced by ex 
vivo T-lymphocytes enriched before treating the patients was by MSD kits. BMD was 
measured using DEXA. Correlations were with Spearman’s correlation coefficient (r).  
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Figure 4.21: Relationship between culture supernatant levels of TNFα and BMD at 
the hand. TNFα levels in culture supernatants of activated T-lymphocytes was 
determined by MSD kits, BMD of the hand was measured using DXR and correlation 
determined by Spearman’s correlation coefficient (r).  
 
There was also a negative correlation between culture supernatant levels of IL-1 and 
BMD of the lumbar spine, hip and the hand (r=-0.6, p=0.2; r=-0.5, p=0.3 and r=-0.5, p=0.2, 
respectively) (Figures 4.22 and 4.23). Furthermore, there was a trend for correlations between 
reduced levels of IL-1 after treatment and improvement in BMD at the lumbar spine and hip 
but the correlations were not statistically significant (r=-0.3, p=0.6 and r=-0.6, p=0.1, 
respectively) (Figure 4.24). 
There were no correlations between levels of IL-6, IL-17, IL-22 and GM-CSF in 
culture supernatants of the activated T-lymphocytes and BMD at lumbar spine, hip and hand.   
The findings summarised in this section, therefore, provide further evidence for a 
relationship between increased disease-promoting cytokines and accelerated bone loss. This, 
in turn, suggests that the inflammation characteristic of RA patients is associated with the 
generalised bone loss noted in the disease.  
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Figure 4.22: Relationship between culture supernatant levels of IL-1 and BMD at 
the lumbar spine and hip. IL-1 levels produced by ex vivo T-lymphocytes enriched 
before treating the patients was by MSD kits. BMD of the lumbar spine (A) and of hip 
(B) was measured using DEXA and correlations were by Spearman’s correlation 
coefficient.  
 
 
                       
Figure 4.23: Relationship between culture supernatant levels of IL-1 and BMD at 
the hand. IL-1 levels in culture supernatants of activated T-lymphocytes, BMD and the 
statistical analyses were as described in the legend to Figure 4.21.   
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Figure 4.24: The relationships between improvement in BMD at lumbar spine (A) 
and hip (B) with changes in culture supernatant levels of IL-1 after treatment with 
biologic anti-TNFα agents. IL-1 levels in culture supernatants of activated T-
lymphocytes, BMD and the statistical analyses were as described in the legend to Figure 
4.22. 
 
 
4.3.5 Assessment of the relationship between changes in plasma bone biomarkers and 
the clinical response to treatment with biologic anti-TNFα agents. 
 
Plasma levels of bone turnover biomarkers including RANK-L and OPG and pro-
inflammatory cytokines including TNFα, IL-1, IL-6, IL-17, IL-20, IL-22 and GM-CSF were 
measured for the 55 RA patients included in this study.  
Levels of CTX and osteocalcin before treatment were higher in responder patients 
(164±125pg/ml and 15.5±10.5ng/ml) compared with non-responder patients (127±103pg/ml 
and 11.6±8.1ng/ml). However, the differences did not reach statistically significant levels 
(p=0.2 and p=0.7, respectively). There were also no statistically significant differences 
between levels of RANK-L and OPG in both responder and non-responder patients before 
treatment had started (Table 4.8). 
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Table 4.8: Plasma levels of bone turnover biomarkers in responder and non-responder 
patients before the initiation of the treatment with biologic anti-TNFα agents.  
Plasma levels of bone turnover biomarkers, RANK-L and OPG for the 55 RA patients 
included in this study were measured by ELISA as described in the Materials and Methods 
chapter. The data was then evaluated to obtain as comprehensive insight into bone response to 
the treatment with biologic anti-TNFα agents as possible. The patients were divided into 
responder and no-responders to the treatment based on changes in their DAS28. The values 
shown are for the mean and (SD).  
 
 
The level of CTX decreased in responder patients after 3 months of treatment 
compared with before treatment, 164±125pg/ml to 131±129pg/ml. However, the difference 
was not statistically significant (p=0.45). This is, probably, due to the small patient number 
within the cohort. In contrast, non-responder patients had an increase in the plasma level of 
CTX 3 months after treatment compared with before treatment,127±103pg/ml compared 
with140±72pg/ml (p=0.58) (Table 4.9). Interestingly, the level of osteocalcin increased 
significantly after 3 months of treatment in non-responder patients compared with before 
treatment, from 11.6±8.1ng/ml to 14.9±8.1ng/ml (p=0.01). However, there was no statistically 
significant difference in the level osteocalcin in the patients after 1 month of treatment. Thus, 
plasma levels of osteocalcin were 11.6±8.1ng/ml before treatment and 14.3±7.7ng/ml 
(p=0.09) after 1 month of treatment. The level of  osteocalcin also increased in responder 
patients from 15.5 ±10.5ng/ml before treatment to 16.5 ±11.5ng/ml 3 months after treatment 
but the difference was not statistically different (p=0.19) (Figure 4.25).  
Parameters Responders Non-responders All patients 
 
 
CTX (pg/ml)                    Mean (SD) 
 
164 (125) 
 
127 (103) 
 
155 (120) 
 
Osteocalcin (ng/ml)           Mean (SD) 
 
15.5 (10.5) 
 
11.6 (8.1) 
 
14.5 (10) 
 
RANK-L (pg/ml)             Mean (SD) 
 
197 (187) 
 
186 (206) 
 
195 (189) 
 
OPG (ng/ml)                   Mean (SD) 
 
2.87 (1.5) 
 
2.83 (1.2) 
 
2.86 (1.5) 
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Table 4.9: Changes in the level of bone turnover biomarkers after treatment with 
biologic anti-TNFα agents 
Parameters 
 
Before 
treatment   
1 month 
after treatment 
3 months 
after treatment 
 
CTX (pg/ml)                                                   
- Responders  
- Non responders 
 
 
164 (125) 
127 (103) 
 
 
170 (108) 
137 (72) 
 
 
131 (129) 
140 (72) 
Osteocalcin (ng/ml) 
- Responders 
- Non responders  
 
15.5 (10.5) 
11.6 (8.1) 
 
16 (11) 
14.3 (7.7) 
 
16.5 (11.5) 
14.9 (8.1) 
Plasma levels of CTX and osteocalcin were measured for 55 RA patients by ELISA. The 
patients were divided into responder and no-responders to treatment with biologic anti-TNFα 
agents based on changes in their DAS28. The values shown are for the mean and (SD). Full 
statistical analysis is provided in Appendix 4, Tables 1 and 2.  
 
 
        
 
Figure 4.25: Changes in plasma levels of CTX and osteocalcin in RA patients 
treated with biologic anti-TNFα agents. Levels of CTX (A) and osteocalcin (B) were 
measured in the plasma of 55 RA patients by ELISA. The patients were divided into 
responder and non-responder groups based on changes in their DAS28 values. * 
indicates p≤0.05 for values after 3 months of treatment compared with before 
treatment.  
 
 
B 
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Levels of OPG increased in responder patients from their levels before treatment 
2.87±1.5ng/ml to 2.64±1.4ng/ml (p=0.08) and 2.93±1.4ng/ml (p=0.4) 1 and 3 months after 
treatment, respectively. The levels of OPG did not change markedly in non-responder patients 
(from 2.83±1.2ng/ml before treatment to 2.86±1.5ng/ml (p=0.9) and 2.80±1.6ng/ml (p=0.6) 1 
and 3 months after treatment) (Table 4.10) (Figure 4.26A).  
 
The level of RANK-L decreased significantly in responder patients after 3 months of 
treatment compared with its levels before treatment from 197±137pg/ml to 170±100pg/ml      
( p=0.047). In contrast, there was an increase in RANK-L level in non-responder patients after 
treatment but the difference was not statistically significant. The mean level of RANK-L was 
186±90pg/ml before treatment and 223±105pg/ml (p=0.12) after 1 month and 192±110pg/ml 
(p=0.8) after 3 months of treatment (Table 4.10) (Figure 4.26B).  
 
Table 4.10: Changes in the level of OPG and RANK-L after treatment of RA 
patients with biologic anti-TNFα agents 
Parameters 
 
Before 
treatment  
After 1 month  After 3 months  
 
 
OPG (ng/ml) 
- Responders  
- Non responders 
 
 
2.87 (1.5) 
2.83 (1.2) 
 
 
2.64 (1.4) 
2.86 (1.5) 
 
 
2.93 (1.4) 
2.80 (1.6) 
 
RANK-L (pg/ml) 
- Responders  
- Non responders 
 
 
197 (137) 
186 (90) 
 
 
161 (102) 
223 (105) 
 
 
170 (100) 
192 (110) 
Plasma levels of OPG and RANK-L for the 55 RA patients studied were measured by 
ELISA. The patients were divided into responder and no-responders based on changes in 
their DAS28. The values shown are for the mean and (SD). Full statistical analysis is 
provided in Appendix 4, Tables 3 and 4.  
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Figure 4.26: Changes in plasma levels of OPG and RANK-L in RA patients treated 
with biologic anti-TNFα agents. The cohort of 55 RA patients studied was divided into 
responders and non-responders based on changes in their DAS28. Means OPG (A) and 
RANK-L (B) were measured by ELISA. The error bars represent SD. Results were 
compared with values before to after treatment using paired Student’s t-test.* indicates 
p≤0.05 for values before to after treatment.  
 
 
4.3.6 Assessment of changes in pro-inflammatory and bone resorptive cytokines in RA 
patients treated with biologic anti-TNFα agents.  
 
a) Changes in plasma levels of pro-inflammatory and bone resorptive cytokines: 
There were no statistically significant differences in plasma levels of TNFα between 
responder and non- responder patients before the start of treatment. Thus, the mean and SD 
level of plasma TNFα in responder patients before treatment was 22.8±15pg/ml compared 
with 23.3±23pg/ml in non-responder patients. Interestingly, the plasma levels of TNFα 
increased in the responder patients after treatment. Thus, levels of plasma TNFα were 
40.2±30pg/ml (p=0.3) and 37±33pg/ml (p=0.13) after 1 and 3 months of treatment, 
respectively. In non-responders patients, plasma levels of TNFα increased significantly after 1 
and 3 months of treatment to 73±51pg/ml and 70±46pg/ml, respectively (both p<0.05) (Table 
4.11) (Figure 4.27A). Plasma level of IL-1 was lower in responder patients at 1.7±2.5pg/ml 
                                                                                                                                   
- 149 - 
 
compared with 4.1±3pg/ml in non-responder patients before treatment. Level of plasma IL-1 
in non-responder patients increased to 7.2±3pg/ml (p=0.3) after 1 month of treatment but then 
declined to 2.4±3pg/ml (p=0.3) 3 months after treatment. There were no significant 
differences in plasma levels of IL-1 among responders patients from before to after 1 and 3 
months of treatment at 2.5±4pg/ml (p=0.7) and 2±2.7pg/ml (p=0.4), respectively (Table 4.11) 
(Figure 4.27B). 
 
Table 4.11: Changes in TNFα and IL-1 cytokine levels after treatment 
with biologic anti-TNFα agents 
Parameters  
 
Before 
treatment  
After 1 
month  
After 3 months  
 
TNFα (pg/ml) 
- Responders 
- Non responders 
 
22.3 (15) 
23.3 (23) 
 
40.2 (30) 
73 (51) 
 
37 (33) 
70 (46) 
IL-1(pg/ml)       
- Responders 
- Non responders                                             
 
1.7 (2.5) 
4.1 (3) 
 
2.5 (4) 
7.2 (3) 
 
2 (2.7) 
2.4 (3) 
Plasma levels of TNFα and IL-1 cytokines for 55 RA patients included in 
this study were measured by ELISA. The patients were divided into 
responder and no-responders to treatment with biologic anti-TNFα agents 
based on changes in their DAS28. The values shown are for the mean and 
(SD).  
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Figure 4.27: Changes in plasma levels of TNFα and IL-1 in RA patients treated 
with biologic anti-TNFα agents. Levels of TNFα and IL-1 were measured by 
ELISA. Response to treatment was based on changes of more than 1.2 in DAS28 
scores. Means and SD of TNFα and IL-1 values in responder and non-responder 
patients are presented in pg/ml. The analysis was carried out using paired Student’s 
t-test.* indicates p≤0.05. 
 
Plasma levels of IL-6 before treatment were 11±7pg/ml in responder and 9±11pg/ml 
in non-responder patients (Table 4.12). The mean level of IL-6 decreased in responder 
patients to 8±10pg/ml and 9±10pg/ml at 1 and 3 months post treatment, respectively. 
However, these differences did not reach statistically significant levels (p=0.8 and p=0.2,). 
There were also no significant differences in plasma levels of IL-6 in non-responder patients 
after 1 and 3 months of treatment with biologic anti-TNFα agents from before treatment 
(8±6pg/ml and 10±8pg/ml respectively) (Figure 4.28A). Plasma levels of GM-CSF were 
higher in responder patients compared with non-responders, 3.5±2pg/ml compared to 
1.6±2pg/ml before treatment. There were reductions in plasma levels of GM-CSF in 
responder patients after 1 and 3 months of treatment to 1.7±2.5pg/ml (p=0.2) and 2.3±3.7 
(p=0.3), respectively. In non-responder patients, plasma levels of GM-CSF increased after 1 
month of treatment but not after 3 months. Thus, plasma levels of GM-CSF in non-responder 
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patients were 2.5±2pg/ml (p=0.5) and 1.2±1.7pg/ml (p=0.5) after 1 and 3 months of 
treatment, respectively (Figure 4.28B).  
 
Table 4.12: Changes in plasma levels of IL-6 and GM-CSF after 
treatment with biologic anti-TNFα agents. 
Parameters 
 
Before 
treatment  
After 1 
month  
After 3 
months  
 
IL-6 (pg/ml)    
- Responders 
- Non responders     
 
11 (7) 
 9 (11) 
 
8 (10) 
8 (6) 
 
9 (10) 
10 (8) 
GM-CSF (pg/ml)  
- Responders 
- Non responders                                         
 
3.5 (2) 
1.6 (2) 
 
1.7 (2.5) 
2.5 (2) 
 
2.3 (3.7) 
1.2 (1.7) 
Plasma levels of IL-6 and GM-CSF were measured by ELISA as described 
in the legend to the other figures. The values shown are for the mean and 
(SD). 
 
 
Figure 4.28: Changes in plasma levels of IL-6 and GM-CSF in RA patients 
treated with biologic anti-TNFα agents. Levels of IL-6 and GM-CSF were 
measured by ELISA. Patient response was based on changes of more than 1.2 in the 
DAS28 scores. The data were analysed using paired Student’s t-test. 
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The measurement of plasma levels of IL-20 showed significant reduction in responder 
patients after 3 months of treatment with biologic anti-TNFα agents compared with before 
treatment. Thus, the mean and SD level of IL-20 was 12.4±9.5ng/ml at 3 months after 
treatment compared with 20±15ng/ml before treatment (p=0.041). Somewhat unexpectedly, 
however, the level of IL-20 was lower before the start of treatment in non-responder patients 
at 2±2.6ng/ml compared with responder patients (Table 4.13). However, caution may be 
applied to avoid over interpretation of this observation since the number of non-responder 
patients was relatively small (IL-20 could only be detected in the plasma of 2 of 13 non-
responder patients studied) (Figure 4.29A).  
The level of IL-22 was also lower in non-responder patients (1.2±0.9ng/ml) compared 
with responder patients before the start of treatment (8.4±6.4ng/ml). After treatment, the mean 
level of IL-22 decreased in responder patients after 1 and 3 months of treatment. However, 
these differences did not reach statistically significant levels. Thus, plasma levels of IL-22 
were 8.4±6.4ng/ml before treatment and 6.7±3 (p=0.7) after 1 month and 7.7±4ng/ml after 3 
months of treatment (p=0.18). Further, no significant differences were observed in plasma 
levels of IL-22 in non-responder patients from before treatment to after 1 and 3 months of 
treatment, 1.1±0.7ng/ml (p=0.2) and 1.3±1.3 (p=0.9), respectively (Figure 4.29B).  
 
Table 4.13: Changes in plasma levels of IL-20 and IL-22 cytokines after 
treatment with biologic anti-TNFα agents 
Parameters 
 
Before 
treatment  
After 1 
month  
After 3 
months  
IL-20 (ng/ml) 
- Responders 
- Non responders 
 
20 (15) 
2 (2.6) 
 
15.8 (12) 
1.5 (2) 
 
12.4 (9.5) 
1.1 (1.4) 
IL-22 (ng/ml) 
- Responders 
- Non responders 
 
8.4 (6.4) 
1.2 (0.9) 
 
6.7 (3) 
1.1 (0.7) 
 
7.7 (4) 
1.3 (1.3) 
Plasma levels of IL-20 and IL-22 were measured by ELISA and patients 
divided into responder and no-responders to treatment with biologic anti-
TNFα agents based on changes in their DAS28.  
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Figure 4.29: Changes in plasma levels of IL-20 and IL-22 in RA patients 
treated with biologic anti-TNFα agents. Levels of IL-20 and IL-22 were 
determined by ELISA. Error bars represent +/- SD. * indicates p≤0.05 at 1 or 3 
months after treatments compared with the values before treatment had started.   
 
 
 
b) Changes in the levels of pro-inflammatory cytokines produced in culture of 
activated T-lymphocytes and bone resorptive biomarkers: 
 
Quantification of the levels of TNFα from before to after treatment revealed that 
these were reduced in responder patients after 1 and 3 months of treatment. Thus, the mean 
and SD level of TNFα in the culture supernatants before treatment was 120±483ng/ml and 
this decreased to 11.4±20ng/ml and 6.7±4ng/ml after 1 and 3 months of treatment. However, 
these differences were not statistically significant at p=0.3 and 0.4, respectively, perhaps due 
to the sample number. The level of TNFα was lower in non-responder patients at 8.2±5ng/ml 
before treatment compared with responder patients (120±483ng/ml; Table 4.14). In addition, 
the level of TNFα in culture supernatants increased in the non-responder patients after 1 and 3 
months to 7±2ng/ml (p=0.3) and 10±10ng/ml (p=0.8), respectively (Figure 4.30A).  
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The level of IL-1 in the culture supernatants also decreased in the responder 
patients after 1 and 3 months. However, these reductions did not reach statistically significant 
levels. Thus, the the mean and SD level of IL-1 in the culture supernatants of stimulated T-
lymphocytes before treatment was 550±500pg/ml and this decreased to 472±500pg/ml 
(p=0.8) and 205±250pg/ml (p=0.4) after 1 and then 3 months of treatment. Similar to what 
was seen with the level of TNFα in culture supernatants of activated T-lymphocytes, the level 
of IL-1 in non-responder patients increased from 63±69pg/ml before treatment to 
202±483pg/ml (p=0.7) and 73±75pg/ml (p=0.3) after 1 and 3 months of treatment, 
respectively (Table 4.14) (Figure 4.30B). 
 
 
Table 4.14: Changes in the levels of TNFα and IL-1 in culture 
supernatants of ex vivo activated T-lymphocytes from RA patients 
treated with biologic anti-TNFα agents. 
Parameters 
 
Before 
treatment  
After 1 
month  
After 3 
months  
 
TNFα (ng/ml) 
- Responders 
- Non responders 
 
120 (483) 
8.2 (5) 
 
11.4 (20) 
7 (2) 
 
6.7 (4) 
10 (10) 
IL-1(pg/ml)       
- Responders 
- Non responders 
 
550 (500) 
63 (69) 
 
472 (500) 
202 (483) 
 
205 (250) 
73 (75) 
Levels of TNFα and IL-1 in culture supernatants of T-lymphocytes from 
treated RA patients stimulated ex vivo with anti-CD3 and anti-CD28 (both 
at 10µg/mL). Levels of the two cytokines were determined using multiplex 
MSD kits. Patients were divided into responder and no-responders based 
on changes in their DAS28. The values shown are for the mean and (SD).  
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Figure 4.30: Changes in the levels of TNFα and IL-1 in culture supernatants of 
ex vivo activated T-lymphocytes from RA patients treated with biologic anti-
TNFα agents. The T-lymphocytes were activated with anti-CD3/CD28 as described 
in the legend to Table 4.14 and TNFα and IL-1 content of the culture supernatants 
quantified using MSD kits. Patients were considered responders or non-responders 
depending on changes in their DAS28 scores.  
 
The mean ± SD level of IL-6 in culture supernatants of activated ex vivo T-
lymphocytes before treatment was 3.2±7ng/ml in responder patients compared with 
0.9±1ng/ml in non-responder patients (Table 4.15). The mean level of IL-6 increased in both 
groups of patients after 1 month of treatment with biologic anti-TNFα agents. Thus, the mean 
±SD level of IL-6 after 1 month was 3.5±5ng/ml (p=0.8) in responder patients and 
2±2.7ng/ml (p=0.08) in non-responder patients. The level of IL-6 decreased after 3 months of 
treatment in the responder patients to 1.5±2ng/ml (p=0.3) but remained higher than before 
treatment in non-responder after 3 months of treatment at 1.1±1ng/ml (p=0.6) (Figure 4.31A).  
The mean and SD level of IL-17 in culture supernatant of the activated T-lymphocytes 
increased in the responder patients after 1 and 3 months of treatment. Thus, the mean and SD 
levels of IL-17 were 0.5±0.3ng/ml before treatment and 1±1ng/ml (p=0.3) and 0.8±0.7ng/ml 
(p=0.4) after 1 and 3 months of treatment. The level of IL-17 decreased in the non-responder 
patients after 1 month but increased after 3 months of treatment. Thus, the mean and SD 
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levels of IL-17 were 0.6±0.4ng/ml before treatment, 0.5±0.2ng/ml (p=0.5) and 0.8±0.6ng/ml 
(p=0.5) after 1 and 3 months of treatment (Table 4.15) (Figure 4.31B). 
 
Table 4.15: Levels of IL-6 and IL-17 in culture supernatants of 
activated ex vivo T-lymphocytes from RA patients treated with biologic 
anti-TNFα agents. 
Parameters 
 
Before 
treatment  
After 1 
month  
After 3 
months  
 
IL-6 (ng/ml)    
- Responders 
- Non responders     
 
3.2 (7) 
0.9 (1) 
 
3.5 (5) 
2.0 (2.7) 
 
1.5 (2) 
1.1 (1) 
IL-17 (ng/ml )              
- Responders 
- Non responders                       
 
0.5 (0.3) 
0.6 (0.4) 
 
1.0 (1) 
0.5 (0.2) 
 
0.8 (0.7) 
0.8 (0.6) 
Levels of IL-6 and IL-17 were measured using MSD multiplex kits as 
described in Table 4.14. The values shown are for the mean and (SD).  
 
         
Figure 4.31: Changes in the levels of IL-6 and IL-17 produced into culture 
supernatants by activated ex vivo T-lymphocytes from RA patients treated with 
biologic anti-TNFα agents. Levels of the two cytokines and patient classification 
were as described in the legend of Table 4.14. 
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The level of IL-22 in the culture supernatants increased after treatment in the 
responder patients at 1 and 3 months of treatment. However, the differences did not reach 
statistically significant levels. Thus, the mean and SD levels of IL-22 were 5.1±2ng/ml before 
treatment and 7±5ng/ml (p=0.5) and 6.5±3ng/ml (p=0.7) at 1 and 3 months after treatment. In 
contrast, the level of culture supernatant IL-22 decreased in non-responder patients from 
5.8±4ng/ml before treatment to 3.3±2ng/ml (p=0.2) after 1 month then increased after 3 
months of treatment to 8.7±9ng/ml (p=0.5) (Table 4.16) (Figure 4.32A).  
 
The level of GM-CSF was higher at 2.9±2ng/ml in responder patients than in non-
responder patients at 1.7±0.9ng/ml before treatment. The mean level of GM-CSF increased in 
both groups of patients after 1 and 3 months of treatment but the differences were not 
statistically significant. Thus, the mean and SD levels of GM-CSF after 1 and 3 months of 
treatment were 3.7±2.6ng/ml (p=0.06) and 3.4±2.4ng/ml (p=0.2) in responder patients and 
1.9±1.1ng/ml (p=0.4) and 1.9±1.7ng/ml (p=0.9) in non-responder patients (Table 4.16) 
(Figure 4.32B).  
 
Table 4.16: Levels of IL-22 and GM-CSF in culture supernatants of ex 
vivo activated T-lymphocytes from RA patients treated with biologic 
anti-TNFα agents. 
Parameters 
 
Before 
treatment  
After 1 
month  
After 3 
months  
 
IL-22 (ng/ml) 
- Responders 
- Non responders 
 
5.1 (2) 
5.8 (4) 
 
7 (5) 
3.3 (2) 
 
6.5 (3) 
8.7 (9) 
GM-CSF (ng/ml)  
- Responders 
- Non responders                                         
 
2.9 (2) 
1.7 (0.9) 
 
3.7 (2.6) 
1.9 (1.1) 
 
3.4 (2.4) 
1.9 (1.7) 
Levels of the two cytokines and patient classification were as described in 
the legend to Table 4.14. The values shown are for the mean and (SD). 
 
                                                                                                                                   
- 158 - 
 
 
     
Figure 4.32: Changes in the levels of IL-22 and GM-CSF in culture 
supernatants of activated ex vivo T-lymphocytes from RA patients treated with 
biologic anti-TNFα agents. Levels of the two cytokines and patient classification 
were as described in the legend to Table 4.14. Means and SD of IL-22 and GM-CSF 
are presented in ng/ml. Levels of the two cytokine after treatment were compared 
with before treatment using paired Student’s t-test. 
 
 
4.3.7 Relationship between levels of bone turnover biomarkers with pro-inflammatory 
cytokines in RA patients treated with biologic anti-TNFα agents. 
 
To further assess the relationship between inflammation and bone loss in RA and the 
impact of biologic anti-TNFα agents, the relationship between bone turnover biomarkers and 
the level of key cytokines affected by the treatment was studied. The analysis involved 
correlating the level of cytokines in plasma and culture supernatant from activated T- 
lymphocytes and bone turnover biomarkers in plasma. The results are summarised below. 
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a) Relationship between plasma levels of bone turnover biomarkers and pro-
inflammatory and bone resorptive cytokines. 
 
Analysis of the relationship before treatment between TNFα and RANK-L 
showed a positive trend for a correlation between plasma levels of the two proteins. However, 
the correlation was not statistically significant (r=0.2, p=0.4) (Figure 4.33).  
 
                       
Figure 4.33: The relationship between plasma levels of RANK-L and TNFα before 
treatment with biologic anti-TNFα agents. Plasma levels of RANK-L were 
determined in the treated patients by ELISA while the level of TNFα was determined 
using multiplex MSD kits. Correlations made using Spearman’s correlation coefficient 
(r).  
 
After treatment, the analysis of the correlation between changes in RANK-L and 
TNFα revealed a direct positive correlation. This correlation was statistically significant, 
r=0.4, p=0.02 (Figure 4.34A). There was also a positive correlation between changes in 
RANK-L and IL-20 levels after 3 months of treatment, r=0.6, p=0.08. Thus, the level of 
RANK-L decreased with reduction in IL-20 after treatment with biologic anti-TNFα agents 
(Figure 4.34B). 
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Figure 4.34: The relationship between changes in plasma level of RANK-L with 
changes in levels of TNFα (A) and IL-20 (B) after 3 months of treatment with 
biologic anti-TNFα agents. The levels of RANK-L, TNFα and IL-20 were determined 
by ELISA. Correlations were with Spearman’s correlation coefficient (r).  
 
A strong positive correlation was observed between changes in plasma levels of the 
bone resorption marker CTX and TNFα after 3 months of  treatment with biologic anti-TNFα 
agents, (r=0.7, p=0.01) indicating an involvement of TNFα in bone erosion (Figure 4.35).  
                     
Figure 4.35: The relationship between changes in plasma levels of CTX and TNFα in RA 
patients after 3 months of treatment with biologic anti-TNFα agents. The levels of CTX 
and TNFα were determined by ELISA and correlations were calculated by Spearman’s 
correlation coefficient (r).  
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Although, a strong positive correlation was observed before treatment between CTX and 
plasma levels of IL-22 this did not reach statistically significant levels (r=0.5, p=0.06) (Figure 
4.36). The analysis of the correlation between changes in CTX and IL-22 after 3 months of 
treatment revealed a direct positive correlation, r=0.6, p=0.06 (Figure 4.37). 
 
                           
Figure 4.36: The relationship between plasma levels of CTX and IL-22 in RA patients 
before treatment with biologic anti-TNFα agents. CTX and IL-22 levels were measured by 
ELISA and correlations calculated by Spearman’s correlation coefficient (r). 
 
 
Figure 4.37: The relationship between changes in plasma level of CTX and changes 
in IL-22 level after 3 months of treatment with biologic anti-TNFα agents. The 
levels of CTX and IL-22 were determined by ELISA. Correlations were with 
Spearman’s correlation coefficient (r).  
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In contrast to CTX, a negative correlation was observed between changes in plasma 
levels of the OPG and osteocalcin with changes in IL-22 level after 3 months of treatment 
with biologic anti-TNFα agents, (r=-0.3, p=0.2 and r=-0.4, p=0.06) (Figures 4.38 and 4.39).  
                        
Figure 4.38: The relationship between changes in plasma level of OPG and changes 
in IL-22 level after 3 months of treatment with biologic anti-TNFα agents. The 
levels of OPG and IL-22 were determined by ELISA. Correlations were with 
Spearman’s correlation coefficient (r).  
 
                               
Figure 4.39: The relationship between changes in plasma level of osteocalcin and 
changes in IL-22 level after 3 months of treatment with biologic anti-TNFα agents. 
The levels of osteocalcin and IL-22 were determined by ELISA. Correlations were with 
Spearman’s correlation coefficient (r).  
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b)  Relationship between the levels of pro-inflammatory and bone resorptive 
cytokines produced by ex vivo T-lymphocytes and bone turnover biomarkers.  
 
The ability of T-lymphocytes from treated RA patients to produce pro-bone 
resorption cytokines before and after treatment with biologic anti-TNFα was correlated with 
the level of bone turnover biomarkers. This was carried out with two questions in mind: 1) 
whether the production of these cytokines influenced bone loss in RA patients, and 2) whether 
changes in the level of these cytokines after treatment correlated with similar changes in the 
bone biomarkers which would confirm the effect of TNFα on both sets of variables. The 
ability of T-lymphocytes to produce cytokines was studied using enriched ex vivo T-
lymphocytes stimulated with anti-CD3/CD28. The level of cytokines secreted into the culture 
supernatants of the cultured T-lymphocytes was measured using a combination of MSD kits 
and ELISA protocols.   
 
Analysis of the level of OPG in plasma with the level of TNFα and IL-6 in culture 
supernatants of the T-lymphocytes before treatment showed that the level of OPG inversely 
correlated with the levels of TNFα and IL-6 in the culture supernatants (r=-0.4, p=0.05; and 
r=-0.3, p=0.04, respectively) (Figure 4.40). The changes in level of OPG also inversely 
correlated with changes in IL-1, TNFα, IL-17 and GM-CSF levels after 3 months of treatment 
with biologic anti-TNFα agents, r=-0.5, p=0.02; r=-0.4, p=0.1; r=-0.3, p=0.4 and r=-0.4, 
p=0.01, respectively (Figures 4.41 and 4.42).  
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Figure 4.40: The relationship between plasma level of OPG with TNFα and IL-6 
produced ex vivo by activated T-lymphocytes from RA patients. Levels of TNFα (A) 
and IL-6 (B) were determined by a multiplex MSD kit. Plasma OPG levels were 
determined by ELISA. The correlations are for patients before treatment with biologic 
anti-TNFα agents had started. Correlations were calculated by Spearman’s correlation 
coefficient (r). 
 
          
Figure 4.41: Relationship between changes in plasma level of OPG and changes in 
IL-1 and TNFα after 3 months of treatment with biologic anti-TNFα agents. Plasma 
levels of OPG were determined by ELISA. Levels of IL-1 and TNFα in culture 
supernatants of enriched and ex vivo activated T-lymphocytes were determined using 
MSD kits. Correlations were by Spearman’s correlation coefficient (r).  
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Figure 4.42: Relationship between changes in plasma level of OPG and changes in 
IL-17 and GM-CSF after 3 months of treatment with biologic anti-TNFα agents. 
Plasma levels of OPG were determined by ELISA. Levels of IL-17 and GM-CSF in 
culture supernatants of enriched and ex vivo activated T-lymphocytes were determined 
using MSD kits. Correlations were by Spearman’s correlation coefficient (r).  
 
 
There were significant correlations between plasma level of CTX and the level of IL-
1, IL-6, IL-17 and GM-CSF (r=0.7, p<0.001; r=0.5, p=0.004; r=0.8, p=0.01; and r=0.4, 
p=0.01, respectively). These correlations again support the existent of a relationship between 
the potential of T-lymphocytes in RA patients to produce pro-inflammatory cytokines and 
bone loss (Figures 4.43 and 4.44).  
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Figure 4.43: Relationship between plasma levels of CTX with IL-1 and IL-6 in 
culture supernatants of ex vivo activated T-lymphocytes from RA patients. Levels 
of IL-1 (A) and IL-6 (B) were determined in culture supernatants of enriched and 
activated T-lymphocytes from RA patients before the start of treatment with biologic 
anti-TNFα agents using multiplex MSD kits. Plasma levels of CTX were determined by 
ELISA. Correlations were determined by Spearman’s correlation coefficient (r). 
 
        
Figure 4.44: Relationship between plasma levels of CTX with IL-17 and GM-CSF 
in culture supernatants of ex vivo activated T-lymphocytes from RA patients. 
Levels of IL-17 (A) and GM-CSF (B) were determined in culture supernatants of 
enriched and activated T-lymphocytes using multiplex MSD kits. Correlations were 
determined as described in the legend to the previous figures.  
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The analyses also revealed a positive correlation between plasma levels of CTX and IL-22 in 
the culture supernatants of the enriched and activated T-lymphocytes from the patients before 
the start of treatment. This correlation, however, was not statistically significant (r=0.7 and 
p=0.08) (Figure 4.45).  
 
                           
Figure 4.45: Relationship between plasma levels of CTX with IL-22 in culture 
supernatants of ex vivo activated T-lymphocytes from RA patients. Levels of IL-22 
in the culture supernatants were determined using ELISA.  
 
In addition to the direct relationship between the level of pro-inflammatory cytokines 
and biomarker of bone resorption before treatment, there was also a strong positive 
relationship between changes in the plasma levels of CTX with changes in the levels of IL-17 
and TNFα produced by activated ex vivo T-lymphocytes in culture after 3 months of treatment 
at the same time point, r=0.7, p=0.03 and r=0.4, p=0.4, respectively (Figure 4.46).  
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Figure 4.46: Relationships between changes plasma levels of CTX with changes in 
levels of IL-17 (A) and TNFα (B) produced by enriched and activated T-
lymphocytes obtained from RA patients after 3 months of treatment with biologic 
anti-TNFα agents. The level of CTX in plasma was determined by ELISA. The level of 
IL-17 and TNFα in culture supernatant was by MSD. Correlations were by Spearman’s 
correlation coefficient (r).  
 
The analyses also revealed a significant positive correlation between plasma levels of 
RANK-L and IL-17 in the culture supernatants of the enriched and activated T-lymphocytes 
from the patients after 3 months of treatment, r=0.6 and p=0.04 (Figure 4.47).  
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Figure 4.47: Relationships between changes plasma levels of RANK-L with changes 
in levels of IL-17 produced by enriched and activated T-lymphocytes obtained 
from RA patients after 3 months of treatment with biologic anti-TNFα agents. The 
level of RANK-L in plasma was determined by ELISA. The level of IL-17 in culture 
supernatant was by MSD. Correlations were by Spearman’s correlation coefficient (r).  
 
 
4.3.8 The relationship between the clinical response of patients with RA to biologic 
anti-TNFα agents and their bone response to the treatment. 
 
The clinical response of patients to treatment with biologic anti-TNFα agents as 
measured in DAS28 at 3 months after treatment was correlated with bone turnover 
biomarkers. The analyses revealed a trend for positive correlation between increased levels of 
osteocalcin and OPG with reduction in DAS28 (initial DAS28 - DAS28 at 3 months post 
treatment) after 3 months of treatment (r=0.2, p=0.1; and r=0.1, p=0.5), respectively, (Figure 
4.48). In contrast, a trend for negative correlation between increased levels of CTX and 
RANK-L with reduction in DAS28 after 3 months of treatment (r=-0.2, p=0.7; and r=-0.1, 
p=0.5), respectively, (Figure 4.49).    
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Figure 4.48: The relationships between changes in the levels of osteocalcin and 
OPG with reduction in DAS28 after treatment with biologic anti-TNFα agents. The 
figure depicts the relationship between reduction in disease activity measured in DAS28 
and levels of osteocalcin and OPG after 3 months of treatment with biologic anti-TNFα 
agents. Osteocalcin and OPG levels were determined by ELISA. The correlations were 
by Spearman’s correlation coefficient (r).  
 
         
Figure 4.49: The relationships between changes in the levels of CTX and RANK-L 
with reduction in DAS28 after treatment with biologic anti-TNFα agents. The figure 
depicts the relationship between reduction in disease activity measured in DAS28 and 
levels of CTX and RANK-L after 3 months of treatment with biologic anti-TNFα 
agents. CTX and RANK-L levels were determined by ELISA. The correlations were by 
Spearman’s correlation coefficient (r).  
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The effect of age, gender and ethnic origin on improvement in the level of bone 
turnover biomarkers in the treated RA patients was also investigated. For that reason, patients 
were divided into responder and non-responders to treatment with biologic anti-TNFα agents 
based on changes in their DAS28. These patients were then divided into subgroups according 
to gender, age groups and ethnic origin. Variations in the level of the bone turnover 
biomarkers among the different groups were then analysed using contingency tables. 
 
a) The impact of gender, age and ethnic origins on changes in the level of 
osteocalcin following treatment of RA patients with biologic anti-TNFα agents. 
 
Patients were assessed for the effect of gender on changes in the level of 
osteocalcin after treatment. No significant differences in the level of osteocalcin before 
treatment were observed between the male and female patients. Thus, mean osteocalcin (±SD) 
levels in male and female patients were 13±9ng/ml and 15±11ng/ml, respectively. The mean 
increase in osteocalcin level in male patients was greater than in female patients after 1 and 3 
months of treatment, 2ng/ml (15%) and 6ng/ml (46%) (p=0.1 and p=0.06) vs. 1ng/ml (6.6%) 
and 1ng/ml (6.6) (p=0.2 and p=0.5), respectively. The plasma level of osteocalcin was 
improved in 9 of 11 responder males (82%) compared with 14 of 27 responder female patients 
(52%) (p=0.1). Further, changes in the level of osteocalcin in non-responder patients was 
compared between females (n=11) and males (n=2). Osteocalcin level increased in the plasma 
of all male patients and in 8 (73%) female patients (p=1.0) (Table 4.17). 
To study the effect of age on changes in the level of osteocalcin following treatment, 
levels of osteocalcin was assessed by determining increases in its level in 12 ≤50 year old 
patients and 39 >50 year old patients. Plasma levels of osteocalcin before treatment were 
12±9ng/ml in ≤50 year old patients compared with 14±111ng/ml in >50 year old patients. The 
mean levels of osteocalcin increased in both groups of patients after 1 and 3 months of 
treatment with biologic anti-TNFα agents, however, these differences did not reached the 
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statistically significant levels. Thus, the mean difference and percentage of increase in 
osteocalcin levels after 1 and 3 months of treatment were 1ng/ml (8%) and 1ng/ml (8%) 
(p=0.5 and p=0.6) in ≤50 year old patients and 1ng/ml (7%) and 2ng/ml (14%) (p=0.1 and 
p=0.07) in >50 year old patients.  
No significant differences were observed in changes in the level of osteocalcin 
between the two subgroups of patients. The level of osteocalcin increased in 5 of 8 ≤50 year 
age responder patients (63%) and 18 of 30 >50 year responder patients (60%) (p=1.0). In non-
responder patients, the level of osteocalcin increased after treatment with the biologic anti-
TNFα agents in 2 of 4 ≤50 year old non-responder patents (50%) and in 8 of 9 >50 year old 
patients (89%)  (p=0.2) (Table 4.17).  
 
Changes in the level of osteocalcin after treatment with biologic anti-TNFα agents in 
patients from different ethnic groups were also investigated. Plasma levels of osteocalcin 
before treatment were 12±8ng/ml in Caucasian patients compared with 13±9ng/ml in Asian 
patients. The increase in osteocalcin level in Caucasian patients was greater than in Asian 
patients after 1 and 3 months of treatment, 3ng/ml (25%) and 3ng/ml (25%) (p=0.01 and 
p=0.02) vs. 1ng/ml (7%) and 1ng/ml (7%) (p=0.3 and p=0.07), respectively. In responder 
patients, the osteocalcin level increased in the plasma of 13 of 17 Caucasian patients (76%) 
and 8 of 12 Asian patients (67%) (p=0.7). In non-responder patients, osteocalcin was 
increased in the plasma of all 5 Caucasian patients and in the plasma of 3 of 6 Asian patients 
(50%) (Table 4.17). 
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Table 4.17: Changes in the level of osteocalcin in RA patients treated with biologic 
anti-TNFα agents.  
Parameters for patients classification 
 
Increased 
osteocalcin 
No change in 
osteocalcin levels 
Total of 
patients 
studied  
Gender 
 Responder            
- Male                  n (%) 
- Female              n (%) 
 Non responder    
- Male                  n (%) 
- Female               n (%)  
 
 
9 (82) 
14 (52) 
 
2 (100) 
8 (73) 
 
 
2 (18) 
13 (48) 
 
0 (0) 
3 (27) 
 
 
11 
27 
 
2 
11 
Age group 
 Responder            
- ≤50 years old     n (%) 
- >50 years old     n (%) 
 Non responder    
- ≤ 50 years old    n (%)                                  
-  >50 years old    n (%) 
 
 
5 (63) 
18 (60) 
 
2 (50)
8 (89) 
 
 
3 (47) 
12 (40) 
 
2 (50) 
1 (11) 
 
 
8 
30 
 
4 
9 
Ethnic origin* 
 Responder            
- Caucasians        n (%) 
- Asians               n (%) 
 Non responder    
- Caucasians        n (%) 
- Asians               n (%)  
 
 
13 (76) 
8 (67) 
 
5 (100) 
3 (50) 
 
 
4 (24) 
4 (33) 
 
0 (0) 
3 (50) 
 
 
17 
12 
 
5 
6 
RA patients treated with biologic anti-TNFα agents were divided into responder and 
non-responder patients based on changes in their DAS28. The patients from the two 
groups were further subdivided into subgroups according to gender, age and ethnic 
origin. Changes in osteocalcin levels were defined as having an increase in its level 
after treatment compared with its level before treatment. No change in the level of 
osteocalcin was defined as having level similar to or reduced after treatment compared 
with its level before treatment. The differences in osteocalcin among patient groups 
were assessed by using contingency tables. Information on ancestral origin of 11 
patients wasn’t available. 
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b) The effect of gender, age and ethnic origin on changes in the level of CTX 
following treatment of RA patients with biologic anti-TNFα agents. 
 
Patients were assessed for the effect of gender on changes in the level of CTX after 
treatment. No significant differences in the level of CTX before treatment were observed 
between the male and female patients. Thus, mean CTX (±SD) levels in male and female 
patients were 164±166pg/ml and 158±100pg/ml, respectively. The mean reduction in CTX 
levels in male patients was greater than in female patients after 1 and 3 months of treatment, 
5pg/ml (4%) and 65pg/ml (40%) (p=0.4 and p=0.5) vs. 1pg/ml (0.6%) and 8pg/ml (4%) 
(p=0.3 and p=0.6), respectively. The level of CTX decreased in the plasma of 5 of 9 male 
patients (56%) and 11 of 19 female patients (58%) within the responder group (p=1.0). In 
non-responder patients, plasma levels of CTX did not change in both male patients but 
decreased in the plasma of 4 of the 7 (57%) female patients studied (Table 4.18). 
The effect of age on change in plasma levels of CTX was assessed by determining 
reduction in its level in 7 ≤50 year old patients and 30 >50 year old patients. Plasma levels of 
CTX before treatment were 169±99pg/ml in ≤50 year old patients compared with 
158±131pg/ml in >50 year old patients. The mean levels of CTX decreased in both groups of 
patients after 1 and 3 months of treatment with biologic anti-TNFα agents, however, these 
differences did not reached the statistically significant levels. Thus, the mean difference and 
percentage of reduction in CTX levels after 1 and 3 months of treatment were 21pg/ml (12%) 
and 26pg/ml (15%) in ≤50 year old patients and 2pg/ml (1.3%) and 29pg/ml (18%) in >50 
year old patients. The level of CTX decreased in the plasma of 3 of 4 ≤50 year old responder 
patients (75%) compared to 13 of 24 >50 year old responder patients (54%) (p=0.6). CTX 
was detectable in the plasma of 3 ≤50 year old and 6 >50 year old non-responder patients. The 
analysis revealed a higher level of reduction in plasma levels of CTX in the ≤50 year patients 
compared with the >50 old (p=0.04) (Table 4.18).  
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Changes in the level of CTX in patients from different ethnic origins were also 
assessed. No differences were observed in the level of CTX before treatment between 
Caucasian and Asian patients. Thus, the mean plasma levels of CTX before treatment were 
159±134pg/ml in Caucasian patients compared with 161±91pg/ml in Asian patients. The 
reduction in CTX levels in Asian patients were greater than Caucasian patients after 1 and 3 
months of treatment, 1pg/ml (0.6%) and 63pg/ml (39%) (p=0.8 and p=0.01) vs. 1pg/ml 
(0.6%) and 4pg/ml (3%) (p=0.9 and p=0.2), respectively. The plasma levels of CTX 
decreased in 7 of 12 Caucasian responder patients (58%) and 8 of 10 Asian responder patients 
(80%) (p=0.4).  In the non-responder group, the level of CTX did not decrease in the plasma 
of 3 Caucasian patients but decreased in plasma of 4 of 5 Asians patients (80%)  (p=0.1) 
(Table 4.18). 
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Table 4.18: Changes in the level of CTX in RA patients treated with biologic 
anti-TNFα agents.  
Parameters for patients classification 
 
Decreased  
CTX levels 
No change in 
CTX levels  
Total of 
patients 
studied  
Gender 
 Responder            
- Male            n (%) 
- Female         n (%) 
 Non responder    
- Male             n (%) 
- Female          n (%)  
 
 
5 (56) 
11 (58) 
 
0 (0) 
4 (57) 
 
 
4 (44) 
8 (42) 
 
2 (100) 
3 (43) 
 
 
9 
19 
 
2 
7 
Age group 
 Responder            
- ≤50 year old   n (%) 
- >50 year old   n (%) 
 Non responder    
- ≤ 50 year old   n (%)                                  
-  >50 year old   n (%) 
 
 
3 (75) 
13 (54) 
 
3 (100)
1 (17) 
 
 
1 (25) 
11 (46) 
 
0 (0) 
5 (83) 
 
 
4 
24 
 
3 
6 
Ethnic origin* 
 Responder            
- Caucasians       n (%) 
- Asians              n (%) 
 Non responder    
- Caucasians       n (%) 
- Asians              n (%)  
 
 
7 (58) 
8 (80) 
 
0 (0) 
4 (80) 
 
 
5 (42) 
2 (20) 
 
3 (100) 
1 (20) 
 
 
12 
10 
 
3 
5 
Patients were divided into responder and non-responders described in the legend to 
Table 4.17. Reduction the level of CTX was based on lower levels after treatment 
compared with before treatment. Significant differences in reductions in the level of 
CTX among patient groups were assessed by using contingency tables. Information 
on the ethnic origin of 7 patients was not available. 
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c) The effect of gender, age and ethnic origin on changes in plasma levels of 
RANK-L in RA patients treated with biologic anti-TNFα agents. 
 
Patients were separately assessed for the effect of gender on changes in the level of 
RANK-L after treatment. No significant differences in the level of RANK-L were observed 
between the male and female patients before treatment. Thus, mean RANK-L (±SD) levels in 
male and female patients were 161±136pg/ml and 178±171pg/ml, respectively. The mean 
reduction in RANK-L levels in female patients was greater than in male patients after 1 and 3 
months of treatment, 32pg/ml (18%) and 30pg/ml (17%) (p=0.03 and p=0.8) vs. 4pg/ml (2%) 
and 5pg/ml (4%) (p=0.3 and p=0.6), respectively. In the responder group, RANK-L level 
decreased after treatment in the plasma of 5 of 11 male patients (45%) and in 17 of 28 females 
(61%) (p=0.5). In the non-responder group the level of RANK-L did not decrease in the 
plasma of 2 male patients but decreased in plasma of 7 of 9 female patients (p=0.1) (Table 
4.19).  
 The effect of age on change in plasma levels of RANK-L was assessed by 
determining reduction in its level in 13 ≤50 year old patients and 37 >50 year old patients. 
Plasma levels of RANK-L before treatment were 142±107pg/ml in ≤50 year old patients 
compared with 162±128pg/ml in >50 year old patients. The mean levels of RANK-L 
decreased in both groups of patients after 1 and 3 months of treatment with biologic anti-
TNFα agents, however, these differences did not reached the statistically significant levels. 
Thus, the mean difference and percentage of reduction in RANK-L levels after 1 and 3 
months of treatment were 10pg/ml (7%) and 17pg/ml (12%) in ≤50 year old patients and 
6pg/ml (4%) and 11pg/ml (8%) in >50 year old patients. The level of RANK-L in plasma of 
responder patients decreased in 6 of 9 ≤50 year old group patients (67%) and in 16 of 30 >50 
year old patients (53%) (p=0.7) (Table 4.19). In non-responder patients, the level of RANK-L 
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decreased in the plasma of 3 of 4 ≤50 year old patients (75%) and in 4 of 7 >50 year old 
patients (57%) but this difference was not statistically significant (p=1.0) (Table 4.19). 
 
Changes in the level of RANK-L after treatment in relation to ethnic origin of the 
patients were also assessed. Plasma levels of RANK-L before treatment were 165±169pg/ml 
in Caucasian patients compared with 134±111pg/ml in Asian patients. The mean difference 
and percentage of reduction in RANK-L levels after 1 and 3 months of treatment were 6pg/ml 
(4%) and 7pg/ml (4%) in Caucasian patients and 10pg/ml (7%) and 12pg/ml (9%) in Asian 
patients. The level of RANK-L decreased in the plasma of 8 of 18 Caucasian responder 
patients (44%) and in 6 of 11 Asian responder patients (55%) (p=0.7). In the non-responder 
patients, the level of RANK-L decreased in the plasma of 2 of 3 Caucasian non-responder 
patients (67%) and in 4 of 6 Asian non-responders (67%) (p=1.0) (Table 4.19). 
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Table 4.19: Changes in the level of RANK-L after treatment of RA patients 
with biologic anti-TNFα agents.  
Parameters for patients classification 
 
 
Decreased 
RANK-L 
levels 
No change in 
RANK-L levels 
Total  
Gender 
 Responder            
- Male           n (%) 
- Female        n (%) 
 Non responder    
- Male           n (%) 
- Female        n (%)  
 
 
5 (45) 
17 (61) 
 
0 (0) 
7 (78) 
 
 
6 (55) 
11 (39) 
 
2 (100) 
2 (22) 
 
 
11 
28 
 
2 
9 
Age group 
 Responder            
- ≤ 50 years old    n (%) 
- >50 years old     n (%) 
 Non responder    
- ≤ 50 years old     n (%)                                  
-  >50 years old    n (%) 
 
 
6 (67) 
16 (53) 
 
3 (75) 
4 (57) 
 
 
3 (33) 
14 (47) 
 
1 (25) 
3 (43) 
 
 
9 
30 
 
4 
7 
Ancestral origin* 
 Responder            
- Caucasians  n (%) 
- Asians         n (%) 
 Non responder    
- Caucasians  n (%) 
- Asians         n (%)  
 
 
8 (44) 
6 (55) 
 
2 (67) 
4 (67) 
 
 
10 (56) 
5 (45) 
 
1 (33) 
2 (33) 
 
 
18 
11 
 
3 
6 
Patients were divided into responder and non-responders as described above. 
Improvement in RANK-L was defined as having RANK-L decrease after treatment. 
Non-improved RANK-L was defined as having RANK-L remaining the same or 
increased after treatment. The differences in RANK-L among patient groups were 
assessed by using contingency tables. Information on ancestral origin of 12 patients 
wasn’t available. 
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d) The effect of gender, age and ethnic origin on changes in plasma level of OPG 
after treatment of RA patients with biologic anti-TNFα agents. 
 
Patients were separately assessed for the effect of gender on changes in the level of 
OPG after treatment. The plasma level of OPG in female patients was greater than in male 
patients before treatment. Thus, mean OPG (±SD) levels in female and male patients were 
3.1±1.4ng/ml and 2.4±1.7ng/ml, respectively. There were higher increases in the level of 
OPG in male patients compared with female patients after 1 and 3 months of treatment. 
However, the difference did not reach statistically significant levels. The increase and 
percentage of changes in OPG level in male patients after 1 and 3 months of treatment were 
0.1ng/ml (4%) and 5ng/ml (21%) (p=0.6 and p=0.2), respectively. In contrast, OPG level in 
female patients decreased after 1 and 3 months of treatment by 0.2ng/ml (-6%) and 0.1ng/ml 
(-3%) (p=0.2 and p=0.9), respectively. In responder group the level of OPG increased after 
treatment in 7 of 11 male patients (64%) and in 13 of 28 female patients (46%) (p=0.7). In 
non-responder patients, the level of OPG increased more in male patients compared with the 
female patients. Thus, the level of OPG increased in the plasma of all male patients and in 7 
of the 11 female patients (64%) (Table 4.20). 
 
Analysis of the level of OPG in plasma in relation to age of patients was carried out in 
40 >50 year old patients and 12 ≤50 year old patients. The plasma level of OPG in >50 year 
old patients was greater than in ≤50 year old patients before treatment. Thus, mean OPG 
(±SD) levels in >50 year old patients and ≤50 year old patients were 3±1.6ng/ml and 
2.4±0.9ng/ml, respectively. There were reductions in plasma levels of OPG in the ≤50 year 
old patients after 1 and 3 months of treatment to 2.1±0.6ng/ml (p=0.2) and 2.2±0.8 (p=0.3), 
respectively. The plasma level of OPG in >50 year old patients did not change after 1 and 3 
months of treatment. In the responder patients, the level of OPG increased after treatment in 
the plasma of 17 >50 year old patients (55%) and 3 ≤50 year old patients (38%), but this 
difference was not statistically significant (p=0.5). In the non-responder patients, the levels of 
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OPG increased in 3 of 4 ≤50 year olds (73%) compared with 6 of 9 >50 year olds patients 
(67%) (p=1.0) (Table 4.20). 
 
Changes in the level of OPG in relation to ethnic origin was analysed in 23 Caucasian 
and 17 Asian patients. There were no significant differences in the level of OPG before and 
after treatment between the two ethnic groups. Thus, mean OPG (±SD) levels before 
treatment in Caucasian and Asian patients were 2.6±1.4ng/ml and 2.7±1.5ng/ml, respectively. 
The plasma levels of OPG after 1 and 3 months of treatment were 2.4±1.2ng/ml and 
2.8±1.6ng/ml, respectively (p=0.1 and p=0.2) in Caucasian patients and 2.7±1.7ng/ml and 
2.5±1.4ng/ml, respectively (p=0.9 and p=0.8) in Asian patients. The level of OPG increased 
in the plasma of 11 of 18 responder Caucasian patients (61%) and in the plasma of 5 of 11 
responder Asian patients (42%) (p=0.5). In non-responder patients, the level of OPG 
increased after treatment in the plasma of 2 of 5 (40%) treated Caucasian patients and in 4 out 
of 6 (67%) Asian patients (p=0.6) (Table 4.20). 
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Table 4.20: Changes in the level of OPG after treatment of RA patients with 
biologic anti-TNFα agents.  
Parameters of patients classification  
 
Increased 
OPG levels 
No change in 
OPG levels  
Total  
Gender 
 Responder            
- Male           n (%) 
- Female        n (%) 
 Non responder    
- Male           n (%) 
- Female        n (%)  
 
 
7 (64) 
13 (46) 
 
2 (100) 
7 (64) 
 
 
4 (36) 
15 (54) 
 
0 (0) 
4 (36) 
 
 
11 
28 
 
2 
11 
Age group 
 Responder            
- ≤ 50 year old     n (%) 
- >50 year old      n (%) 
 Non responder    
- ≤ 50 year old      n (%)                                  
-  >50 year old      n (%) 
 
 
3 (38) 
17 (55) 
 
3 (75) 
6 (67) 
 
 
5 (62) 
14 (45) 
 
1 (25) 
3 (33) 
 
 
8 
31 
 
4 
9 
Ancestral origin* 
 Responder            
- Caucasians  n (%) 
- Asians         n (%) 
 Non responder    
- Caucasians  n (%) 
- Asians         n (%)  
 
 
11 (61) 
5 (42) 
 
2 (40) 
4 (67) 
 
 
7 (39) 
6 (58) 
 
3 (60) 
2 (33) 
 
 
18 
11 
 
5 
6 
Patients were divided into responder and non-responders as described above. 
Improvement in plasma levels of OPG was defined as having OPG increased after 
treatment compared with before treatment. No change in OPG was defined as having 
OPG remaining relatively the same or decreasing in the patients after treatment 
compared with before treatment. The differences in OPG among patient groups were 
assessed by using contingency tables. Information on the ethnic origin of 12 patients 
was not available. 
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4.4 Discussion  
 
Key findings from studies reported in this chapter are that treatment of RA patients 
with biologic anti-TNFα agents reduces generalised bone loss and alters the balance of bone 
turnover in favour of new bone formation as evidenced by increased BMD at lumbar spine 
and total hip, and by improvement in plasma levels of a range of bone biomarkers. In 
addition, the study provides preliminary evidence for decreased localised bone loss in the 
hand of patients with RA treated with the biologic anti-TNFα agents. 
 
Previous studies in this field have shown that generalised bone loss in patients with 
RA usually starts as a result of disease activity and the resulting immobilisation of the patients 
(35,185). Bone loss of up to 0.7% at the spine and 1.1% at the hip after 1 year of disease have 
been reported in historical control group studies of patients with RA when treated with 
conventional DMARDs (186,187). Furthermore, in early RA, generalised annual bone loss is 
even greater than the values cited above at 4.2% at the spine and 2.1% at the hip (189). 
Comparing the results of the present study with those of the earlier historical control group 
studies of patients with RA clearly indicates that bone loss is far less in patients treated with 
biologic anti-TNFα agents compared with patients treated with other agents. In addition to the 
effect of biologic anti-TNFα agents on BMD in the spine and the hip, the current study 
provides preliminary evidence for improvement in localised BMD of the hand as measured by 
DXR. Thus, the results show that no reduction in hand BMD was seen after six months of 
treatment with biologic anti-TNFα agents. Since there are no DXR data on hand BMD in 
patients with RA treated with DMARDs, it is unclear how this effect by biologic anti-TNFα 
agents on localised bone loss in the hand compares with the effect of DMARDs. A double-
blind randomised controlled trail revealed that the rate of hand bone loss measured by DXR 
was significantly reduced in patients with RA treated with prednisolone compared with 
patients treated with placebo (190). However, this improvement decreased considerably over 
time (190). In contrast to our findings, a group of investigators reported a decrease in hip and 
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hand BMD of RA patients treated with adalimumab (124). However, these investigators 
measured hand BMD after one year of treatment and 22% of their patients were treated with 
bisphosphonates, while in this study, hand BMD was measured six months after treatment had 
started and patients receiving bisphosphonates were excluded from the study.  
 
As expected, the bone resorption biomarker, CTX decreased in responder patients after 
3 months of treatment compared with its levels before treatment. In contrast, non-responder 
patients showed an increase in the level of CTX after 3 months of treatment compared with 
before treatment. This supports the view that treatment with biologic anti-TNFα agents 
reduces disease activity and thereby supresses bone loss. However, there was no significant 
association between changes in disease activity and CTX levels. Reduction of CTX in patients 
treated with biologic anti-TNFα agents was reported by other investigators (124,136,138) 
indicating That treatment with biologic anti-TNFα has potential to inhibit generalised bone 
loss in patients with RA in addition to its clinical efficacy in reducing disease activity. 
 
Measurement of osteocalcin levels, in contrast, revealed significant increases 3 months 
after treatment compared with before treatment in non-responder patients but not after one 
month. This data can be explained by an initial inhibitory effect of TNFα on osteoblast 
metabolic function (191). Levels of osteocalcin also increased in responder patients. 
However, the differences between the two response groups did not reach statistical 
significance. The effect of biologic anti-TNFα agents after 1 year of treatment was reported in 
other studies (124,131-134). These studies reported persistent increases in osteocalcin levels, 
which are consistent with the results presented in this study. 
 
The osteoclast-activating RANK-L decreased significantly after three months of 
treatment in responder patients compared with its levels before treatment (197±137pg/ml vs. 
170±100pg/ml; p=0.047). However, there was an increase in the level of RANK-L in non-
responder patients although this was not statistically significant (186±90pg/ml vs. 
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192±110pg/ml; p=0.8). The decrease in plasma levels of RANK-L in responder patients, 
which was paralleled by an increase in OPG levels, and the tendency for increased RANK-L 
in non-responders suggests that RANK-L production is regulated by TNFα in RA patients 
(192,193). In this respect, it seems possible that the production of RANK-L is induced 
through several pathways one of which involves TNFα. In RA patients in whom TNFα is not 
the prime inducer of RANK-L, treatment with biologic anti-TNFα agents do not induce 
remission nor reduce RANK-L levels since inflammatory pathways other than TNFα drive 
disease and RANK-L. This proposition is based on the observation that non-responder 
patients have a preponderance of T-lymphocytes that produce IL-17 (184). Overall, changes 
in bone biomarkers during treatment with biologic anti-TNFα agents support the effect of this 
treatment on bone-protection. 
 
Previous studies have indicated that pro-inflammatory cytokines other than TNFα, 
such as IL-1, IL-6, IL-17, IL-20 and IL-22 are involved in inhibiting of OPG production but 
promote RANK-L production with the net result being an obvious rise in osteoclasts 
formation and functions (144-147). The results reported in this chapter were consistent with 
these studies. Positive correlations were observed between changes in plasma levels of 
RANK-L and CTX with levels of TNFα, IL-20 and IL-22. In addition, GM-CSF and pro-
inflammatory cytokines including IL-1, IL-6, IL-17 showed significant positive correlations 
with the level of CTX, (r=0.7 (p<0.001), r=0.5 (p=0.004), r=0.8 (p=0.01) and r=0.4 (p=0.01), 
respectively, indicating a strong relationship between inflammation and bone loss. In contrast, 
OPG levels increased with reductions in TNFα, IL-1, IL-17 and IL-22 levels. Negative 
correlations were also observed between changes in plasma levels of osteocalcin and IL-22. 
These observations can be explained as being a consequence of the involvement of pro-
inflammatory cytokines in the suppression of OPG and promoting RANK-L upregulation as it 
was reported in earlier studies (144-147).  
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The relationship between inflammation and bone loss has been clearly established in 
numerous clinical and experimental models (144-147,180,194). Key pro-inflammatory 
cytokines including TNFα, IL-1, IL-6 and IL-17 as well as IL-20, IL-22 and GM-CSF have 
bone actions to induce generalised bone loss and subchondral bone resorption in 
inflammatory diseases such as RA. Results presented in this study are consistent with these 
studies. BMD values of the lumbar spine, hip and hand negatively correlated with increases in 
TNFα, IL-1, IL-6, IL-22 and GM-CSF, indicating that a good control of inflammation would 
prevent further bone loss. 
 
Although many studies of the effect of biologic anti-TNFα agents on markers of bone 
turnover have been carried out (132-134,138), the impact of individual factors on the 
improvement of bone turnover biomarkers in RA patients have rarely been evaluated and 
most of these studies have focused on the relation between disease severity and low BMD. 
Lems and colleagues (195) measured variables associated with BMD in subgroups of patients 
and they found that low BMD improvement was associated with older age, longer duration of 
menopause and lower body mass in female patients. Similarly, findings in this study are 
consistent with results from an audit (retrospective study) cited at the beginning of this 
chapter and results from the analysis of changes in BMD among osteoporosis patients cited in 
chapter 3. Better improvement in both bone turnover biomarkers and BMD was observed 
among male patients compared with female patients, as well as younger (≤50 years) compared 
with older patients (>50 years). However, the differences did not reach statistically significant 
levels due, probably, to the effect of sample size. Importantly, a beneficial effect was also 
observed in the apparently non-responder patients despite the effect of being female and 
older.  
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Chapter 5 
 
The effect of biologic anti-TNFα agents on bone 
in patients with RA: direct effects on osteoclast 
precursor cell generation and differentiation  
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5.1 Introduction  
 
There is compelling evidence to indicate that local and systemic bone loss in RA result 
from osteoclast-mediated bone resorption mediated by increased production of TNFα 
(179,183,195). Furthermore, TNFα has been shown to act as key factor in the development 
and differentiation of osteoclast precursor cells (OCPs) in TNFα-transgenic mice (183). In 
addition, TNFα promotes osteoclast differentiation from progenitor cells in cooperation with 
RANK-L, an essential growth factor for osteoclast lineage cell generation (38,59,196). In 
support of these observations in humans, treatment of psoriatic arthritis patients with biologic 
anti-TNFα agents decreases the frequency of OCPs (197). Furthermore, these agents also 
suppress RANK expression on peripheral blood mononuclear cells (PBMNCs) and RANK-L 
on synovial fibroblasts in patients with RA in parallel with an increase in the number of OPGs 
(198). Indeed, there are studies showing that treatment of RA patients with biologic anti-
TNFα agents reduces joint damage (199). The aim of this study was to determine the direct 
effect of blocking TNFα in patients with RA on the frequency of OCPs. The effect of 
treatment with biologic anti-TNFα agents on the frequency of ex-vivo blood OCPs cells and 
on the differentiation of blood monocytes/macrophages in-vitro were studied. The data were 
then correlated with the clinical response of patients with RA treated with the biologic anti-
TNFα agents.  In addition, the data on the direct effect of the agents on changes in bone 
biomarkers were determined. In order to determine the ability of biologic anti-TNFα agents 
on the production of other potential factors that promote OCP generation in blood, the ability 
of culture supernatants of PBMNCs from RA patients to promote the differentiation of 
monocytes from healthy control to OCPs after treatment was also determined.The effect of 
TNFα and RANK-L blockade in vitro on suppressing osteoclast differentiation was also 
studied. 
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5.2 Patients and Methods: 
 
Blood samples from 8 RA patients treated with biologic anti-TNFα agents were 
obtained for the study. The samples were collected just before treatment had commenced and 
at 1 and 3 months after treatment. The mean and SD of their ages were 54±18 years with a 
range of 24-77 years old.  All patients with severe disease and a mean ±SD of DAS28 scores 
of 5.4±0.9 at the time they were prescribed biologic anti-TNFα agents. All patients were 
prescribed the treatment after they have failed other disease-modifying anti rheumatic drugs 
one of which was always methotrexate. The patients included 7 females and 1 male. None of 
the patients were receiving bisphosphonates or hormone replacement therapy. The patients 
received combination therapy including biologic anti-TNFα with methotrexate (12.5mg/day); 
6 received etanercept and 2 adalimumab. Three patients were taking calcium (1g/day) and 
vitamin D (800 IU/day). A total of 12 healthy controls were also recruited for the study, with 
the mean and SD of their age been 44±12 years with a range of 27-62 years old. All healthy 
controls were males.  
 
a) Enrichment and analyses of PBMNCs: 
Peripheral bloods were obtained by venous puncture into EDTA/heparin containing 
tubes. PBMNCs were obtained from 25ml blood by centrifugation on Ficoll-Paque, as 
described in the Materials and Methods’ chapter. Plasma samples from the blood were 
obtained and stored until tested for the level of RANK-L, OPG, and bone turnover biomarkers 
including osteocalcin and CTX using adapted ELISA protocols. The number of PBMNCs was 
counted using an equal volume of 0.5% Trypan blue under an inverted light microscope. One 
million of the PBMNCs were then placed in a well of a 24-well culture plates with RPMI1640 
medium containing 10% FCS and antibiotics. 
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The cultured cells were incubated in a humidified incubator at 37°C with 6% CO2 in 
the air for 14 days. Culture media were replenished every 3 days and culture supernatants 
collected, filtered, and stored at –20°C until used to study the effects of TNFα inhibition on 
OCP differentiation. Cultured cells incubated with monocyte colony stimulating factor (M-
CSF) at 25ng/ml and RANK-L (100ng/ml) served as positive controls (all from R&D). 
 
After 14 days of culture, the cells were stained for tartrate-resistant acid phosphatase 
(Acid Phosphatase, Leukocyte (TRAP) Kit; Sigma-Aldrich, UK) and viewed and quantified 
by light microscopy. The number of TRAP-positive cells with three or more nuclei was 
counted as osteoclasts in cultures of monocytes from the RA patients and matched healthy 
controls.  
 
b) Fluorescence-activated cell sorting (FACS) analysis for measuring the frequency 
of OCPs before and after treatment of RA patients with biologic anti-TNFα 
agents 
Flow cytometry (or FACS) analysis was carried to calculate the frequency of OCPs 
before and after treatment of RA patients with the biologic anti-TNFα agents. For this 
purpose, the cells were washed and resuspended in cold PBS containing 4% FBS. Aliquots of 
0.1 x 106 cells were incubated with anti–human CD11b (clone ICRF44), anti–human CD14 
(clone M5E2) (both from BD Pharmingen TM, UK) and antibody to RANK (R&D). The 
latter staining was carried out to determine the percentage of cells expressing RANK within 
the cell population because RANK is a key marker of OCPs. The cells were washed with 4% 
FBS-PBS and fixed using paraformaldehyde and stored at 4°C until analysed (within 24-
48hrs). Data were acquired using a FACS Calibur flow cytometer and analysed by CellQuest 
software, version 3.1 (both from Becton Dickinson Immunocytometry Systems, Bedford, 
Massachusetts, USA).  
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c) Inhibition of osteoclastogenesis by OPG and anti-TNFα 
PBMNCs from 3 healthy controls were seeded in 96-well flat-bottomed culture plates 
at 1 × 106 cells per well with 50% culture supernatants obtained from the cultured PBMNCs 
obtained from RA patients and mixed with an equal volume of fresh culture medium in a total 
of 200μl. To assess the effect of inhibiting TNFα in the culture supernatants from the RA 
patients, anti-TNFα antibody (infliximab; courtesy of Prof. A. Jawad) was added to parallel 
wells at a final concentration of 2.5μg/ml. To assess the effect of OPG on reducing the 
differentiation of osteoclast in the culture system, OPG-Fc (R&D Systems Inc.) was added at 
a final concentration of 1.0μg/ml. The medium was replenished every 3 days and after 14 
days in culture, the cells were stained for TRAP and osteoclasts counted as described 
previously. The results were compared for PBMNCs from healthy controls cultured with 
supernatant from the RA cells to similar cells cultured in the presence of TNFα inhibitors and 
OPG. Personal and clinical details of the 8 RA patients involved in the study are summarised 
in Table 5.1. 
 Table 5.1: Clinical and demographic details of RA patients 
included in the study of OCP. 
 
 
 
 
 
 
Eight RA patients were recruited to determine the direct effect of blocking 
TNFα on the in vivo and in vitro OCP frequency.  
Parameters of patient assessment Patients 
   n=8 
Gender                                             
                                                 Male    (%) 
                                                 Female (%) 
- (Post-menopausal) (%)                                                 
 
1 (13) 
7 (87) 
5 (71) 
Age (year)                                                  Mean (range) 54 (24-77) 
Disease activity score 28                        Mean (SD)                                      5.4 (0.9) 
Calcium and Vitamin D intake               n (%) 3 (38) 
Ethnic origin 
-    White             n (%) 
-    Asian             n (%) 
-    Black             n (%) 
 
3 (38) 
4 (50) 
1 (12) 
Methotrexate use                                              n (%)                                                          8 (100) 
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5.3 Results 
 
5.3.1 Patients with RA manifest increased numbers of osteoclasts in unstimulated in 
vitro cultures of PBMNCs before treatment  
 
Large numbers of multinucleated TRAP positive cells, which are markers of 
osteoclasts, were identified in the unstimulated cultures of PBMNCs from RA patients before 
treatment with the biologic anti-TNFα agents. These observations were made without the 
addition of RANK-L or M-CSF, which have been shown to promote the generation of 
osteoclast (200,201). The number of these cells was significantly higher than osteoclasts seen 
in cultures of PBMNCs from healthy controls (mean ±SD, 41±15.9 vs. 11.4±3.3 osteoclasts 
per 106 PBMNCs; p< 0.001) (Figure 5.1A and B). The addition of RANK-L and M-CSF 
increased the number and size of osteoclasts in PBMNC cultures from RA patients (222.5±64 
osteoclasts per 106 PBMNCs; p< 0.001) (Figure 5.1C) and, to a lesser extent, in cultures of 
PBMNC from the healthy controls (16±9 osteoclasts per 106 PBMNCs; p< 0.001) (Figure 
5.1D). These results suggested that more OCPs circulate in the peripheral blood of RA 
patients compared with healthy controls (Figure 5.2). Moreover, OCPs in the blood of RA 
patients but not the controls progressed to mature osteoclasts without the addition of RANK-L 
or M-CSF to the cultures. 
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D C 
 
Figure 5.1: Multinucleated TRAP+ cells (osteoclasts) in cultured, unstimulated 
peripheral PBMNCs of patients with RA before treatment and healthy controls. 
PBMNCs were enriched from the blood of 8 RA patients and 12 healthy controls and 
cultured in the absence (A and B) or presence (C and D) of M-CSF (25ng/ml) and 
RANK-L (100 ng/ml) for 14 days. The cultured cells were then fixed and stained for 
TRAP, and photographed at ×20 magnification. Numbers in parentheses under each 
figure represent the total number of osteoclasts per 106 PBMNCs for each sample 
shown. 
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Figure 5.2: The number of osteoclast in peripheral blood of RA patients and 
healthy controls. More osteoclasts differentiate from unstimulated PBMNCs of patients 
with RA compared with healthy controls. PBMNCs were enriched from the blood of 8 
RA patients and 12 healthy controls. The cells were cultured and stained for TRAP as 
described in the legend to Figure 5.1. The number of TRAP-positive multinucleated 
cells (osteoclasts) was counted and is presented as osteoclasts per million PBMNCs that 
were cultured at the start of the experiment. The results are presented as Mean and SD. 
** indicates p<0.001. 
 
 
5.3.2 Treatment with biologic anti-TNFα agents reduces the differentiation and 
frequency of OCPs in the blood of patients with RA 
 
To assess the effect of TNFα on osteoclasts in vivo, the frequency of OCPs was 
determined in the blood of 8 RA patients treated with biologic anti-TNFα agents before 
treatment and at 1 and then 3 months after treatment. PBMNCs were cultured as described in 
the Methods and the number of TRAP-positive multinucleated cells (osteoclasts) determined 
after 14 days of culture. As mentioned above, 6 of the patients were treated with etanercept 
while 2 were treated with adalimumab. All patients were responders to treatment according to 
their clinical assessment by DAS28. Osteoclasts number reduced significantly in all patients 
after treatment with the biologic anti-TNFα agents (41% and 56% after 1 and 3 months post 
treatment, respectively; p=0.03) (Figure 5.3). 
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Figure 5.3: Treatment of RA patients with biologic anti-TNFα agents results in the 
reduction of osteoclast numbers in vitro. PBMNCs from the blood of 8 RA patients 
treated with biologic anti-TNFα agents were cultured for 14 days, as described in the 
text, to determine the impact of this treatment on the frequency of osteoclast generation 
in vitro. Data are expressed as mean osteoclasts per 106 PBMNCs. The error bars 
represent +/- standard deviation (SD).* p≤0.05 compared with before treatment.  
 
To confirm the noted effect of treatment with biologic anti-TNFα agents on the 
generation of OCPs an alternative approach was also used. This approach was based on FACS 
analysis of the frequency of mononuclear OCPs, as compared with multinucleated TRAP-
positive cells in culture. This approach was based on the knowledge that blood mononuclear 
OCPs express RANK as well as CD11b and CD14. For this purpose, freshly enriched 
PBMNCs from 8 RA patients and 12 healthy controls were stained for CD11b, CD14 and 
RANK and analysed by flow cytometry. The mean fluorescence intensity (MFI) of RANK on 
CD11b+CD14+ cells decreased in the RA patients by 42% after 1 month and by 44% after 3 
months after treatment. This finding confirms that treatment with biologic anti-TNFα agents 
has a significant impact on reducing the levels of RANK+ cells and the generation of OCPs in 
RA patients and that more OCPs circulate in the peripheral blood of RA patients compared 
with healthy controls (Figure 5.4). 
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Figure 5.4: Treatment of RA patients with biologic anti-TNFα agents reduces the 
frequency of blood mononuclear OCPs. The frequency of mononuclear OCPs in the 
blood of RA patients and healthy controls was determined by FACS analysis of 
PBMNCs from 8 RA patients and 12 healthy controls. PBMNCs were stained for 
CD11b (APC mouse anti-human CD11b), CD14 (FITC mouse anti-human CD14) and 
RANK (PE anti-human RANK).The Figure depicts percentages of PBMNCs (R2) 
expressing CD11b and CD14 in a RA patient before (A) and post treatment with 
etanercept (B) and in a healthy  control (C).   
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5.3.3 Supernatants of cultured RA patients’ PBMNCs before treatment with biologic 
anti-TNFα agents enhanced the differentiation of PBMNCs from healthy 
controls to osteoclasts  
 
Previous studies have shown that systemic TNFα in TNFα-transgenic mice directly 
increases the frequency of OCPs while treatment of these mice with anti-TNFα reduces the 
number of OCPs (183). Results described in the previous sections revealed that the frequency 
of mononuclear OCPs is significantly higher in the blood of patients with RA compared with 
healthy controls. Furthermore, there was evidence for increased differentiation of cultured RA 
PBMNCs into osteoclasts compared with cultured PBMNCs from healthy controls. 
Furthermore, treatment of the RA patients with biologic anti-TNFα agents resulted in a 
significant reduction in the frequency of blood mononuclear OCPs and differentiated 
multinucleated osteoclasts in culture. These data indicate that TNFα is involved in the 
increases of differentiated osteoclasts. To provide further evidence that the increase in the 
number of osteoclasts is related to elevated levels of TNFα in RA patients, supernatants 
collected from the culture of PBMNCs from 2 RA patients were added to PBMNCs from 2 
healthy control and the cultures maintained for 14 days (Figure 5.5). When unstimulated 
PBMNCs from the healthy controls were cultured for two weeks without added supernatants 
from the RA PBMNCs, there were 20±7.7 osteoclasts per 1 million of the cultured PBMNCs. 
When PBMNCs from the healthy controls were cultured in the presence of supernatants 
obtained from the PBMNCs from the patients obtained before treatment, the osteoclast 
numbers increased to 65 ±14 per 1 million. Although the number of osteoclasts was less than 
those obtained when the PBMNCs were cultured in the presence of recombinant RANK-L 
and M-CSF at 222.5 ± 64 per 1 million of the cultured PBMNCs, the results, nevertheless, 
indicate that culture supernatants of PBMNCs from the RA patients before treatment 
contained factors that promote the differentiation of healthy PBMNCs into osteoclasts.  
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Figure 5.5: Supernatants of cultured PBMNCs from patients with RA before their 
treatment with biologic anti-TNFα agents promotes the differentiation of 
osteoclasts. PBMNCs from 2 healthy controls were seeded in 96-well flat-bottomed 
culture plates at 1×106 cells per well with 50% culture supernatants obtained from the 
PBMNCs obtained from 2 RA patients and mixed with an equal volume of fresh culture 
medium in a total of 200μl. The cultures were maintained for 14 days to induced 
osteoclastogenesis as described in the Methods. The mean number of differentiated 
osteoclasts from the unstimulated PBMNCs from the healthy controls was compared 
with PBMNCs from the healthy controls cultured in the presence of RANK-L and M-
CSF, or supernatant from cultured PBMNCs of RA patients.  The results are presented 
as the mean ± SD.  
 
 
 To confirm that of TNFα in culture supernatants of PBMNCs from the RA 
patients is one of the factors that contribute to the differentiation of PBMNCs from the 
healthy controls, experiments were carried out in which 2.5μg/ml of anti-TNFα antibody 
(infliximab) was added to the supernatants before initiating the culture systems. The results 
revealed significant inhibition of the differentiation of PBMNCs from healthy controls to 
osteoclasts under the influence of culture supernatants from the RA patients. Thus, the 
addition of infliximab reduced the number of osteoclasts to 5±4 cells per 1 million of the 
cultured PBMNCs (Figure 5.6). These experiments indicate that cultured PBMNCs from RA 
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patients untreated with biologic anti-TNFα agents secrete TNFα that promote the 
differentiation of PBMNCs to osteoclasts and that TNFα is an important element in the 
differentiation of osteoclasts. 
 
                  
Figure 5.6: Anti-TNFα antibody inhibits the differentiation of PBMNCs from 
healthy controls to osteoclasts under the influence of RA PBMNCs supernatants. 
Supernatants obtained from culturing PBMNCs of 2 RA patients were added to cultured 
PBMNCs of two healthy controls in the presence or absence of anti-TNFα antibody 
(infliximab). Data are presented as the mean ± SD.  
 
 
5.3.4 OPG inhibits osteoclastogenesis  
 
As cited earlier, it is established that OPG reduces osteoclastogenesis and prevents bone 
erosion as has been shown in the collagen-induced arthritis (CIA) model in mice (202,203). 
Indeed, results presented in the previous chapter have shown that there was an increase in the 
level of OPG in RA patients treated with biologic anti-TNFα agents. To test if the reduction in 
the frequency of mononuclear OCPs in the blood of patients and of differentiated 
multinucleated osteoclasts in the culture system was likely to have been influenced by OPG, 
experiments were carried out to assess the effect of recombinant OPG on the number of 
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osteoclasts generated in the culture of PBMNCs from 3 RA patients. In unstimulated cultures, 
the average number of osteoclasts was 45±11 per 1x106 PBMNCs. However, this number was 
reduced considerably to 15±3.5 cells when PBMNCs were cultured with 1.0µg/ml of OPG in 
the culture. The effect of OPG on the number of osteoclasts was enhanced in combination 
with infliximab. Thus, the number of osteoclasts cells declined to 5±4 osteoclasts per 1x106 
PBMNCs with this combination (Figure 5.7). However, the results indicated that the effect of 
the combined OPG and infliximab on the number of osteoclasts was additive rather than 
synergistic which may indicate that both act, probably, through the same or related pathways.  
 
                                   
Figure 5.7: OPG inhibits the differentiation of PBMNCs to osteoclasts in culture. 
The number of multinucleated TRAP+ cells (osteoclasts) was measured as described in 
the legend to Figure 5.2. The number of these cells was determined in cultures of 
PBMNCs from 3 RA patients with further stimulation in the presence or absence of 
recombinant OPG-Fc (1μg/ml) alone or in combination with 1μg/ml infliximab. Data are 
expressed as the mean ± SD of four independent wells (* p<0.05). 
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5.3.5 Reduction in the frequency and differentiation of OCPs in RA patients correlate 
with their responsiveness to treatment with biologic anti-TNFα agents and with 
improvements in bone biomarkers 
 
Data presented in Chapter 4 indicated that RA patients treated with biologic anti-
TNFα agents had beneficial bone responses whether they had improvements in their DAS28 
scores or not. Data presented in this chapter indicated that there was a potential reduction 
osteoclastogenesis in RA patients treated with biologic anti-TNFα agents as suggested by the 
reduction in the number of CD11b+CD14+RANK+ cells in blood and of TRAP-positive cells 
(osteoclasts) in cultured PBMNCs from the patients. Due to the limited number of patients 
that could be recruited for the study of OCPs and that all were responder patients to treatment 
with the biologic anti-TNFα agents it was not possible to confirm whether or not the reduction 
in frequency and differentiation of OCP was or was not related to the clinical response. 
However, the data were analysed to assess the correlation between reduction in DAS28 
(initial DAS28 – DAS28 at 3 months) and the reduction in number of cultured osteoclasts. 
This analysis revealed a positive correlations between reduction in DAS28 and number of 
cultured osteoclasts (r=0.6, p=0.1) (Figure 5.8).  
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Figure 5.8: Correlations between the reduction in number of differentiated 
osteoclasts and reduction in DAS28 at 3 months of treatment with biologic anti-
TNFα agents. Osteoclasts were obtained from culturing PBMNCs of RA patients as 
described in the legend to Figure 5.2, while DAS28 was measured before treatment and 
at 3 months after treatment had started as described in Materials and Methods chapter. 
Correlations were calculated using Spearman’s correlation coefficient (r). PBMNCs 
were not cultured for two patients at 3 months post treatment. 
 
Next, reduction in number of differentiated osteoclasts was compared with blood 
biomarkers of bone turnover in plasma measured using the ELISA-based protocol described 
in Chapter 4. The data revealed that number of differentiated osteoclasts in culture correlated 
with plasma levels of both CTX and RANK-L (r=0.3, p=0.5 and r=0.5, p=0.2, respectively) 
(Figure 5.9).  Furthermore, a significant positive correlation was observed between reduction 
in numbers of cultured osteoclasts and plasma levels of CTX and RANK-L after 3 months of 
treatment (r=0.8, p=0.04 and r=0.8, p=0.03, respectively) (Figure 5.10). No statistically 
significant correlations were observed between levels of OCPs and plasma levels of 
osteocalcin and OPG before treatment had started and then at 1 month and 3 months after 
treatment with the biologic anti-TNFα agents (p>0.05).  
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Figure 5.9: The relationships between the number of differentiated osteoclasts in 
culture and plasma levels of CTX (A) and RANK-L (B). Osteoclasts were obtained 
from cultured PBMNCs of 8 RA patients before treatment had started as described in the 
legend to Figure 5.2, while plasma levels of CTX and RANK-L were determined by 
ELISA as described in Materials and Methods chapter. The correlation was with 
Spearman’s correlation coefficient (r).  
 
 
              
 
Figure 5.10: Relationships between the reduction in number of differentiated 
osteoclasts in culture and reduction in plasma levels of CTX (A) and RANK-L (B). 
Reduction in plasma levels of CTX and RANK-L were correlated with reduction in 
number of differentiated osteoclasts in culture of PBMNCs from 8 RA patients 3 months 
after treatment with biologic anti-TNFα agents. The correlations were made using 
Spearman’s correlation coefficient (r). Data of both CTX and RANK-L were only 
available for 5 patients.  
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Although plasma levels of osteocalcin increased 1 month after treatment had started, 
there were no significant differences in the level of osteocalcin in patients cohort included in 
this study after treatment with biologic anti-TNFα agents. Thus, plasma levels of osteocalcin 
were 17±6.2ng/ml before treatment and 20±8ng/ml (p=0.2) and 13±7.3 (p=0.9) 1 and 3 
months after treatment, respectively. Furthermore, plasma levels of CTX were increased 1 
month after treatment but declined after 3 months. However, the difference was not 
statistically significant, probably due to patient numbers. Thus, plasma levels of CTX were 
304±458pg/ml before treatment and 406±687pg/ml (p=0.3) and 101±68 pg/ml (p=0.3) 1 and 3 
months after treatment, respectively (Table 5.2) (Figure 5.11).  
 
Table 5.2: Changes in bone turnover biomarkers after treatment with 
biologic anti-TNFα agents. 
Parameters of patient 
assessment 
 
Before 
treatment  
1 month 3 months 
 
 
Osteocalcin (ng/ml) 
 
17 (6.2) 
 
20 (8) 
 
13 (7.3) 
 
CTX (pg/ml)                                                   
 
304 (458)
 
406 (687) 
 
101 (68) 
Plasma levels of bone turnover biomarkers for 8 RA patients included in this 
study were measured by ELISA before and then at 1 and 3 months after 
treatment as described in the Materials and Methods chapter. The values 
shown are for the mean and (SD).  
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Figure 5.11: Changes in plasma levels of osteocalcin and CTX in RA patients 
treated with biologic anti-TNFα agents. Levels of osteocalcin (A) and CTX (B) were 
measured in the plasma of 8 RA patients treated with biologic anti-TNFα agents. 
Osteocalcin and CTX levels were determined using ELISA. The data presented are for 
the values of the two biomarkers from before treatment and after 1 and 3 months of 
treatment. The values shown are for the mean and the error bars represent +/- standard 
deviation (SD).  
 
 
Plasma levels of RANK-L decreased at 1 and 3 months after treatment compared with 
their levels before treatment had started (162±81pg/ml (p=0.9) and 135±124pg/ml (p=0.6) 1 
and 3 month  after treatment compared with 168±87pg/ml before treatment. There were no 
significant differences in levels of OPG after treatment with biologic anti-TNFα agents, which 
probably a result of sample size. Thus, plasma levels of OPG were 3.4±1.4ng/ml before 
treatment and 3.1±1.4ng/ml (p=0.2) and 2.4±0.9ng/ml (p=0.6) 1 and 3 months after treatment, 
respectively (Table 5.3) (Figure 5.12).  
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Table 5.3: Changes in RANK-L and OPG after treatment with biologic 
anti-TNFα agents. 
Parameters of patient 
assessment  
 
Before 
treatment  
1 month 3 months 
 
 
RANK-L (pg/ml) 
 
168 (87) 
 
162 (81) 
 
135 (124) 
 
OPG (ng/ml) 
 
3.4 (1.4) 
 
3.1 (1.4) 
 
2.4 (0.9) 
Plasma levels of osteoprotegerin (OPG) and RANK-L for the 8 RA patients included in this 
study were measured by ELISA as described in the Materials and Methods. The values shown 
are for the mean and (SD).  
 
 
         
Figure 5.12: Changes in plasma levels of RANK-L and OPG in RA patients treated 
with biologic anti-TNFα agents. Mean RANK-L (A) and OPG (B) levels were 
determined using ELISA for plasma samples obtained from patients before treatment 
and at 1 and then 3 months after treatment. The errors bars represent +/- SD. Results 
were compared with values of the biomarkers before treatment using paired Student’s t-
test.  
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5.4 Discussion 
 
The results presented in this chapter reveal the impact of inhibiting TNFα in patients 
with RA on the frequency and potential for differentiation of cells that mediate bone erosion. 
Furthermore, the data throw light on the relationship between the number of circulating OCPs 
and differentiation potential of PBMNCs in patients and healthy controls with blood 
biomarkers of bone including RANK-L, OPG, CTX and osteocalcin. 
 
The results reported in the chapter show that the frequency of mononuclear OCPs is 
significantly increased in the blood of RA patients compared with healthy controls. These 
blood cells express surface markers CD11b, CD14 and RANK and have been identified as 
mononuclear OCPs (59,204,205). A key role for TNFα in stimulating OCP formation is 
supported by the observations that blocking TNFα in vivo significantly reduces the number of 
circulating OCPs. The results presented in the chapter also showed that the number of these 
cells was increased in RA patients compared with the healthy control before the patients had 
started treatment with biologic anti-TNFα agents but declined significantly after treatment. In 
addition, neutralisation of TNFα in the in vitro cultures with infliximab reduced the 
differentiation of PBMNCs into multinucleated TRAP-positive (osteoclasts) cells.  
 
A number of early studies have shown that systemic TNFα directly increases the 
frequency of blood OCPs in mice and this increase is inhibited by treatment with biologic 
anti-TNFα agents (59,206). In the experiments described in this chapter, this proposition was 
shown to also be true for RA patients, as the frequency of TRAP+ cells decreased markedly in 
6 of 8 patients treated with biologic anti-TNFα agents. Interestingly, this reduction in the 
number of TRAP+ cells in culture paralleled the clinical improvement of the patients.  
 
Results of culturing PBMNCs from healthy controls with culture supernatants of 
PBMNCs from the RA patients before treatment with biologic anti-TNFα agents, indicated 
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that the cultured RA PBMNCs produced factors sufficient for the differentiation of PBMNCs 
from healthy controls into multinucleated TRAP+ cells (osteoclasts) in vitro. This is 
important as the data highlights the relevance of studying peripheral blood from patients with 
RA to assess the factors that determine disease progression and response of RA patients to 
treatment of a systemic disease that primarily affects joints. Subsequent inhibition 
experiments confirmed that one key factor in the culture supernatant of the PBMNCs from the 
patients that promoted the differentiation of PBMNCs from healthy controls to OCPs was 
TNFα. 
 
The additional finding in this study was that the decrease in osteoclasts obtained from 
culturing PBMNCs correlated with reduction in disease activity, measured by DAS28, 
indicating that disease activity may be a dependent factor in bone loss in RA. This result is 
consistent with findings from numerous animal model studies of inflammation, together with 
clinical evidence, showing that disease activity plays a key role in inducing bone loss 
(32,59,207,208).  
 
To gain further insights into how blocking TNFα could inhibit/suppress the 
differentiation of PBMNCs to osteoclasts, parallel experiments were carried out to inhibit 
RANK-L with OPG. The experiments revealed that OPG was capable of reducing the number 
of differentiated osteoclasts in culture, presumably, through reducing the level of RANK-L 
which is also partly induced by TNFα. Therefore, these results may suggest that TNFα causes 
a systemic increase in the number of circulating OCPs thought enhancing RANK-L 
expression. This finding is in agreement with our finding that positive correlations were 
observed by analysing the relationship between plasma levels of RANK-L and the number of 
cultured osteoclasts. In general, these findings are consistent with a previous study (207) in 
which TNFα was shown to induce bone loss directly by stimulating osteoclast precursors, and 
indirectly through releasing RANK-L which activates osteoclasts. Furthermore, this finding is 
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consistent with findings by Lam and colleagues (59) that suggested a local regulation of the 
differentiation of OCPs into osteoclasts by RANK-L. Therefore, the observed reduction in 
bone resorption upon treatment with biologic anti-TNFα agents may also be caused by the 
blockade of the RANK-L-independent stimulatory effects of TNFα on the number of 
circulating OCPs. In addition, blocking TNFα resulted in a strong reduction in OCPs numbers 
and of cultured osteoclasts. This effect corresponded with a decrease of plasma CTX levels. 
This result is in line with a previous study (133), which had provided a description on the 
cellular levels for the anti-catabolic effects of TNF neutralisation on bone. 
 
In summary, the discovery of osteoclatogenic mediators, including OPG–RANK–
RANK-L system, provided an important step in identifying mechanisms involved in chronic 
inflammation-induced bone loss. Based on the literature and the outcomes of this study it is 
possible to conclude that treatment with biologic anti-TNFα agents provides reduced 
osteoclastogenesis in RA patients. This is suggested by the reduction in the number of 
CD11b+CD14+RANK+ cells in blood and in TRAP-positive cells (osteoclasts) in cultured 
PBMNCs from patients. 
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6.1) General discussion 
 
One of the most significant risk factors for bone fracture is low bone mineral density 
(BMD) (209).  Key objectives of treating patients suffering from low BMD are suppressing 
osteoclast activity with anti-resorptive agents, enhancing osteoblast activity with anabolic 
agents and regulating bone marrow adipogenesis. Other approaches include reducing the level 
of factors that contribute to bone loss (210). Bisphosphonates are the most widely-used first-
line anti-resorptive agents. They are recommended for the treatment of patients with low 
BMD following the success of numerous randomised trials in which these agents 
demonstrated significant anti-fracture efficacy and good safety profiles (211,212). 
 
Results reported in this thesis on changes in BMD after treatment with 
bisphosphonates in relation to factors that influence such changes are in line with earlier 
studies (164-167,213). Furthermore, results on differences in the pattern of BMD change in 
the lumbar spine versus the hip are also consistent with previous studies. These regional 
differences in the effect of bisphosphonate may reflect differences in the composition of bone 
in the lumbar spine, which has a larger component of trabecular than cortical bone compared 
with the hips (163,209). 
 
The results presented in the thesis have also revealed that there is a disparity in 
patients’ response to treatment that relate to differences in age, gender, ethnic origin and 
lifestyle. More than two folds increase in BMD at the lumbar spine and hip was observed in 
men compared with women after two years of treatment with bisphosphonates. 
Postmenopausal women, especially those who are 50-60 years of age are prone to 
osteoporosis because the level of their oestrogen drops, thus, accelerating bone resorption by 
90%. In contrast, the level of bone formation in these individuals increases by only 45% and 
this imbalance between resorption and new bone formation leads to lower improvement in 
overall BMD in women treated with anti-resorptive agents (163,214). In men, testosterone has 
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beneficial effects on BMD and on their responsiveness to treatment (214). Similar to results 
presented in this thesis on lower improvement in BMD in female patients at 50-60 years of 
age compared with other age groups, a previous study observed that bone loss is greatest 
among women aged 50–54 who were transitioning from premenopausal to postmenopausal 
status (209).  
 
In addition to the effect of age and gender on responsiveness to anti-resorptive agents, 
this study provides data on the effect of ethnic origin on responsiveness to treatment with 
anti-resorptive agents. Thus, results reported in the study show that individuals of Afro-
Caribbean origin of similar age and gender to Caucasian and Asian patients with osteoporosis 
have significantly higher BMD before treatment with anti-resorptive agents. This data is 
consistent with findings by Hochberg et al. and Yates et al. on BMD in the lumbar spine and 
hips in individuals from different ethnic origins (172,173). However, due to the small number 
of patients examined in the current study, the data does not lend itself to statistically 
meaningful comparisons for the effect of ethnic origin on responsiveness to anti-resorptive 
agents. Interestingly, and within the same context, the data has also revealed that the average 
change in BMD at the lumbar spine in Caucasians is higher than in Asians. However, this 
variation in change following treatment in BMD between Caucasians and Asians was not 
statistically significant. This is in line with previous reports (215) revealing that variations in 
change in BMD after treatment between Caucasian and Asian patients can be partially related 
to the different ethnic genetic background.  
In attempting to evaluate the effect of lifestyle on the response of osteoporosis patients 
to treatment with anti-resorptive agents, information was collected on the effect of smoking. 
This data showed a significant association between lower improvement in BMD after 
treatment of smokers compared with non-smoker patients of similar age, gender and ethnic 
background. This is consistent with data that has established smoking as a risk factor for 
reduced bone health. Current evidence suggest that this effect is likely to be due to the effect 
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of smoking on hormone metabolism, levels of vitamin D, blood circulation, body weight, 
calcium absorption, elevation in oxidative stress, local hypoxia, free radical generation and 
the production of pro-inflammatory cytokines. Changes in the balance of these factors affect 
both bone resorption and formation leading ultimately to osteoporosis and reduced healing 
from fractures (216-218).  
 
By and large, results presented in this thesis on factors that affect the response of 
patients to treatment with anti-resorptive agents are consistent with previous studies 
(209,172,215). However, the current study has limitations, as do earlier studies of changes in 
BMD, including low samples size, limited age ranges of patients examined and different 
inclusion and exclusion criteria with most studies excluding men (219-222). Another 
limitation to the study of using BMD as a measure of responsiveness to anti-resorptive agents 
is the need to wait for 1-2 years before been able to assess a patients’ response to therapy 
(174). This highlights the potential benefit of using biomarkers of bone turnover which have 
been suggested to provide indications on responsiveness within days to months of starting 
treatment (175). 
 
Elevated levels of TNFα have been reported in cultures of mononuclear cells derived 
from the blood of postmenopausal women and osteoporosis patients, suggesting an 
association between high levels of TNFα and osteoporosis (68). Therefore, identifying factors 
that affect the response of patients suffering from bone density loss in the local area with its 
diversity, while highly beneficial, has the added benefit of providing the backdrop for 
studying the effect of treatment with biologic anti-TNFα agents on bone in patients with RA. 
The study of factors that impact bone in patients with RA and the beneficial effects of 
treatment are clouded by the complex nature of factors that affect changes in bone. Thus, bone 
loss in RA is generally thought to come in two forms: periarticular (local) and general. 
Periarticular bone loss in RA is first seen at the end of inflamed joints, which is a hallmark of 
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early disease. In contrast, generalised bone loss is observed as an extra-articular outcome of 
the inflammatory response in RA which ultimately leads to fractures (68). This generalised 
bone loss results from three main causes: inflammation, long-term treatment with suppressive 
medications such as corticosteroids and disability as a result of the disease (35,185). 
Treatment with corticosteroids and disease-modifying anti-rheumatic agents has two 
contradictory effects: increase the risk of osteoporosis, but also inhibit inflammatory activity, 
which this thesis argues is an important risk factor for generalised bone loss in RA. 
 
Biologic anti-TNFα agents have been developed and successfully used to inhibit 
inflammation, but they have also been shown to slow, or even arrest local bone resorption in 
mice (177). However, their potential to impact bone loss in RA has not been adequately 
analysed. Furthermore, it is unclear if bone turnover is affected in all patients treated with 
biologic anti-TNFα agents, the degree of variability in responsiveness and whether the 
beneficial/lack of clinical response to biologic anti-TNFα agents is consistent with any 
beneficial effects on bone.   
In addition, there is a clear lack of direct evidence as to the relationship between 
localised bone loss (e.g. in the hands) and generalised bone loss (in the spine and hip) in 
patients with RA. Available data suggests that a common pathway could underlie both. The 
RANK-L/OPG system provides a theoretical background for such a common mechanism 
(177). RANK-L expression is key, perhaps, among others upregulated by several pro-
inflammatory mediators including TNFα, IL-1, IL-6, IL-17, IL-20 and IL-22 
(146,178,182,184). The data presented in this thesis revealed that treatment with biologic anti-
TNFα agents reduces generalised bone loss as shown by improvement in BMD at the lumbar 
spine and hip of RA patients. Interestingly, the results showed that this beneficial effect of 
biologic anti-TNFα agents did not parallel improvement in DAS28 in all patients. This data is 
consistent with findings in experimental arthritis in mice in that blockade of TNFα has a 
greater effect on cartilage degradation and joint destruction than on inflammation (182). This 
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data may raise the prospect that whereas TNFα is the key pro-inflammatory mediator in both 
local and generalised bone loss, that the inflammatory response in different patients may be 
driven by other mediators instead of, or in addition to TNFα. For example, there is evidence 
that IL-17 could be a key pro-inflammatory mediator in patients who do not respond to 
biologic anti-TNFα agents although the role of this cytokine in bone loss in the disease is to 
be determined (184). Indeed, data on assessing the effect of treatment with biologic anti-
TNFα agents on localised bone loss have shown that these agents have arrested localised bone 
loss in RA.  This data, however, is inconsistent with observations by Vis and his colleagues 
who have reported a decrease in hand BMD as measured by DXR in RA patients treated with 
infliximab (125). However, these investigators have measured hand BMD after one year of 
treatment and 84% of their patients were females.  
 
When the effect of biologic anti-TNFα agents on bone was assessed by quantifying the 
level of bone turnover biomarkers, the data were consistent with previous studies 
(124,125,131-134,137,139,223). Although, there are a number of studies addressing the effect 
of biologic anti-TNFα agents on bone turnover biomarkers, comparative studies in responder 
and non-responder patients are limited. Results presented in the thesis are based on dividing 
the RA patients treated with biologic anti-TNFα agents into responder and non-responder 
patients based on changes in their DAS28 scores. The results strongly support the proposition 
that biologic anti-TNFα agents have beneficial effects on bone which is not entirely in line 
with its anti-inflammatory properties. Thus, the results show beneficial bone effects also in 
clinically non-responder RA patients. 
Previous studies have documented that pro-inflammatory cytokines, such as TNFα, 
IL-1, IL-6, IL-17, IL-20, IL-22 and GM-CSF are associated with enhanced osteoclastogenesis 
through affecting the OPG-RANK-RANK-L circuit with the net result being an obvious rise 
in osteoclast formation and functions (144-147,179,192). In the current report, the studies 
revealed that levels of TNFα, IL-1, IL-6, IL-20, IL-22 and GM-CSF are reduced in patients 
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with RA in response to the treatment with biologic anti-TNFα agents. Furthermore, GM-CSF 
and the other pro-inflammatory cytokines including IL-1, IL-6 and IL-17 showed significant 
positive correlations with CTX indicating a strong relationship between inflammation and 
bone loss in RA. In addition, BMD values for the lumbar spine, hips and hands negatively 
correlated with increases in TNFα, IL-1, IL-6, IL-22 and GM-CSF. This can be explained as 
being a consequence of the involvement of pro-inflammatory cytokines in suppressing OPG 
and promoting RANK-L upregulation. The results presented also confirmed the firm 
relationship between inflammation and bone loss which has been clearly established in many 
clinical and experimental models before (131,178,203).  
 
The available evidence indicates that the key determining factor in bone loss by the 
inflammatory pathways operating in RA is osteoclastogenesis (183,203). The results 
presented in the thesis clearly show that treatment of RA with biologic anti-TNFα agents are 
consistent with a beneficial effect on bone as also supported by the suppressive effect on 
osteoclast precursor (OCPs) generation and reduction in the level of RANK and RANK-L and 
increasing OPG levels. TNFα acts as a key factor in inducing the development and 
differentiation of OCPs in TNFα-transgenic mice (224). This observation in mice was 
confirmed in the current study in humans and also showing that blocking TNFα in patients 
significantly reduces the number of circulating OCPs. Indeed, the addition of infliximab to 
cultured PBMNCs from patients with RA inhibited osteoclast formation as shown by reduced 
positive TRAP staining and multinuclearity. This data is consistent with previous studies 
(128,179) which showed that osteoclasts can grow from unstimulated PBMNCs from healthy 
individuals when grown in the presence of RANK-L and M-CSF, or by TNFα and this is 
inhibited after the addition infliximab to cultured PBMNCs (179,224). 
 
The results described in the thesis also showed that the decrease in the frequency of 
OCPs in cultured PBMNCs from RA patients treated with biologic anti-TNFα agents 
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correlated with a reduction in disease activity in the treated patients suggesting, perhaps, that 
disease activity may correspond with the extent of bone resorption in RA. The reduction in 
bone loss was in correlation with reduction in disease activity and inflammation was also 
reported in previous studies (125,128) indicating that the beneficial effects of TNFα agents 
could be related to their anti-inflammatory activity. 
 
The difference between treatment with biologic anti-TNFα agents and traditional 
pharmaceutical DMARDs on bone loss have been studied in only two randomised clinical 
trials, the Behandelstrategieen RA (BeSt) and the PREMIER. In BeSt, the effect of four 
treatment strategies was examined (126). Monotherapy, step-up therapy, initial combination 
of DMARD with high dose prednisone and combination of DMARD with infliximab were 
assessed. The study reported higher bone loss in patients treated with traditional DMARDs 
compared with combination therapy involving infliximab. In PREMIER trial, combination of 
methotrexate (MTX) with adalimumab led to less hand bone loss compared with monotherapy 
of either adalimumab or MTX alone. Hand bone loss was correlated with treatments not 
involving adalimumab, with age and with level of inflammation (225). Patients with 
high/moderate DAS28 scores had greater hand bone loss compared with those with low 
DAS28. The findings of this trial indicated that the advantages of treatment with biologic 
anti-TNFα agents may not be restricted to the control of inflammation but also to the ability to 
suppress osteoclast activation. 
Treatment with biologic anti-TNFα agents has also been demonstrated to suppress 
bone loss in the spine and hip in a number of studies (124,126,225). Thus, Marotte and 
colleagues reported that hip and spine BMD was reduced in patients treated with MTX alone, 
but was conserved in patients treated with the combination of infliximab and MTX (99). 
Furthermore, these investigators observed that changes in BMD did not correlate with the 
clinical response of the patients to the combination therapy. However, in other studies of 
treatment with biologic anti-TNFα agents, suppression of bone loss paralleled improvements 
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in DAS28 (125-128), suggesting that a good control of inflammation could prevent bone loss 
in RA patients. 
 
Despite previous studies and the results reported in this thesis, larger sample size 
studies are required in order to establish a definitive database on the effect of age, gender, 
ethnic origin and lifestyle such as smoking on the bone effects of biologic anti-TNFα agents 
in patients with RA. Interestingly, however, the current investigation whose results are 
summarised in this thesis has clearly identified a slight disparity in beneficial response of 
bone and the chronic inflammation. Thus, the data indicated that in some patients who did not 
benefit clinically from treatment with biologic anti-TNFα there was evidence for 
improvement in bone turnover.  
 
6.2) Study limitations 
 
Results reported in this thesis provide interesting and potentially important new 
insights into the relationship between chronic inflammation and bone loss in patients with 
RA. The initial part of the study established statistically-relevant and scientifically meaningful 
information and the relationships between patient demographics and lifestyle with 
responsiveness to treatment with anti-osteoporotic agents. These studies were made possible 
because of the cooperation between and support from the Rheumatology and Radiology 
departments at Barts Health NHS Trust. This enabled the study to recruit a relatively large 
cohort of patients with osteoporosis. The outcome provided a good foundation on which to 
build the next stage of the study which involved applying the findings from the first part of 
the study to gain insights into mechanistic relationships between chronic inflammation in RA 
and bone loss in the patients. The key strategy for this part of the study was to assess the 
relationship between chronic inflammation and bone loss based on the outcome of treating 
patients with biologic anti-TNFα agents. TNFα is a principal pro-inflammatory and 
pleiotropic cytokine widely implicated in chronic inflammation in, at least, a majority of 
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patients with RA. Although, it is established that TNFα, in combination with other cytokines, 
is involved in local bone loss in the joint of RA patients, its role in generalized bone loss in 
the disease is only emerging. This proposition is based on the ability of TNFα to upregulate 
RANK/RANK-L expression and the induction of osteoclasts.   
 
The design of the second part of the study was for a two stage analysis. The first was 
to be based on a retrospective analysis of the general relationship between the clinical 
response of patients to treatment with anti-TNFα based on changes in DAS28 and BMD 
measured by DEXA scans at 1 and 2 years after treatment. This part of the study also enabled 
limited application of the model established from the osteoporosis study to assess the effect of 
patient demographics on clinical and bone response to treatment with biologic anti-TNFα. 
The second part of the analysis was to explore the question in depth by assessing changes in 
physiology in patients including changes in BMD, bone biomarkers and the immune response 
that is known to be directly influenced by TNFα in RA patients following treatment with anti-
TNFα agents. For this purpose, efforts were directed at recruiting RA patients treated with 
biologic anti-TNFα agents from September 2011  to April 2014. These patients were to be 
recruited mainly from the rheumatology clinics at Barts Health NHS trust at the Mile End 
Hospital. However, due to the large number of clinical trials that were either ongoing or to be 
started by the Professor Costantino Pitzalis and his group that were recruiting patients from 
the same cohort, it was decided to approach colleagues at the Royal Free Hospital NHS to 
recruit patients from their cohort. This was carried out after obtaining all necessary ethical 
approval from the local committee of the Health Research Authority and the Trust itself. The 
objective was to recruit patients prescribed treatment with biologic anti-TNFα agents who 
were also to be assessed for changes in BMD by DEXA scans. For this group, it was also 
decided to carry out parallel assessments of changes in BMD by DXR to obtain quantitative 
data and also compare the protocol with data obtained by DEXA. Barts and the London 
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Hospitals are among the largest centres in England in treating RA patients with biologic anti-
TNFα agents with more than 50 patients treated annually. In addition,  25-30 RA patients are 
prescribed anti-TNFα agents at the Royal Free Hospital NHS Trust. It was, therefore, 
expected that enough patients will be recruited to render the results statically significant. 
However, a number of factors contributed to limiting the number of patients recruited to the 
study. These factors related primarily to the large number of clinical trials and studies carried 
out by Professor Pitzalis and his group who granted themselves priority access to the patients 
because the research set up was established and managed by Professor Pitzalis and his 
colleagues. Another limitation on recruitment of RA patients treated with anti-TNFα agents to 
the study described in the thesis was that only patients who were sent for BMD density 
analyses by DEXA were to be recruited to obtain the necessary information for the study. 
These could not be artificially increased because of NHS budgetary limitations and conditions 
set for our ethical permission. Furthermore, the study faced serious problems in that specific 
conditions were required to carry out hand X-rays of single hand for the information to be 
properly analysed by DXR. For these conditions to be set up there were numerous processes 
and approvals that had to be granted which took lengthy periods of time. 
Due to the relatively large number of studies by Prof. Piztalis’ group recruitment for 
the current study were seriously restricted and were generally  advised to recruit from patients 
that did not fit the criteria set for the current study and only from patients that were surplus to 
studies by Prof. Pitzalis. Unfortunately, it was subsequently discovered that most of these 
latter groups of patients were those more inclined not to consent to participate in research. 
Any attempts by other staff at the clinic to help us recruit patients to the study were not 
looked at favourably by Prof. Pitzalis and his staff. In addition, attempts to obtain ethical 
approval to recruit patients from the Royal Free Hospital NHS Trust did take an unusually 
lengthy time to be put in place. 
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6.3) Conclusions  
 
One of the most significant risk factors for fracture in patients with osteoporosis or 
chronic inflammatory conditions is low BMD (209). Anti-resorptive agents have been used 
for the treatment of low BMD in several randomised controlled trials, and the results have 
shown that their usefulness is related to their ability to increase, or stabilise bone density 
(211,212). However, it has been established that there is disparity in patients’ response to 
treatment with anti-resorptive agents including bisphosphonates. Most of the reasons for this 
disparity, but not all, are known and these include age, gender, ethnic origin and lifestyle. 
However, the extent of the effect of biologic anti-inflammatory agents, such as anti-TNFα 
agents on bone in patients with RA and whether such effects are consistent with their anti-
inflammatory effects are not been adequately explored. 
 
The pathogenesis of bone loss in osteoporosis is multi-factorial including aging and 
the menopause. Thus, oestrogen deficiency promotes T-cell activation and the production of 
TNFα. Subsequently, TNFα is established as a key promoter of bone resorption acting 
through the expression of RANK-L which, in turn, leads to the activation and differentiation 
of osteoclasts through binding to RANK (62,118). TNFα, however, also promotes bone loss 
through the inhibition of bone formation by promoting osteoblast apoptosis and reducing the 
differentiation and proliferation of osteoblasts and their precursors (62,226).  
 
Bone loss in patients with RA is observed in two forms: peri-articular (local) bone loss 
near inflamed joints, which is a hallmark of early disease and generalised bone loss as one of 
the extra-articular features of RA which causes increased risks of fractures (68). Thus, bone 
loss in RA is a risk factor for secondary osteoporosis and it is thought to be a result of three 
main factors: inflammation, long-term treatment with medications such as corticosteroids and 
disability as a result of the disease (35,185). 
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In the recent literature, there has been reports of a clear association between localised 
bone loss (in the hands) in RA patients and generalised bone loss (in the spine and hip), 
suggesting a common pathway. The RANK-L and OPG circuit provides a theoretical 
background for such a common mechanism (177). RANK-L upregulation is one among a 
number of factors influenced by pro-inflammatory cytokines such as TNFα, IL-1, IL-6, IL-17, 
IL-20 and IL-22 (146,147,179,191,192). All these cytokines activate osteoclasts through 
influencing the RANK/RANK-L/OPG circuit.  
 
Findings reported in this thesis support the notion that treatment with biologic anti-
TNFα agents arrests both generalised bone loss at lumbar spine and hip and localised bone 
loss in the hand of patients with RA. Interestingly, the beneficial effects of biologic anti-
TNFα agents on BMD did not completely parallel improvements in the patients’ DAS28 
scores. The beneficial effects of biologic anti-TNFα agents were also consistent with changes 
in plasma levels of biomarkers of bone turnover and regulatory proteins.  
 
In general, this study and several previous studies highlight the beneficial effects of 
biologic anti-TNFα agents on bone. However, the precise mechanism(s) though which such 
beneficial effect is achieved remains unclear partly due to the relatively small sample size, 
short follow-up periods and lack adequate controls. Studies of the molecular correlates and 
targets of the beneficial effects of biologic anti-TNFα agents requires large sample size, 
longer and sustained disease control to identify such factors and targets. However, similar to 
patients with osteoporosis, factors such as gender, age and ethnic origin all impact bone 
response to the treatment with biologic anti-TNFα agents. 
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6.4) Future Perspectives 
 
Biologic anti-TNFα agents are highly effective in suppressing disease in numerous 
inflammatory conditions (223). However, whilst the anti-inflammatory and disease-modifying 
effects on biologic anti-TNFα agents have been shown to supress bone loss in vivo in animal 
models and in vitro using human cells, their effectiveness in reducing osteoporosis and 
fractures has not been universally recognised. 
 
There are many pathways through which osteoclasts can be activated in addition to 
pathway(s) triggered by TNFα and these include pathways mediated, or triggered by IL-1, IL-
6 and IL-17 (227). However, the results presented in this thesis clearly indicate TNFα is the 
major inducer of bone loss in RA. Nevertheless, despite the limited evidence provided herein, 
further larger studies will be required to identify the exact pathways and targets through 
which inhibiting TNFα with the biologic agents could bring about such outcome.  
 
There is some evidences to indicate that treatment with biologic anti-TNFα agents 
have indirect anti-resorptive effects through controlling inflammation. However, several 
studies that have addressed this issue have relatively short follow-up periods, small sample 
size, or lack suitable controls (118,126,128,225). Thus, to provide evidence for such 
mechanisms the effect of biologic anti-TNFα agents would require longer and continued 
disease control to clarify how such effects benefit bone in patients with RA.  
 
As part of the national research programme in the Kingdom of Saudi Arabia, part of 
the current work will be expanded to include RA patients from the country. Furthermore, the 
study will form a platform for identifying the factors that impact patients with osteoporosis 
since this disease has a high prevalence in that area with, potentially, additional more risk 
factors, particularly lifestyle.  
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In recent years, advanced imaging techniques have been explored to evaluate bone 
quality at multi levels, such as microarchitecture of trabecular bone, mineralisation, micro-
damage and bone remodelling rates (228). At present, the microarchitecture of trabecular 
bone can be evaluated in vivo using high-resolution peripheral quantitative computed 
tomography (CT). Combining bone mineral density measurements by DEXA with CT images 
may offer an alternative option to assess bone response and treatment progress. Part of my 
future work will involve using CT to measure BMD in parallel with DEXA to link that with 
DEXA scan department of the Royal London Hospital under the supervision Dr. Akanle. 
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                                                       Appendix 1 
 
 
Table 1: Group statistics and independent samples test of BMD for short-term precision 
assessments.  
                              Case  N  Mean  Std. Deviation Std. Error 
Mean 
Short-term precision 
- With repositioning      
of phantom 
 
- Without repositioning 
of phantom 
 
20 
 
 
20 
 
 
0.996 
 
 
0.994 
 
0.003 
 
 
0.003 
 
0.001 
 
 
0.001 
The spine phantom was scanned 20 times with and without repositioning between scans. The data 
was analysed as described in the Materials and Methods.  
 
 
 
Table 2: Levene’s test and independent sample t-test assessment for measuring the equality 
of BMD means of short-term precision.  
 
 
 
Levene’s Test for 
Equality of Variances 
                             
                          t-test for Equality of Means 
 
F 
 
Sig. 
 
T 
 
df 
Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Err. 
Diff. 
99% Confidence 
interval of the 
Difference 
Lower Upper 
Short-term precision                    
- Equal Variances   
assumed  
 
- Equal Variances  
not  assumed  
 
 
.057 
 
 
 
.813 
 
 
1.983 
 
 
 
1.983 
 
 
38 
 
 
 
37.94 
 
 
.055 
 
 
 
.055 
 
 
.002 
 
 
 
.002 
 
 
.001 
 
 
 
.001 
 
 
-.001 
 
 
 
-.001 
 
 
.005 
 
 
 
.005 
 
The spine phantom was scanned 20 times with and without changing its position between scans. 
Data analysed as described in the Material and Methods.  
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Table 3: Group statistics and independent samples test of changes in lumbar and hip BMD 
for male and female patients.  
 Gender N Mean Std. 
Deviation 
Std. Error 
Mean 
BMD change at lumbar 
spine 
Male 114 6.90 8.075 .756 
Female 533 3.54 6.839 .295 
BMD change at hip 
Male 114 2.48 6.066 .568 
Female 533 -.78 4.990 .215 
 
Group statistics and independent samples test for changes in BMD in male and female patients 
are presented as the mean and data analysed as described in the Materials and Methods.  
 
 
 
 
 
 
Table 4: Levene’s test and independent sample t-test assessment to measure the equality of 
changes in BMD of lumbar spine and hip between male and female patients. 
 Levene’s 
Test for 
Equality of 
Variances 
                          
 
 t-test for Equality of Means 
F Sig. t df Sig. (2-
tailed) 
Mean 
Diff. 
Std. 
Error 
Diff. 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
BMD change at 
lumbar spine 
        Equal variances     
assumed 
6.06 .014 4.61 651 .000 3.36 .729 1.931 4.793 
Equal variances  
not assumed 
  
4.14 149 .000 3.36 .812 1.759 4.966 
BMD change 
at hip 
Equal variances  
assumed 
.105 .746 6.09 650 .000 3.26 .535 2.209 4.312 
Equal variances     
not assumed 
  
5.37 147 .000 3.26 .607 2.060 4.461 
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Table 5: Group statistics and independent samples test of changes in lumbar and 
total hip BMD for smoker and non-smoker patients.  
                       Smoking 
N   Mean Std. 
Deviation 
Std. Error 
Mean 
BMD change at lumbar 
spine 
   Smoker 121 2.18 5.739 .522 
   non smoker 360 4.96 7.656 .401 
BMD change at hip 
   Smoker 121 -1.61 4.771 .434 
   non smoker 360 0.7 5.600 .293 
Group statistics and independent samples test for changes in BMD in smoker and non-smoker 
patients are presented as the mean and data analysed as described in the Materials and Methods.  
 
 
 
 
Table 6: Levene’s test and independent sample t-test assessment to measure the equality of 
changes in BMD of lumbar spine and total hip between smoker and non-smoker patients. 
 Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df Sig. 
(2-
taile
d) 
Mean 
Differ
ence 
Std. Error 
Differenc
e 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
BMD 
change at 
lumbar 
spine 
Equal variances 
assumed 
10.725 .001 -3.67 484 .000 -2.783 .758 -4.272 -1.293 
Equal variances 
not assumed 
  
-4.23 272 .000 -2.783 .658 -4.078 -1.487 
BMD 
change at 
hip 
 
Equal variances 
assumed 
.344 .001 -2.97 484 .003 -1.683 .567 -2.797 -.568 
Equal variances 
not assumed 
  
-3.22 238 .001 -1.683 .523 -2.714 -.652 
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                                                                Appendix 2 
 
 
 
 
 
 
 
 
     
Data on changes in BMD in 62 RA patients treated with biologic anti-TNFα agents were 
compared before and 2 years after treatment. 
 
 
 
 
Table 1b: Paired sample t-test to measure the equality of changes in BMD of lumbar spine 
for RA patients before and 2 years after treatment with biologic anti-TNFα agents. 
 Paired Differences T df Sig. 
(2-
tailed) Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
BMD lumbar before 
-BMD lumbar after 2 yrs 
-.0314 .05056 .00701 -.04552 -.01737 -4.49 51 .000 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1a: Paired samples test of changes in lumbar spine BMD for RA patients 
treated with biologic anti-TNFα agents. 
Lumbar  spine Mean N Std. Deviation Std. Error Mean 
Pair 1 
BMD before treatment .917 62 .143993 .019968 
BMD after 2 years of 
treatment 
.949 62 .156637 .021722 
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Table.1c: Wilcoxon signed rank test to measure changes in lumbar spine BMD of RA 
patients treated with biologic anti-TNFα agents.  
 
Data on changes in BMD of 62 RA patients treated with biologic anti-TNFα agents were 
compared before and 2 years after treatment. 
 
 
Table 2a: Paired samples test of changes in hip BMD for RA patients treated with biologic 
anti-TNFα agents. 
Total hip Mean N Std. Deviation Std. Error 
Mean 
 
BMD before treatment  .832 62 .112484 .017851 
BMD after treatment (2 yrs) .827 62 .112180 .018509 
 
Data on changes in BMD in 62 RA patients treated with biologic anti-TNFα agents were 
compared before and 2 years after treatment. 
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Table 2b: Paired sample t-test to measure the equality of changes in BMD of total hip for 
RA patients before and 2 years after treatment with biologic anti-TNFα agents. 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
Total hip BMD before  
-BMD after treatment 
(2 yrs) 
.0053 .03469 .00486 -.0044 .0151 1.09 50 .412 
 
 
 
 
 
 
 
 
 
Table 2c: Wilcoxon signed rank test to measure changes in total hip BMD RA patients 
treated with biologic anti-TNFα agents. 
 
 
Data on changes in BMD in 62 RA patients treated with biologic anti-TNFα agents were 
compared before and 2 years after treatment. 
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                                                                 Appendix 3 
 
 
 
 
Table 1a: Changes in lumbar spine BMD for RA patients treated with biologic anti-TNFα 
agents. 
 
Lumbar spine (responder patients) 
Mean N Std. Deviation Std. Error 
Mean 
Pair 1 
BMD before treatment 1.069 7 .20147 .07615 
BMD after 1 year of treatment 1.063 7 .19328 .07305 
 
Data on changes of BMD in 7 responder patients, based on improvement in DAS28 were 
compared before and 1 year after treatment. 
 
 
 
 
Table 1b: Paired sample t-test to measure the equality of changes in BMD of lumbar spine 
for responder RA patients before and 1 year after treatment with biologic anti-TNFα 
agents. 
 
 
 
 
Lumbar spine BMD 
Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
BMD before treatment 
-BMD after 1 year of 
treatment 
.0071 .03390 .0128 -.0242 .0385 .557 6 .597 
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Table 1c: Changes in lumbar spine BMD for RA patients treated with biologic 
anti-TNFα agents. 
 
Lumbar spine (non-responder patients) 
Mean N Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
BMD before treatment .941 3 .068923 .039793 
BMD after 1 year of treatment .91 3 .076788 .044333 
 
Data on changes of BMD in 3 non-responder patients, based on improvement in DAS28 were 
compared before and 1 year after treatment. 
 
 
 
 
 
Table 1d: Paired sample t-test to measure the equality of changes in BMD of lumbar spine 
for non-responder RA patients before and 1 year after treatment with biologic anti-TNFα 
agents. 
 
 
 
 
 
Lumbar spine BMD  
Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
BMD before 
-BMD after 1 year 
of treatment 
.0310 .01345 .00777 -.00242 .06442 3.991 2 .057 
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Table 2a: Changes in hip BMD for RA patients treated with biologic anti-TNFα agents. 
 
Hip (responder patients) 
Mean N Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
BMD before treatment  .992 7 .29175 .11027 
BMD after 1 year of treatment .989 7 .27443 .10373 
Data on changes of BMD in 7 responder patients, based on improvement in DAS28 were 
compared before and 1 year after treatment. 
 
 
 
 
 
 
 
 
Table 2b: Paired sample t-test to measure the equality of changes in BMD of hip for 
responder RA patients before and 1 year after treatment with biologic anti-TNFα agents. 
 
 
 
 
Hip BMD 
Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
BMD before 
treatment – BMD 
after 1 year 
.0033 .03487 .01318 -.02897 .03554 .249 6 .811 
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Table 2c: Changes in hip BMD for RA patients treated with biologic anti-TNFα agents. 
 
Hip (non-responder patients) 
Mean N Std. Deviation Std. Error Mean 
Pair 1 
BMD before treatment .926 3 .069981 .040404 
BMD after 1 year .931 3 .092065 .053154 
Data on changes of BMD in 3 non-responder patients, based on improvement in DAS28 were 
compared before and 1 year after treatment. 
 
 
 
 
 
 
 
Table 2d: Paired sample t-test to measure the equality of changes in BMD of hip for non-
responder RA patients before and 1 year after treatment with biologic anti-TNFα agents. 
 
 
 
 
Total hip 
Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
BMD before –BMD 
after 1 year of 
treatment 
-.005 .034429 .0199 -.09086 .08019 -.268 2 .814 
 262 
 
 
 
 
Table 3a: Changes in hand BMD for RA patients treated with biologic anti-TNFα 
agents. 
 
Hand BMD (responder patients) 
Mean N Std. Deviation Std. Error 
Mean 
Pair 1 
BMD before treatment  .58 6 .09214 .04607 
BMD after 6m of 
treatment 
.60 6 .09684 .04842 
Data on changes of BMD in 6 responder patients, based on improvement in DAS28, were 
compared before and 6 months after treatment. 
 
 
 
Table 3b: Paired sample t-test to measure the equality of changes in BMD of hand for 
responder RA patients before and 6 months after treatment with biologic anti-TNFα 
agents. 
 
 
 
 
Hand BMD 
Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
BMD before – 
BMD after 6m of 
treatment 
-.0002 .00487 .00244 -.00793 .00758 -.073 3 .947 
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Table 3c: Changes in hand BMD for RA patients treated with biologic anti-
TNFα agents. 
 
Hand BMD (non-responder patients) 
Mean N Std. Deviation Std. Error 
Mean 
Pair 1 
BMD before treatment  .52254 3 .032919 .023277 
BMD after 6m of treatment .51876 3 .035268 .024938 
Data on changes of BMD in 3 non-responder patients, based on improvement in DAS28 were 
compared before and 6 months after treatment. 
 
 
 
 
 
 
 
 
 
Table 3d: Paired sample t-test to measure the equality of changes in BMD of hand for non-
responder RA patients before and 6 months after treatment with biologic anti-TNFα 
agents. 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
BMD before – BMD 
after 6m of treatment 
 
.0038 .002349 .00166 -.01734 .02488 2.27 1 .264 
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Appendix 4 
 
 
 
Table 1a: Paired sample t-test to measure changes in osteocalcin for RA patients treated 
with biologic anti-TNFα agents. 
 Mean  
(pg/ml) 
N Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
       Osteocalcin (t0) 15566.1 37 10493.1 1708.6 
       Osteocalcin (t1m) 15916.7 37 10960.8 1801.9 
Pair 2 
       Osteocalcin (t0) 14510.3 31 11102.8 1994.1 
       Osteocalcin (t3m) 16454.7 31 11533.8 2071.5 
Data on changes of osteocalcin in responder patients were compared before (t0) and 1 (t1m) and 
3 months (t3m) after treatment. 
 
  
 
 
 
 
 
Table 1b: Paired sample t-test to measure the paired differences in osteocalcin for 
responder RA patients before and 1 and 3 months after treatment with biologic anti-TNFα 
agents. 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
Osteocalcin (t0) – 
Osteocalcin (t1m) 
-850.6 4554.5 748.76 -2369.18 667.93 -1.14 36 .263 
Pair 2 
Osteocalcin (t0) – 
Osteocalcin (t3m) 
-1944.3 8240.4 1480.1 -4966.94 1078.3 -1.31 30 .199 
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Table 1c: Paired sample t-test to measure changes in osteocalcin for RA patients treated 
with biologic anti-TNFα agents. 
 Mean 
(pg/ml) 
N Std. Deviation Std. Error 
Mean 
Pair 1 
Osteocalcin (t0) 11614.8 12 8078.6 2332.1 
Osteocalcin (t1m) 14266.1 12 7740.2 2234.4 
Pair 2 
Osteocalcin (t0) 10775.8971 10 8416.1 2661.4 
Osteocalcin (t3m) 14854.6042 10 8060.3 2548.9 
Data on changes of osteocalcin in non-responder patients were compared before (t0) and 1 (t1m) 
and 3 months (t3m) after treatment. 
 
 
  
 
 
 
 
 
Table 1d: Paired sample t-test to measure the paired differences in osteocalcin for non-
responder RA patients before and 1 and 3 months after treatment with biologic anti-TNFα 
agents. 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
 Osteocalcin (t0) -      
Osteocalcin (t1m) 
-2651.2 5605.1 1618.1 -6212.6 910.13 -1.639 11 .130 
Pair 2 
Osteocalcin (t0) – 
Osteocalcin (t3m) 
-4068.7 3958.5 1251.8 -6900.5 -1236.95 -3.250 9 .010 
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Table 2a: Paired sample t-test to measure changes in CTX for RA patients treated with 
biologic anti-TNFα agents. 
 Mean 
(pg/ml) 
N Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
CTX (t0) 163.8 28 125.2 24.1 
CTX (t1m) 169.9 28 108.1 20.4 
Pair 2 
CTX (t0) 146.8 23 107.4 22.4 
CTX (t3m) 131.8 23 129.9 27.1 
Data on changes of CTX in responder patients were compared before (t0) and 1 (t1m) and 3 
months (t3m) after treatment. 
 
 
 
 
 
 
 
 
Table 2b: Paired sample t-test to measure the paired differences in CTX for responder 
RA patients before and 1 and 3 months after treatment with biologic anti-TNFα agents. 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair1 
CTX (t0)-                    
CTX (1m) 
-8.28 78.47 14.83 -38.71 22.15 -.558 27 .581 
Pair2 
CTX (t0) -      
CTX (3m) 
15.1 94.54 19.71 -25.88 55.86 .761 22 .455 
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Table 2c: Paired sample t-test to measure changes in CTX for RA patients 
treated with biologic anti-TNFα agents. 
 Mean 
(pg/ml) 
N Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
CTX (t0) 127.1 9 103.6 34.5 
CTX (t1m) 137.1 9 72.4 24.1 
Pair 2 
CTX (t0) 132.6 8 109.3 38.9 
CTX (3m) 140.4 8 72.7 25.7 
Data on changes of CTX in non-responder patients were compared before (t0) and 1 (t1m) and 3 
months (t3m) after treatment. 
 
  
 
 
 
 
 
Table 2d: Paired sample t-test to measure the paired differences in CTX for non-
responder RA patients before and 1 and 3 months after treatment with biologic anti-
TNFα agents. 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
CTX (t0) -    
CTX (t1m) 
-10.1 93.18 31.1 -81.69 61.56 -.324 8 .75 
Pair 2 
CTX (t0 -   
CTX (t3m) 
-7.8 93.3 32.98 -85.8 70.2 -.236 7 .58 
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Table 3a: Paired sample t-test to measure changes in RANK-L for RA patients treated with 
biologic anti-TNFα agents. 
 Mean 
(pg/ml) 
N Std. Deviation Std. Error 
Mean 
Pair 1 
        RANK-L (t0) 197.3 38 148.3 24.1 
        RANK-L (t1m) 160.6 38 102.2 24.7 
Pair 2 
        RANK-L (t0) 212.3 33 193.8 33.7 
        RANK-L (t3m) 170.4 33 100.4 26.1 
Data on changes of RANK-L in responder patients were compared before (t0) and 1 (t1m) and 3 
months (t3m) after treatment. 
 
 
 
 
 
 
 
Table 3b: Paired sample t-test to measure the paired differences in RANK-L for responder 
RA patients before and 1 and 3 months after treatment with biologic anti-TNFα agents. 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
RANK-L (t0) – 
RANK-L (t1m) 
17.8 63.83763 10.36 -3.21 38.76 1.717 37 .094 
Pair 2 
RANK-L (t0) – 
RANK-L (t3m) 
41.9 116.65653 20.30730 .51 83.23 2.062 32 .047 
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Table 3c: Paired sample t-test to measure changes in RANK-L for RA patients treated with 
biologic anti-TNFα agents. 
 Mean 
  (pg/ml) 
N Std. Deviation Std. Error 
Mean 
Pair 1 
RANK-L (t0) 185.6 10 89.7 65.4 
RANK-L (t1m) 222.7 10 104.7 91 
Pair 2 
RANK-L (t0) 200.5 9 213.5 71.2 
RANK-L (t3m) 192.5 9 110.4 70.3 
Data on changes of RANK-L in non-responder patients were compared before (t0) and 1 (t1m) 
and 3 months (t3m) after treatment. 
  
 
 
 
 
Table 3d: Paired sample t-test to measure the paired differences in RANK-L for non-
responder RA patients before and 1 and 3 months after treatment with biologic anti-TNFα 
agents. 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
RANK-L (t0) – 
RANK-L (t1m) 
-37.1 106.3 33.6 -113.1 39 -1.10 9 .12 
Pair 2 
RANK-L (t0) – 
RANK-L (t3m) 
7.9 38.5 12.8 -21.6 37.5 .619 8 .83 
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Table 4a: Paired sample t-test to measure changes in OPG for RA patients treated with 
biologic anti-TNFα agents.  
 Mean 
   (pg/ml) 
N Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
OPG (t0) 2874.1 38 1529.6 248.1 
OPG (t1m) 2637.7 38 1387.9 225.1 
Pair 2 
OPG (t0) 2807.4 33 1508.5 262.6 
OPG (t3m) 2927 33 1438.9 250.5 
Data on changes of OPG in responder patients were compared before (t0) and 1 (t1m) and 3 
months (t3m) after treatment. 
 
 
  
Table 4b: Paired sample t-test to measure the paired differences in OPG for responder RA 
patients before and 1 and 3 months after treatment with biologic anti-TNFα agents. 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 
 OPG (t0) –   
OPG (t1m) 
190.3 657.7 106.7 -25.8 406.5 1.78 37 .083 
Pair 2 
OPG (t0) – 
OPG (t3m) 
-119.6 732.7 127.5 -379.4 140.2 -.94 32 .355 
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Table 4c: Paired sample t-test to measure changes in OPG for RA patients treated with 
biologic anti-TNFα agents.  
 Mean 
(pg/ml) 
N Std. Deviation Std. Error 
Mean 
Pair 1 
OPG (t0) 2829.4 12 1208.4 348.8 
OPG (t1m) 2861.9 12 1462.2 422.1 
Pair 2 
OPG (t0) 2911.8 11 1231.5 371.3 
OPG (t3m) 2791.3 11 1588.1 478.8 
Data on changes of OPG in non-responder patients were compared before (t0) and 1 (t1m) and 3 
months (t3m) after treatment. 
 
  
 
 
 
Table 4d: Paired sample t-test to measure the paired differences in OPG for non-responder 
RA patients before and 1 and 3 months after treatment with biologic anti-TNFα agents. 
 Paired Differences t df Sig. (2-
tailed) Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 1 OPG (t0) – OPG (t1m) -32.6 920.1 265.6 -617.2 551.9 -.123 11 .904 
Pair 2 OPG (t0) – OPG (t3m) 195.5 1338.3 403.5 -703.6 1094.6 .485 10 .638 
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